var title_f4_27_4528="Optic nerve hypoplasia";
var content_f4_27_4528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic nerve hypoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At first glance, the disc may appear pale but the actual disc substance is within this pale area. Arrows indicate actual nerve borders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4528=[""].join("\n");
var outline_f4_27_4528=null;
var title_f4_27_4529="Calculator: Body Surface Area (Mosteller, square root method)";
var content_f4_27_4529=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BodySurfaceArea_SR_form\" name=\"BodySurfaceArea_SR_form\" onkeydown=\"clrResults();\" onkeyup=\"BodySurfaceArea_SR_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Body Surface Area (Mosteller, square root method)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         BSA = sqr(Height * Weight / 3600)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Height",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Height_param\" onblur=\"BodySurfaceArea_SR_fx(); minMaxCheck();\" onchange=\"BodySurfaceArea_SR_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"BodySurfaceArea_SR_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|cm\">",
"              cm",
"             </option>",
"             <option value=\"30.48|0|ft\">",
"              ft",
"             </option>",
"             <option value=\"2.54|0|in\">",
"              in",
"             </option>",
"             <option value=\"1e-04|0|micm\">",
"              micm",
"             </option>",
"             <option value=\"0.1|0|mm\">",
"              mm",
"             </option>",
"             <option value=\"100|0|m\">",
"              m",
"             </option>",
"             <option value=\"1e-07|0|nm\">",
"              nm",
"             </option>",
"             <option value=\"91.44|0|yd\">",
"              yd",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Weight",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Weight_param\" onblur=\"BodySurfaceArea_SR_fx(); minMaxCheck();\" onchange=\"BodySurfaceArea_SR_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"BodySurfaceArea_SR_fx();\" style=\"width:105px;\">",
"             <option value=\"0.001|0|gm\">",
"              gm",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|kg\">",
"              kg",
"             </option>",
"             <option value=\"0.45359237|0|lb\">",
"              lb",
"             </option>",
"             <option value=\"1e-06|0|mg\">",
"              mg",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             BSA",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"BSA_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"BSA_unit\" onchange=\"BodySurfaceArea_SR_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0001|0|cm^2\">",
"               cm^2",
"              </option>",
"              <option value=\"0.0001|0|sqcm\">",
"               sqcm",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|sqm\">",
"               sqm",
"              </option>",
"              <option value=\"0.0001|0|sqrcm\">",
"               sqrcm",
"              </option>",
"              <option value=\"1|0|sqrm\">",
"               sqrm",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"BodySurfaceArea_SR_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      <font color=\"#aa0000\">",
"       The default unit of measure for weight is kilograms.  Please verify that the correct unit of measure has been selected.",
"      </font>",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Mosteller RD. Simplified calculation of body surface area.",
"       <i>",
"        NEJM",
"       </i>",
"       . 1987; 317:1098.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4529=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function BodySurfaceArea_SR_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.BodySurfaceArea_SR_form){",
"",
"",
"doCalc = true;",
"if (Height_param.value.indexOf(',') >= 0){ Height_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"BSA =  sqr(Height * Weight / 3600);",
"",
"unit_parts = BSA_unit.options[BSA_unit.selectedIndex].value.split('|');",
"if (doCalc) BSA_param.value = fixDP((BSA - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodySurfaceArea_SR_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodySurfaceArea_SR_form){",
"",
"BSA_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f4_27_4529=null;
var title_f4_27_4530="Ulcer with clean base Endosc";
var content_f4_27_4530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74032%7EGAST%2F52497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74032%7EGAST%2F52497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulcer with a clean base",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The opalescent ulcer in the center of this image taken during endoscopy has a \"clean\" base, which has a low risk of bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Peptic ulcers at low risk for rebleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcers with a clean base (panel A) or those with a flat pigmented red spot (panel B) are at low risk for rebleeding and do not need to be treated endoscopically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4530=[""].join("\n");
var outline_f4_27_4530=null;
var title_f4_27_4531="Patient information: Weaning from breastfeeding (The Basics)";
var content_f4_27_4531=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15829\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/13/38111\">",
"         Hand method to release breast milk",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/21/24927\">",
"          Blocked milk duct (galactocele)",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/22/36194\">",
"         Patient information: Breast pumps (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/43/17075\">",
"         Patient information: Breastfeeding (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/26/3491\">",
"         Patient information: Common breastfeeding problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/19/38194\">",
"         Patient information: Deciding to breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/13/7379\">",
"         Patient information: Health and nutrition for women who breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/25/17813\">",
"         Patient information: Breast pumps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/19/1333\">",
"         Patient information: Breastfeeding guide (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/61/37845\">",
"         Patient information: Common breastfeeding problems (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/32/41476\">",
"         Patient information: Starting solid foods during infancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/0/25602\">",
"         Patient information: Weaning from breastfeeding (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Weaning from breastfeeding (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/weaning-from-breastfeeding-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29712996\">",
"      <span class=\"h1\">",
"       What is weaning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Weaning is when a woman stops breastfeeding. After babies are weaned, they no longer drink breast milk.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29713003\">",
"      <span class=\"h1\">",
"       How long should I breastfeed before weaning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most doctors recommend that women breastfeed their baby for at least 1 year (12 months). But some women breastfeed longer. &nbsp;",
"     </p>",
"     <p>",
"      For the first 4 to 6 months of life, breast milk is the only food babies need. Most babies start eating and drinking other foods (in addition to breast milk) when they are 4 to 6 months old. These foods include juices, infant cereal, and mashed up vegetables, fruits, and meats. Babies should not drink cow&rsquo;s milk until they are 1 year old. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29713010\">",
"      <span class=\"h1\">",
"       When should I wean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women choose to stop breastfeeding at different times and for different reasons. Most of the time, the mother chooses when to wean. But sometimes, weaning happens because a baby no longer wants to breastfeed.",
"     </p>",
"     <p>",
"      Some babies wean quickly. Other babies can take months to wean.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29713017\">",
"      <span class=\"h1\">",
"       How do I wean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When you decide to wean, do not stop breastfeeding all at once. Instead, try to reduce your breastfeeding slowly. To do this, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Drop 1 breastfeeding session every 2 to 5 days",
"       </li>",
"       <li>",
"        Shorten each breastfeeding session",
"       </li>",
"       <li>",
"        Increase the time between breastfeeding sessions",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some women start to wean by stopping the daytime feedings first. They might still breastfeed at night or before bedtime. The night or bedtime feedings are usually the last feedings to be stopped.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29713024\">",
"      <span class=\"h1\">",
"       Should I give my baby a bottle or cup when I wean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can give your baby a bottle or a cup. Most babies younger than 6 months old are weaned to a bottle. Most babies older than 1 year are weaned to a cup. Babies between 6 months old and 1 year old can be weaned to a bottle or a cup.",
"     </p>",
"     <p>",
"      To help your baby&rsquo;s first bottle or cup feedings go smoothly, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have someone else give your baby the bottle or cup",
"       </li>",
"       <li>",
"        Give the bottle or cup before your baby gets too hungry",
"       </li>",
"       <li>",
"        Put breast milk in the bottle or cup",
"       </li>",
"       <li>",
"        Use a cup with 2 handles and a snap-on lid (if you use a cup)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29713031\">",
"      <span class=\"h1\">",
"       What breast problems can happen with weaning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different breast problems can happen with weaning. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Engorgement, which is when the breasts become too full of milk &ndash; This can cause the breasts to be swollen, hard, warm, and painful.",
"       </li>",
"       <li>",
"        Blocked milk duct &ndash; This can cause a red and painful breast lump (",
"        <a class=\"graphic graphic_picture graphicRef70540 \" href=\"UTD.htm?24/21/24927\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Breast infection &ndash; This can cause a fever and a hard, red, and swollen area of the breast.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These problems are especially likely to happen if you stop breastfeeding all at once. If you need to wean all at once, there are things that you can do to prevent these problems. For example, you can use a breast pump or your hand to release some milk from your breasts (",
"      <a class=\"graphic graphic_figure graphicRef73810 \" href=\"UTD.htm?37/13/38111\">",
"       figure 1",
"      </a>",
"      ). You can do this a few times a day for a few days until your breasts stop hurting.",
"     </p>",
"     <p>",
"      Breast problems from weaning are treated in different ways, depending on the problem. If you have any of the above symptoms or problems, let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29713038\">",
"      <span class=\"h1\">",
"       How might my breasts change after weaning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many women find that their breasts feel emptier and get smaller after weaning. Some women have stretch marks on their breasts. But stretch marks usually fade over time.",
"     </p>",
"     <p>",
"      After you stop breastfeeding, your breasts will stop making milk. But it can be normal to still have some milk in your breasts for months or years after weaning.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29713045\">",
"      <span class=\"h1\">",
"       What if I feel sad or guilty when I wean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is normal for women to feel sad or guilty when they wean. Weaning can also be hard for babies. Your baby might need extra love during this time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29713052\">",
"      <span class=\"h1\">",
"       What if I have questions?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have any questions about breastfeeding or weaning, ask your doctor or nurse. Some women also find it helpful to work with a breastfeeding expert, called a &ldquo;lactation consultant.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29713194\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=see_link\">",
"       Patient information: Breastfeeding (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=see_link\">",
"       Patient information: Deciding to breastfeed (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3491?source=see_link\">",
"       Patient information: Common breastfeeding problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/22/36194?source=see_link\">",
"       Patient information: Breast pumps (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7379?source=see_link\">",
"       Patient information: Health and nutrition for women who breastfeed (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25602?source=see_link\">",
"       Patient information: Weaning from breastfeeding (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"       Patient information: Starting solid foods during infancy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"       Patient information: Breastfeeding guide (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"       Patient information: Common breastfeeding problems (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"       Patient information: Breast pumps (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/27/4531?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15829 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4531=[""].join("\n");
var outline_f4_27_4531=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29712996\">",
"      What is weaning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29713003\">",
"      How long should I breastfeed before weaning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29713010\">",
"      When should I wean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29713017\">",
"      How do I wean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29713024\">",
"      Should I give my baby a bottle or cup when I wean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29713031\">",
"      What breast problems can happen with weaning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29713038\">",
"      How might my breasts change after weaning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29713045\">",
"      What if I feel sad or guilty when I wean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29713052\">",
"      What if I have questions?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29713194\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15829\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/13/38111\">",
"      Hand method to release breast milk",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/21/24927\">",
"       Blocked milk duct (galactocele)",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=related_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/22/36194?source=related_link\">",
"      Patient information: Breast pumps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=related_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=related_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=related_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3491?source=related_link\">",
"      Patient information: Common breastfeeding problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=related_link\">",
"      Patient information: Deciding to breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7379?source=related_link\">",
"      Patient information: Health and nutrition for women who breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=related_link\">",
"      Patient information: Starting solid foods during infancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25602?source=related_link\">",
"      Patient information: Weaning from breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_27_4532="Inflammatory gingival overgrowth";
var content_f4_27_4532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic inflammatory gingival enlargement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gingival enlargement that occurred in response to long-standing plaque accumulation secondary to orthodontic appliances.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ann Griffen, DDS, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4532=[""].join("\n");
var outline_f4_27_4532=null;
var title_f4_27_4533="Miconazole (topical): Patient drug information";
var content_f4_27_4533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Miconazole (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/50/23334?source=see_link\">",
"     see \"Miconazole (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33844?source=see_link\">",
"     see \"Miconazole (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      3M&trade; Cavilon&trade; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Aloe Vesta&reg; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Baza&reg; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Carrington&reg; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Critic-Aid&reg; Clear AF [OTC];",
"     </li>",
"     <li>",
"      DermaFungal [OTC];",
"     </li>",
"     <li>",
"      Dermagran&reg; AF [OTC];",
"     </li>",
"     <li>",
"      DiabetAid&reg; Antifungal Foot Bath [OTC];",
"     </li>",
"     <li>",
"      Fungoid&reg; [OTC];",
"     </li>",
"     <li>",
"      Lotrimin AF&reg; [OTC];",
"     </li>",
"     <li>",
"      Micaderm&reg; [OTC];",
"     </li>",
"     <li>",
"      Micatin&reg; [OTC];",
"     </li>",
"     <li>",
"      Micro-Guard&reg; [OTC];",
"     </li>",
"     <li>",
"      Miranel AF&trade; [OTC];",
"     </li>",
"     <li>",
"      Mitrazol&reg; [OTC];",
"     </li>",
"     <li>",
"      Monistat&reg; 1 Day or Night [OTC];",
"     </li>",
"     <li>",
"      Monistat&reg; 1 [OTC];",
"     </li>",
"     <li>",
"      Monistat&reg; 3 [OTC];",
"     </li>",
"     <li>",
"      Monistat&reg; 7 [OTC];",
"     </li>",
"     <li>",
"      Neosporin&reg; AF [OTC];",
"     </li>",
"     <li>",
"      Podactin Cream [OTC];",
"     </li>",
"     <li>",
"      Secura&reg; Antifungal Extra Thick [OTC];",
"     </li>",
"     <li>",
"      Secura&reg; Antifungal Greaseless [OTC];",
"     </li>",
"     <li>",
"      Ting&reg; Spray Powder [OTC];",
"     </li>",
"     <li>",
"      Zeasorb&reg;-AF [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dermazole;",
"     </li>",
"     <li>",
"      Micatin&reg;;",
"     </li>",
"     <li>",
"      Micozole;",
"     </li>",
"     <li>",
"      Monistat&reg;;",
"     </li>",
"     <li>",
"      Monistat&reg; 3",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, you must have your blood work checked often. This drug could cause a bleeding problem.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to miconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696941",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug if you have belly pain, fever, or bad-smelling discharge. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the yeast infection keeps coming back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray or sprinkle powder over affected skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696203",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use tablet or cream vaginally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10867 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4533=[""].join("\n");
var outline_f4_27_4533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196307\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196308\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020415\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020417\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020416\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020421\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020422\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020424\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020419\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020420\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020425\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020426\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/50/23334?source=related_link\">",
"      Miconazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33844?source=related_link\">",
"      Miconazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_27_4534="Measurement of pleural pressure";
var content_f4_27_4534=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Measurement of pleural pressure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/27/4534/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/27/4534/contributors\">",
"     John T Huggins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/27/4534/contributors\">",
"     Peter Doelken, MD, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/27/4534/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/27/4534/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/27/4534/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/27/4534/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/27/4534/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H934087\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direct measurement of pleural pressures in a pleural effusion, also known as pleural manometry, can be performed at the time of thoracentesis. Assessment of the initial pleural fluid pressure and the changes in pressure as fluid is removed (known as the pleural space elastance) is useful in the identification of pleural processes (eg, lung entrapment, trapped lung) that prevent the lung from re-expanding when pleural fluid is removed. In addition, pleural pressure measurements can be used to guide fluid removal during large volume thoracentesis.",
"   </p>",
"   <p>",
"    The technique for direct measurement of pleural fluid pressure will be reviewed here. The techniques for diagnostic thoracentesis and large volume thoracentesis, the analysis of pleural fluid, and the evaluation and management of trapped lung and lung entrapment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32582?source=see_link\">",
"     \"Large volume thoracentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link\">",
"     \"Diagnosis and management of pleural causes of unexpandable lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934245\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pleural elastance is the change in pleural pressure with removal of a given volume of pleural fluid. It is calculated by dividing the change in pleural pressure by the volume removed. A normal pleural elastance is estimated to be &lt;14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H934433\">",
"       'Pleural elastance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Lung entrapment refers to visceral pleural restriction caused by an active pleural process in which the lung expansion is abnormal due to visceral pleural restriction from active pleural disease, such as malignancy or infection. The pleural fluid analysis is consistent with an exudate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link\">",
"       \"Diagnosis and management of pleural causes of unexpandable lung\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trapped lung is a consequence of a remote inflammatory condition that has left behind a collagenous or fibrous peel, which restricts the ability of the lung to expand. The pleural fluid analysis is consistent with a transudate or a protein-discordant exudate and has a mononuclear cell predominance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link\">",
"       \"Diagnosis and management of pleural causes of unexpandable lung\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Large volume thoracentesis refers to removal of more than 1L during a therapeutic thoracentesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32582?source=see_link\">",
"       \"Large volume thoracentesis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934132\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main indications for pleural pressure monitoring during thoracentesis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identifying visceral pleural processes that prevent lung expansion when pleural fluid is removed (eg, lung entrapment and trapped lung). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link&amp;anchor=H13270434#H13270434\">",
"       \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Determining whether lung entrapment will prevent successful pleurodesis for a malignant effusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Lung entrapment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identification of trapped lung as a cause of an undiagnosed pleural effusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\", section on 'Trapped lung'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Guiding fluid removal during therapeutic (large volume) thoracentesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32582?source=see_link&amp;anchor=H25575612#H25575612\">",
"       \"Large volume thoracentesis\", section on 'Determining the volume of fluid to be removed'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Identification of lung entrapment in a patient with a malignant pleural effusion is important, as thoracentesis is less likely to relieve dyspnea and pleurodesis is rarely successful when lung entrapment is present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Treatment'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933967\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct measurement of pleural pressure is performed during thoracentesis. As with diagnostic thoracentesis, the patient&rsquo;s identity and planned procedure are confirmed; the side of the thorax to be accessed is confirmed by reviewing the chest radiograph. The procedure is explained in detail to the patient and informed consent obtained. The correct procedure for site preparation, local anesthesia, and placement of the thoracentesis catheter in the pleural space is discussed separately. We recommend that the patient be in an upright and sitting position. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic thoracentesis\", section on 'Technique'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26408?source=see_link&amp;anchor=H543573657#H543573657\">",
"     \"Thoracic ultrasound: Indications, advantages, and technique\", section on 'Identification of pleural fluid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25576496\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The equipment needed for measurement of pleural pressures during thoracentesis listed in the table (",
"    <a class=\"graphic graphic_table graphicRef83425 \" href=\"UTD.htm?19/7/19579\">",
"     table 1",
"    </a>",
"    ). A water column manometer can be constructed from two lengths of sterile intravenous tubing that are prefilled with normal saline solution and purged of air. A 22G needle is interposed between the thoracentesis catheter and the pleural manometer and serves as a resistor, dampening the pressure oscillations (",
"    <a class=\"graphic graphic_figure graphicRef69925 \" href=\"UTD.htm?3/54/3939\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58189 \" href=\"UTD.htm?20/49/21268\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/3\">",
"     3",
"    </a>",
"    ]. Without the needle resistor, the water column of a simple water manometer swings widely during respiration and is difficult to record [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/4\">",
"     4",
"    </a>",
"    ]. The manometer is attached to a stopcock on the pleural catheter to allow repeated measures of pleural pressure during fluid removal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. When using a water manometer, the zero pressure level on the manometer is set at the level that the catheter enters the chest wall. &nbsp;",
"   </p>",
"   <p>",
"    Alternatively, an electronic hemodynamic transducer attached to an intensive care unit (ICU) monitor can be used in addition to or instead of a water manometer. When both systems are used, two stopcocks are needed to make the connections. An important difference between the water manometer and the electronic transducer is that the electronic system will not measure negative pressure. To compensate, the height of the pressure transducer relative to the zero reference level is lowered such that pleural pressures are recorded as positive numbers and then corrected by subtracting the number of cm that the manometer is below the point of needle insertion (actual zero) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, electronic transducers measure pleural pressure in mmHg, so the transducer pressures need to be converted to cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (1 mmHg = 1.36 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O).",
"   </p>",
"   <p>",
"    Commercially available digital manometers, which can be directly attached to the thoracentesis catheter for easy acquisition of pleural liquid pressure, are in development. A 3-way stopcock should be used to allow closure of the drainage side when pleural pressures are measured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25576459\">",
"    <span class=\"h2\">",
"     Insertion site",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to measure pleural pressures and elastance at the time of thoracentesis, the patient should be in an upright sitting position with his or her arms resting on a surface such as a bedside table. Thoracic ultrasound is employed to confirm the location of the pleural effusion and select a dependent portion that is above the level of the diaphragm through all phases of the respiratory cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The exact puncture site should be immediately above the superior aspect of a rib to avoid the neurovascular bundle and, when possible, 8 to 10 cm lateral to the spine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26408?source=see_link&amp;anchor=H543573657#H543573657\">",
"     \"Thoracic ultrasound: Indications, advantages, and technique\", section on 'Identification of pleural fluid'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link&amp;anchor=H1913760#H1913760\">",
"     \"Diagnostic thoracentesis\", section on 'Avoidance of intercostal arteries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Without moving the patient, a wide area surrounding the puncture site is sterilized with 0.05 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    &nbsp;or 10 percent povidone-iodine solution, and sterile drapes are placed around the site. Local anesthetic (eg, 1 or 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) is administered to the site as for diagnostic thoracentesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnostic thoracentesis\", section on 'Site preparation and local anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thoracentesis catheter with a 50 mL syringe attached via a stopcock is inserted, advanced toward the rib, and then \"walked\" over the superior edge of the rib. As the needle is advanced, aspiration is attempted by intermittently pulling back on the plunger of the syringe. When pleural fluid is returned, the catheter is paced through the needle into the pleural space and the needle withdrawn from the skin. A sample of 50 to 60 mL of pleural fluid is obtained as needed for diagnostic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnostic thoracentesis\", section on 'Specimen preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934253\">",
"    <span class=\"h2\">",
"     Pressure measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial mean pleural pressure is measured just after insertion of the thoracentesis catheter into the pleural space and withdrawal of an initial sample of pleural fluid. We typically record the mean pleural pressure during tidal volume breathing, assessed over four to five respiratory cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/7\">",
"     7",
"    </a>",
"    ]. &nbsp;This method requires use of an electronic pressure system with the capability to record tracings for review after the procedure (",
"    <a class=\"graphic graphic_figure graphicRef59718 \" href=\"UTD.htm?13/11/13502\">",
"     figure 2",
"    </a>",
"    ). The over-damped water manometer with a 22G needle acting as resistor is a validated method for measuring mean pleural pressures (",
"    <a class=\"graphic graphic_picture graphicRef58189 \" href=\"UTD.htm?20/49/21268\">",
"     picture 1",
"    </a>",
"    ). However, with periods of coughing, this system is not reliable and the electronic signal should be used for analysis.",
"   </p>",
"   <p>",
"    During subsequent fluid removal, the pleural pressure is measured after each aliquot (eg, 100 to 250 mL) of pleural fluid, according to the same procedure (assessing mean pleural pressure over four to five respiratory cycles), and recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. We recommend stopping fluid removal when the mean pleural pressure decreases to -20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934433\">",
"    <span class=\"h2\">",
"     Pleural elastance",
"    </span>",
"    &nbsp;&mdash;&nbsp;To calculate the pleural elastance, pleural pressure is measured and recorded after each aliquot (eg, 100 to 250 mL) of pleural fluid is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/7\">",
"     7",
"    </a>",
"    ], and the change in pleural pressure (in cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) is divided by the amount of pleural fluid removed (in liters). As an example, if 500 mL (0.5 L) of pleural fluid is removed, and the pleural pressure decreases from -5 to -24 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, the change in pleural pressure is 19 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, giving a calculated pleural elastance of 19 cm",
"    <span class=\"nowrap\">",
"     H",
"     <sub>",
"      2",
"     </sub>",
"     O/0.5",
"    </span>",
"    L = 38 cm",
"    <span class=\"nowrap\">",
"     H",
"     <sub>",
"      2",
"     </sub>",
"     O/L.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H934245\">",
"     'Definitions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32582?source=see_link&amp;anchor=H25574982#H25574982\">",
"     \"Large volume thoracentesis\", section on 'Definitions and normal values'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elastance may vary depending on whether the assessment is made at a point when a substantial amount of pleural fluid remains, or at a point when the remaining amount of pleural fluid is minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/3\">",
"     3",
"    </a>",
"    ]. Often, the lung has some capacity to re-expand normally, so the elastance remains low during initial fluid removal. When the lung is no longer able to re-expand, the pleural elastance increases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933974\">",
"    <span class=\"h2\">",
"     Interpretation of pleural pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of pleural pressures includes two key components: the initial pressure and the change in pressure as fluid is removed. Understanding of the results is aided by drawing a graph with pleural pressure readings plotted against the volume of pleural fluid withdrawn (",
"    <a class=\"graphic graphic_figure graphicRef69925 \" href=\"UTD.htm?3/54/3939\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58189 \" href=\"UTD.htm?20/49/21268\">",
"     picture 1",
"    </a>",
"    ). The change in pleural pressure as fluid is withdrawn correlates with the ability of the lung to reexpand [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/9\">",
"     9",
"    </a>",
"    ]. The pattern of pressure changes can differentiate free-flowing fluid, lung entrapment, and trapped lung:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Free flowing pleural fluid and an expandable lung &ndash; With a free-flowing pleural effusion and an expandable lung, the initial pleural pressure is slightly positive (pleural pressure in the absence of fluid is slightly negative) and changes minimally as fluid is withdrawn. The",
"      <span class=\"nowrap\">",
"       pressure/volume",
"      </span>",
"      curve is monophasic with a calculated pleural elastance equal to or less than 14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L.",
"      </span>",
"      A terminal pressure deflection occurs in all patients with an expandable lung when minimal pleural fluid remains. Excessively negative pleural pressures occur around the thoracentesis catheter in the absence of pleural fluid due to local deformation forces, which are similar to what occurs in the lobar regions of the lung. Therefore, to validate the last pressure measurement, adequate pleural fluid must be present and documented either by lung ultrasound or subsequent drainage of at least 50 mL of pleural fluid.",
"     </li>",
"     <li>",
"      Lung entrapment &ndash; Lung entrapment is commonly associated with a nearly normal initial pressure, but the pressure decreases gradually as fluid is withdrawn, culminating in a steep decrease in pressure when minimal fluid remains in the pleural space. The terminal decrease in pleural pressure yields a terminal increase in elastance and a biphasic line when pleural pressure is graphed against pleural fluid removal. The typical",
"      <span class=\"nowrap\">",
"       pressure/volume",
"      </span>",
"      curve is biphasic with a calculated pleural elastance equal to or less than 14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L",
"      </span>",
"      during the initial stages of drainage; however, during the terminal stages of drainage, the calculated pleural elastance exceeds 14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L.",
"      </span>",
"      On occasion the",
"      <span class=\"nowrap\">",
"       pressure/volume",
"      </span>",
"      curve of lung entrapment may be monophasic with a pleural elastance exceeding 14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trapped lung &ndash; Trapped lung is usually associated with a negative initial pressure, although low positive values have been recorded. Initial positive values may be due to the needle entering the pleural space at a point below the actual top of the effusion in the chest [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4534/abstract/4,9\">",
"       4,9",
"      </a>",
"      ]. With fluid removal, a rapid decrease in pleural pressure occurs, correlating with a pleural elastance greater than 14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L",
"      </span>",
"      (often greater than 25 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L).",
"      </span>",
"      However, a biphasic",
"      <span class=\"nowrap\">",
"       pressure/volume",
"      </span>",
"      curve may be seen in this setting. This would imply a dual mechanism for pleural fluid formation. An example would be a patient with active heart failure with an underlying trapped lung due prior cardiac surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934095\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The direct measurement of pleural pressures in a pleural effusion, also known as pleural manometry, can be performed at the time of thoracentesis. (See",
"      <a class=\"local\" href=\"#H934087\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main indications for pleural manometry are to identify visceral pleural processes that prevent lung expansion, determine whether lung entrapment will prevent successful pleurodesis, identify trapped lung as a cause of an undiagnosed pleural effusion, and guide fluid removal during therapeutic thoracentesis. Identification of lung entrapment in a patient with a malignant pleural effusion is important, as thoracentesis is less likely to relieve dyspnea and pleurodesis is rarely successful in treating a malignant pleural effusion in the presence of lung entrapment. (See",
"      <a class=\"local\" href=\"#H934245\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H934132\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The equipment used to measure pleural fluid pressure is listed in the table (",
"      <a class=\"graphic graphic_table graphicRef83425 \" href=\"UTD.htm?19/7/19579\">",
"       table 1",
"      </a>",
"      ). Either a water manometer or an electronic hemodynamic transducer that is attached to an intensive care unit (ICU) monitor can be used, or sometimes the two systems are used together (",
"      <a class=\"graphic graphic_picture graphicRef58189 \" href=\"UTD.htm?20/49/21268\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef69925 \" href=\"UTD.htm?3/54/3939\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83425 \" href=\"UTD.htm?19/7/19579\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25576496\">",
"       'Equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient should be in a sitting position for the procedure. Under ultrasound guidance, the location of the pleural effusion is confirmed, and an insertion site into a dependent portion of the fluid identified. After appropriate sterile preparation, draping, and injection of local anesthetic, a catheter is inserted into the pleural fluid. (See",
"      <a class=\"local\" href=\"#H25576459\">",
"       'Insertion site'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pleural pressure is measured after withdrawal of an initial sample of 50 to 60 mL of pleural fluid for diagnostic testing. We typically assess the pleural pressure during tidal volume breathing over four to five respiratory cycles and record the mean pressure. (See",
"      <a class=\"local\" href=\"#H934253\">",
"       'Pressure measurement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnostic thoracentesis\", section on 'Fluid removal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As aliquots of pleural fluid (eg, 100 to 250 mL) are withdrawn, serial measurements of pleural pressure are made. The pleural elastance is calculated by dividing the change in pleural pressure (in cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) by the volume (in liters) of pleural fluid removed. (See",
"      <a class=\"local\" href=\"#H934433\">",
"       'Pleural elastance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung entrapment and trapped lung have different characteristic patterns of pleural pressure and elastance (",
"      <a class=\"graphic graphic_figure graphicRef59718 \" href=\"UTD.htm?13/11/13502\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef69925 \" href=\"UTD.htm?3/54/3939\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef58189 \" href=\"UTD.htm?20/49/21268\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H933974\">",
"       'Interpretation of pleural pressures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link\">",
"       \"Diagnosis and management of pleural causes of unexpandable lung\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lung entrapment is associated with a nearly normal initial pleural pressure, but the pressure decreases gradually as fluid is withdrawn, culminating in a steep decrease in pressure when minimal fluid remains in the pleural space.",
"     </li>",
"     <li>",
"      Trapped lung is usually associated with a slightly negative initial pressure. With fluid removal, a rapid decrease in pleural pressure occurs, correlating with a pleural elastance greater than 14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L",
"      </span>",
"      (often greater than 25 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4534/abstract/1\">",
"      Heidecker J, Huggins JT, Sahn SA, Doelken P. Pathophysiology of pneumothorax following ultrasound-guided thoracentesis. Chest 2006; 130:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4534/abstract/2\">",
"      Lan RS, Lo SK, Chuang ML, et al. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann Intern Med 1997; 126:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4534/abstract/3\">",
"      Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4534/abstract/4\">",
"      Feller-Kopman D, Parker MJ, Schwartzstein RM. Assessment of pleural pressure in the evaluation of pleural effusions. Chest 2009; 135:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4534/abstract/5\">",
"      Daniels CE, Ryu JH. Improving the safety of thoracentesis. Curr Opin Pulm Med 2011; 17:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4534/abstract/6\">",
"      Havelock T, Teoh R, Laws D, et al. Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4534/abstract/7\">",
"      Huggins JT, Doelken P. Pleural manometry. Clin Chest Med 2006; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4534/abstract/8\">",
"      Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. Curr Opin Pulm Med 2007; 13:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4534/abstract/9\">",
"      Light RW, Jenkinson SG, Minh VD, George RB. Observations on pleural fluid pressures as fluid is withdrawn during thoracentesis. Am Rev Respir Dis 1980; 121:799.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16859 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4534=[""].join("\n");
var outline_f4_27_4534=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H934095\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H934087\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H934245\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H934132\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H933967\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25576496\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25576459\">",
"      Insertion site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H934253\">",
"      Pressure measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H934433\">",
"      Pleural elastance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H933974\">",
"      Interpretation of pleural pressures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H934095\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/16859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16859|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/54/3939\" title=\"figure 1\">",
"      Water manometer for pleural pressure measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/11/13502\" title=\"figure 2\">",
"      Pleural pressure volume curve in trapped lung and heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16859|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/49/21268\" title=\"picture 1\">",
"      Water manometer for pleural pressure measurement 22G needle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16859|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/7/19579\" title=\"table 1\">",
"      Equipment for pleural manometry",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=related_link\">",
"      Diagnosis and management of pleural causes of unexpandable lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32582?source=related_link\">",
"      Large volume thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26408?source=related_link\">",
"      Thoracic ultrasound: Indications, advantages, and technique",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_27_4535="Methotrimeprazine (levomepromazine): Drug information";
var content_f4_27_4535=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methotrimeprazine (levomepromazine): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/38/37477?source=see_link\">",
"    see \"Methotrimeprazine (levomepromazine): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methoprazine&reg;;",
"     </li>",
"     <li>",
"      Novo-Meprazine;",
"     </li>",
"     <li>",
"      Nozinan&reg;;",
"     </li>",
"     <li>",
"      PMS-Methotrimeprazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Nonopioid;",
"     </li>",
"     <li>",
"      Antimanic Agent;",
"     </li>",
"     <li>",
"      Antipsychotic Agent, Typical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients receiving parenteral therapy should be switched to oral therapy as soon as possible. If pronounced sedation occurs, administer smaller doses during the day and higher doses at night.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety, mild-moderate pain:",
"     </b>",
"     Oral: Initial: 6-25 mg/day in 3 divided doses; titrate to effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psychoses, severe pain:",
"     </b>",
"     Oral: Initial: 50-75 mg/day in 2-3 divided doses; titrate to effect (doses up to 1000 mg/day or greater have been used in treatment of some patients with psychoses). If higher dosages are used to initiate therapy (100-200 mg/day), patients should be restricted to bed for the first few days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedative:",
"     </b>",
"     Oral: 10-25 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psychoses, severe pain:",
"     </b>",
"     I.M.: 75-100 mg (administered in 3-4 deep I.M. injections)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesia:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Preoperative:",
"     </i>",
"     10-25 mg every 8 hours (final preoperative dose may be 25-50 mg administered ~1 hour prior to surgery)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Postoperative:",
"     </i>",
"     10-25 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intraoperative/labor:",
"     </b>",
"     I.V.: 10-25 mg in 500 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W infused slowly at a rate of 20-40 drops/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Palliative care:",
"     </b>",
"     SubQ (unlabeled route):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous infusion: 6.25-250 mg/day (via syringe driver) (Adam, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bolus administration: Median dose: 6.25 mg/day (range: 3.12-25 mg/day) administered as 1-2 divided doses (Eisenchlas, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F194671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients receiving parenteral therapy should be switched to oral therapy as soon as possible. If pronounced sedation occurs, administer smaller doses during the day and higher doses at night.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General dosing guidelines:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     0.25 mg/kg/day in 2-3 divided doses; may increase gradually based on response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;12 years: Maximum dose: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     0.063-0.125 mg/kg/day in 1-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intraoperative:",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     0.063 mg/kg in 250 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W infused slowly at a rate of 20-40 drops/minute",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F194657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; manufacturer labeling provides no specific recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F194658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10241426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nozinan&reg;: 25 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 2 mg, 5 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12572782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer tablet orally with meals. Injection may be administered parenterally by slow I.V. infusion or deep I.M. injection; or subcutaneously (unlabeled route) as bolus injection (Eisenchlas, 2005) or as continuous infusion over 24 hours (Adam, 1997). For intermittent dosing, may administer smaller doses during day and higher doses at night if pronounced sedation occurs.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F194695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR;",
"     <b>",
"      incompatible",
"     </b>",
"     with alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fentanyl citrate, hydromorphone, methadone, morphine sulfate, sufentanil citrate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, butorphanol, hydromorphone, hydroxyzine, metoclopramide, pentazocine, scopolamine, sufentanil citrate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Heparin, ranitidine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of schizophrenia; psychosis; manic-depressive syndromes; anxiety or tension disorders; management of pain, including pain caused by neuralgia or cancer; adjunct to general anesthesia; management of nausea and vomiting; sedation",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequencies not defined; some reactions listed are based on reports for other agents in this same pharmacologic class, and may not be specifically reported for methotrimeprazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (rare), tachycardia, venous thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness; extrapyramidal symptoms (akathisia, dystonias, pseudoparkinsonism, tardive dyskinesia); headache, impairment of temperature regulation, neuroleptic malignant syndrome (NMS), seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity (rare), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, hyperglycemia or glucose intolerance, libido changes, menstrual irregularity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, ileus, nausea, necrotizing enterocolitis, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculatory disturbances or dysfunction, incontinence, polyuria, priapism, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (rare), eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary embolus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methotrimeprazine, phenothiazines, or any component of the formulation; hepatic disease; hematologic disorders (blood dyscrasia); coma or CNS depression due to ethanol, hypnotics, analgesics, or narcotics",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines. QT prolongation has been reported rarely with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Phenothiazines may cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); therefore, they should be used with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems. Conditions which also may be exacerbated by cholinergic blockade include narrow-angle glaucoma (screening is recommended) and myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms and/or tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Hyperglycemia or glucose intolerance has been reported with use; patients with diabetes or those at risk for diabetes should be monitored for loss of glucose control during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): May be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension, particularly following parenteral administration or with high dosages; use with caution in patients at risk of hypotension or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Patients should remain in bed for the first few days following initiation of parenteral therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Rare cases or priapism have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: May alter temperature regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Use with caution in patients with bone marrow suppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease. Dose reductions may be necessary when initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia: Antipsychotics increase the risk of death in  elderly patients with dementia-related psychosis. Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Methotrimeprazine is not approved for the treatment of dementia or dementia-related psychosis in elderly patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemodynamic instability: Use with caution in patients who are hemodynamically unstable. Venous thromboembolism (including fatalities) has been reported with antipsychotics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use is contraindicated in hepatic disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolactin-dependent tumors: Use with caution  in breast cancer or other prolactin-dependent tumors (may elevate prolactin levels).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease (eg, severe asthma, emphysema) due to potential for CNS effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a predisposition to seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Effects may be potentiated when used with other CNS depressants (eg, analgesics, narcotics, sedatives, or ethanol. Decrease dose of concomitant CNS depressant by 50% until effective methotrimeprazine dose is established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F194686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F194649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Limit caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization). Avoid kava kava, gotu kola, valerian, St John's wort (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12572565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F194630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests (baseline and periodically thereafter); CBC (baseline, during the first 2-3 months of therapy, and regularly thereafter); blood pressure; plasma glucose (patients with or at risk of diabetes); abnormal involuntary movement scale (AIMS); extrapyramidal symptoms (EPS)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F194640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hirnamin (TW);",
"     </li>",
"     <li>",
"      Levium (DE);",
"     </li>",
"     <li>",
"      Levomepromazina (AR);",
"     </li>",
"     <li>",
"      Levozin (FI);",
"     </li>",
"     <li>",
"      Methozane (IL);",
"     </li>",
"     <li>",
"      Neozine (BR);",
"     </li>",
"     <li>",
"      Neurocil (DE);",
"     </li>",
"     <li>",
"      Nozinan (AR, AT, BE, BG, CH, CZ, DK, EE, ES, FI, FR, GB, GR, HN, HR, ID, IE, IT, LU, MT, NL, NO, NZ, PH, PL, PT, PY, RU, SE, SK, TR, UY);",
"     </li>",
"     <li>",
"      Ronexine (IL);",
"     </li>",
"     <li>",
"      Sinogan (CO, MX, PE, VE);",
"     </li>",
"     <li>",
"      Tiscerin (KP);",
"     </li>",
"     <li>",
"      Tisercin (HU, RU);",
"     </li>",
"     <li>",
"      Togrel (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aliphatic phenothiazine that antagonizes D1 and D2 dopamine receptor subtypes; also binds alpha-1, alpha-2, serotonin (5-HT",
"     <sub>",
"      1",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     ), and muscarinic (M",
"     <sub>",
"      1",
"     </sub>",
"     and M",
"     <sub>",
"      2",
"     </sub>",
"     ) receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Injection: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 23-42 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 0.5-1.5 hours; Oral: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 15-30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine; feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adam J, &ldquo;ABC of Palliative Care The Last 48 Hours,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1997, 315(7122):1600-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4535/abstract-text/9437282/pubmed\" id=\"9437282\" target=\"_blank\">",
"        9437282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahl SG, &ldquo;Pharmacokinetics of Methotrimeprazine After Single and Multiple Doses,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1976, 19(4):435-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4535/abstract-text/1269194/pubmed\" id=\"1269194\" target=\"_blank\">",
"        1269194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eisenchlas JH, Garrigue N, Junin M, et al, &ldquo;Low-Dose Levomepromazine in Refractory Emesis in Advanced Cancer Patients: An Open-Label Study,&rdquo;",
"      <i>",
"       Palliat Med",
"      </i>",
"      , 2005, 19(1):71-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4535/abstract-text/15690871/pubmed\" id=\"15690871\" target=\"_blank\">",
"        15690871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hardy J, O&rsquo;Shea A, Gilbert C, et al, &ldquo;Is Levomepromazine Stable Over Time,&rdquo;",
"      <i>",
"       Palliat Med",
"      </i>",
"      , 2011, 25(3):284-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4535/abstract-text/21248181/pubmed\" id=\"21248181\" target=\"_blank\">",
"        21248181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kennett A, Hardy J, Shah S, et al, &ldquo;An Open Study of Methotrimeprazine in the Management of Nausea and Vomiting in Patients With Advanced Cancer,&rdquo;",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 2005, 13(9):715-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4535/abstract-text/15700129/pubmed\" id=\"15700129\" target=\"_blank\">",
"        15700129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lal S, Nair NP, Cecyre D, et al, &ldquo;Levomepromazine Receptor Binding Profile in Human Brain-Implications for Treatment-Resistant Schizophrenia,&rdquo;",
"      <i>",
"       Acta Psychiatr Scand",
"      </i>",
"      , 1993, 87(6):380-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4535/abstract-text/8395131/pubmed\" id=\"8395131\" target=\"_blank\">",
"        8395131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4535/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10147 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4535=[""].join("\n");
var outline_f4_27_4535=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194651\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194690\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194655\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194671\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194656\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194657\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194658\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241426\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234083\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12572782\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194695\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194634\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194688\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194637\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194621\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194686\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194626\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194649\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12572565\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194630\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194640\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194620\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194636\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10147\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10147|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/38/37477?source=related_link\">",
"      Methotrimeprazine (levomepromazine): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_27_4536="Epirubicin: Drug information";
var content_f4_27_4536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epirubicin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/21/36181?source=see_link\">",
"    see \"Epirubicin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ellence&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ellence&reg;;",
"     </li>",
"     <li>",
"      Epirubicin for Injection;",
"     </li>",
"     <li>",
"      Epirubicin Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Pharmorubicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Anthracycline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients receiving 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /cycle as part of combination therapy (CEF-120 regimen) should also receive prophylactic therapy with sulfamethoxazole/trimethoprim or a fluoroquinolone. Details concerning dosing in combination regimens should also be consulted. Lower starting doses may be necessary for heavily pretreated patients, patients with pre-existing myelosuppression, or with bone marrow involvement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, adjuvant treatment:",
"     </b>",
"     I.V.: Usual dose: 100-120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     per 3- or 4-week treatment cycle as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 every 28 days for 6 cycles in combination with cyclophosphamide and fluorouracil (CEF-120 regimen; Levine, 2005)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days for 6 cycles in combination with cyclophosphamide and fluorouracil (FEC-100 regimen; Bonneterre, 2005)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer (unlabeled regimens; as a part of combination chemotherapy):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days for 8 cycles (EC regimen; Piccart, 2001)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days for 4 cycles (FEC regimen; Buzdar, 2005)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days for 6 cycles (EP and EC regimens; Langley, 2005)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days for 4 or 6 cycles (FEC regimen &plusmn; paclitaxel; Martin, 2008)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 every 21-28 days for 6-9 cycles (CEF regimen; Ackland, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Esophageal  cancer (unlabeled use; as part of combination chemotherapy):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days for up to 8 cycles (ECF, ECX, EOF, and EOX regimens; Cunningham, 2008)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days for 3 preoperative and 3 postoperative cycles (ECF regimen; Cunningham, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric cancer (unlabeled use; as part of combination chemotherapy):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days for up to 8 cycles (ECF, ECX, EOF, and EOX regimens [Cunningham, 2008]; ECF regimen [Waters, 1999])",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days for 3 preoperative and 3 postoperative cycles (ECF regimen; Cunningham, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage modifications (breast cancer; labeled dosing):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delay day 1 dose until platelets are &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and nonhematologic toxicities have recovered to &le;grade 1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reduce day 1 dose in subsequent cycles to 75% of previous day 1 dose if patient experiences nadir platelet counts &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ANC &lt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutropenic fever, or grade 3/4 nonhematologic toxicity during the previous cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For CEF-120 regimen, reduce day 8 dose to 75% of day 1 dose if platelet counts are 75,000-100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and ANC is 1000-1499/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; omit day 8 dose if platelets are &lt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or grade 3/4 nonhematologic toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in bone marrow dysfunction:",
"     </b>",
"     Heavily-treated patients, patients with pre-existing bone marrow depression or neoplastic bone marrow infiltration: Lower starting doses (75-90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma clearance of epirubicin in elderly female patients was noted to be reduced by 35%. Although no initial dosage reduction is specifically recommended, particular care should be exercised in monitoring toxicity and adjusting subsequent dosage in elderly patients (particularly females &gt;70 years of age).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F165608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer's labeling recommends lower doses (dose not specified) in patients with severe renal impairment (serum creatinine &gt;5 mg/dL). Other sources (Aronoff, 2007) suggest  no dosage adjustment is needed for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F165609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     The manufacturer's labeling recommends the following adjustments (based on clinical trial information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bilirubin 1.2-3 mg/dL or AST 2-4 times the upper limit of normal: Administer 50% of recommended starting dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bilirubin &gt;3 mg/dL or AST &gt;4 times the upper limit of normal: Administer 25% of recommended starting dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment: Use is not recommended (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 2 mg/mL (25 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ellence&reg;: 2 mg/mL (25 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F165584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 15-20 minutes or slow I.V. push; if lower doses due to dose reduction are administered, may reduce infusion time proportionally. Do not infuse over &lt;3 minutes. Infuse into a free-flowing I.V. solution. Avoid the use of veins over joints or in extremities with compromised venous or lymphatic drainage. Monitor infusion site; avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F165648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with any solution of alkaline pH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in Y-site administration: Compatible:",
"     </b>",
"     Oxaliplatin, palonosetron.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ifosfamide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Fluorouracil, heparin, ifosfamide with mesna.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjuvant therapy component for primary breast cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9294976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of esophageal cancer, gastric cancer, soft tissue sarcoma, uterine sarcoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F165651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       EPIrubicin may be confused with DOXOrubicin, DAUNOrubicin, eriBULin,  idarubicin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ellence [U.S.] may be confused with Elase brand name for dornase alfa [Chile, France, Malaysia]",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Percentages reported as part of combination chemotherapy regimens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Lethargy (1% to 46%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (70% to 96%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea (69% to 72%), hot flashes (5% to 39%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (83% to 92%; grades 3/4: 22% to 25%), mucositis (9% to 59%; grades 3/4: &le;9%), diarrhea (7% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (50% to 80%; grades 3/4: 2% to 59%), neutropenia (54% to 80%; grades 3/4: 11% to 67%; nadir: 10-14 days; recovery: by day 21), anemia (13% to 72%; grades 3/4: &le;6%), thrombocytopenia (5% to 49%; grades 3/4: &le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (3% to 20%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (1% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (15% to 22%; grades 3/4: &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular:   LVEF decreased (asymptomatic; delayed: 1% to 2%), HF (0.4% to 1.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 9%), skin changes (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenic fever (grades 3/4: &le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, case reports, and/or frequency not defined: Acute lymphoid leukemia (ALL), acute myelogenous leukemia (AML), anaphylaxis, arrhythmia, arterial embolism, ascites, atrioventricular block, bradycardia, bundle-branch block, cardiomyopathy, chills, dehydration, dyspnea, ECG abnormalities, erythema, esophagitis, GI bleeding, GI burning sensation, GI erosions/ulcerations, GI pain, hepatomegaly, hyperpigmentation (oral mucosa, nails, skin), hypersensitivity, hyperuricemia, myelodysplastic syndrome, myocarditis, neutropenic typhlitis, phlebitis, photosensitivity, pneumonia, premature menopause, premature ventricular contractions, pulmonary edema, pulmonary embolism, radiation recall, sepsis, shock, sinus tachycardia, stomatitis, ST-T wave changes (nonspecific), tachyarrhythmias, thromboembolism, thrombophlebitis, toxic megacolon, transaminases increased, urine discoloration (red), urticaria, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to epirubicin or any component of the formulation, other anthracyclines, or anthracenediones; previous anthracycline treatment up to maximum cumulative dose; cardiomyopathy and/or heart failure, severe arrhythmias, recent myocardial infarction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: May cause severe myelosuppression;",
"     </b>",
"     neutropenia is the dose-limiting toxicity; severe thrombocytopenia or anemia may occur. Obtain baseline and periodic blood counts. Patients should recover from myelosuppression due to prior chemotherapy treatment before beginning treatments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation:",
"     <b>",
"      [U.S. Boxed Warning]: For I.V. administration only. Vesicant; if extravasation occurs, severe local tissue damage and necrosis may occur. Not for I.M. or SubQ use.",
"     </b>",
"     Injection in to a small vein or repeated administration in the same vein may result in venous sclerosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal toxicity: Epirubicin is emetogenic. Consider prophylactic antiemetics prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial toxicity:",
"     <b>",
"      Myocardial toxicity, including heart failure (HF) may occur, particularly in patients who have received prior anthracyclines, prior or concomitant radiotherapy to the mediastinal/pericardial area, who have pre-existing cardiac disease (active or dormant), or with concomitant cardiotoxic medications. Cardiotoxicity may be concurrent or delayed (months to years after treatment). The risk of HF is ~0.9% at a cumulative dose of 550 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      , ~1.6% at a cumulative dose of 700 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      , and ~3.3% at a cumulative dose of 900 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      . Cardiotoxicity may also occur at lower cumulative doses or without risk factors. The risk of delayed cardiotoxicity increases more steeply with cumulative doses &gt;900 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      , and this dose should be exceeded only with extreme caution.",
"     </b>",
"     Acute toxicity, primarily arrhythmia, and delayed toxicity, including decreased left ventricular ejection fraction (LVEF) and HF, have been described. Delayed toxicity usually develops late in the course of therapy or within 2-3 months after completion. Toxicity may be additive with other anthracyclines or anthracenediones, and may be increased in pediatric patients. Regular monitoring of LVEF and discontinuation at the first sign of impairment is recommended especially in patients with cardiac risk factors or impaired cardiac function. Discontinue treatment with signs of decreased LVEF. The half life of other cardiotoxic agents must be considered in sequential therapy; avoid epirubicin for up to 24 weeks after completing trastuzumab treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Treatment with anthracyclines (including epirubicin) may increase the risk of secondary acute myelogenous leukemia (AML). AML is more common when given in combination with other antineoplastic agents, in patients who have received multiple courses of previous chemotherapy, or with escalated cumulative anthracycline doses (&gt;720 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      for epirubicin). In breast cancer patients, the risk for treatment-related AML or myelodysplastic syndrome (MDS) was estimated at 0.3% at 3 years, 0.5% at 5 years,  and 0.6% at 8 years after treatment.",
"     </b>",
"     The latency period for secondary leukemias may be short (1-3 years).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events: Thrombophlebitis and thromboembolic phenomena (including pulmonary embolism) have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: May cause tumor lysis syndrome (TLS). Although TLS does not generally occur in patients with breast cancer, if TLS risk is suspected, consider monitoring serum uric acid, potassium, calcium, phosphate and serum creatinine after initial administration; hydration and allopurinol prophylaxis may minimize potential TLS complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Dosage reduction is recommended in patients with mild-to-moderate hepatic impairment;",
"     </b>",
"     use is not recommended in severe hepatic impairment. Evaluate hepatic function at baseline and during treatment. Epirubicin is predominantly hepatically eliminated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Dosage reduction is recommended  in patients with serum creatinine &gt;5 mg/dL. Evaluate renal function at baseline and during treatment. Has not been studied in patients on dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Women &ge;70 years of age should be closely monitored for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation recipients: Epirubicin may have radiosensitizing activity; radiation recall (inflammatory) has also been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Patients should recover from acute toxicities (stomatitis, myelosuppression, infections) prior to initiating treatment. Assess baseline labs (blood counts, bilirubin, ALT, AST, serum creatinine) and cardiac function (with LVEF). Prophylactic antibiotics should be administered with the CDF-120 regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should not be immunized with live viral vaccines during or shortly after treatment. Inactivated vaccines may be administered (response may be diminished).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F165575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: May diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of EPIrubicin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: May enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F165598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid black cohosh, dong quai in estrogen-dependent tumors.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects and embryotoxicity were noted in animal studies. If a pregnant woman is treated with epirubicin, or if a woman becomes pregnant while receiving this drug, she should be informed of the potential hazard to the fetus. Limited information is available from retrospective studies of women who received epirubicin during the second or third (prior to week 35) trimester for the treatment of pregnancy-associated breast cancer; premature births and intrauterine growth retardation have been observed (Peccatori, 2009; Ring, 2005). Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant during treatment. Men undergoing treatment should use effective contraception. Epirubicin may cause irreversible amenorrhea in premenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F165590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in human breast milk is unknown, however, other anthracyclines are excreted. According to the manufacturers, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ellence Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/25 mL (25 mL): $67.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/100 mL (100 mL): $268.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Epirubicin HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/25 mL (25 mL): $114.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/100 mL (100 mL): $457.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Epirubicin HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $46.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F165579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor injection site during infusion for possible extravasation or local reactions. Baseline and repeated measurements of CBC with differential, liver function tests, serum creatinine, ECG, and LVEF. The method used for assessment of LVEF (echocardiogram or MUGA) should be consistent during routine monitoring.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F165591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Binarin (MX);",
"     </li>",
"     <li>",
"      Bioepicyna (PL);",
"     </li>",
"     <li>",
"      E.P.Mycin (PH);",
"     </li>",
"     <li>",
"      Eberubi (SG);",
"     </li>",
"     <li>",
"      Epicin (TW);",
"     </li>",
"     <li>",
"      Epidoxo (PY);",
"     </li>",
"     <li>",
"      Epifil (AR);",
"     </li>",
"     <li>",
"      Epilem (MX, TH);",
"     </li>",
"     <li>",
"      Episindan (HK, SG);",
"     </li>",
"     <li>",
"      Ericina (CO);",
"     </li>",
"     <li>",
"      Farmorrubicina RTU (CN);",
"     </li>",
"     <li>",
"      Farmorubicin (AE, AT, BH, CH, CY, CZ, DE, DK, EG, FI, GR, HN, HR, HU, IL, IN, IQ, IR, JO, JP, KW, LB, LU, LY, MX, NO, OM, PK, PL, QA, RU, SA, SE, SY, TR, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Farmorubicin CSU (ZA);",
"     </li>",
"     <li>",
"      Farmorubicin PFS (BG, EE);",
"     </li>",
"     <li>",
"      Farmorubicin RD (BG, EE, ID, MX, ZA);",
"     </li>",
"     <li>",
"      Farmorubicina (ES, IT, PE, PT);",
"     </li>",
"     <li>",
"      Farmorubicina CS (BR, CO, EC);",
"     </li>",
"     <li>",
"      Farmorubicina R.D. (BR);",
"     </li>",
"     <li>",
"      Farmorubicine (BE, FR, NL);",
"     </li>",
"     <li>",
"      Neoquabin (PH);",
"     </li>",
"     <li>",
"      Panbicin (TW);",
"     </li>",
"     <li>",
"      Pharmorubicin (AU, GB, HK, IE, MY, NZ, PH);",
"     </li>",
"     <li>",
"      Pharmorubicin CS (SG, TH);",
"     </li>",
"     <li>",
"      Pharmorubicin PDF (KP);",
"     </li>",
"     <li>",
"      Pharmorubicin PFS (KP, TW);",
"     </li>",
"     <li>",
"      Pharmorubucin RD (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epirubicin is an anthracycline antineoplastic agent; known to inhibit DNA and RNA synthesis by steric obstruction after intercalating between DNA base pairs; active throughout entire cell cycle. Intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Also inhibits DNA helicase, and generates cytotoxic free radicals.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 21-27 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~77% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively via hepatic and extrahepatic (including RBCs) routes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Triphasic; Mean terminal: 33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (34% to 35%); urine (20% to 27%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ackland SP, Anton A, Breitbach GP, et al, &ldquo;Dose-Intensive Epirubicin-Based Chemotherapy is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(4):943-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/11181656/pubmed\" id=\"11181656\" target=\"_blank\">",
"        11181656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonneterre J, Roch&eacute; H, Kerbrat P, et al, &ldquo;Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(12):2686-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/15837983/pubmed\" id=\"15837983\" target=\"_blank\">",
"        15837983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burnell M, Levine MN, Chapman JA, et al, &ldquo;Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(1):77-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/19901117/pubmed\" id=\"19901117\" target=\"_blank\">",
"        19901117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buzdar A, Ibrahim NK, Francis D, et al, &ldquo;Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(16):3676-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/15738535/pubmed\" id=\"15738535\" target=\"_blank\">",
"        15738535",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coukell AJ and Faulds D, &ldquo;Epirubicin. An Updated Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Breast Cancer,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 53(3):453-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/9074845/pubmed\" id=\"9074845\" target=\"_blank\">",
"        9074845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunningham D, Allum WH, Stenning SP, et al, &ldquo;Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(1):11-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/16822992/pubmed\" id=\"16822992\" target=\"_blank\">",
"        16822992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunningham D, Starling N, Rao S, et al, &ldquo;Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(1):36-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/18172173 /pubmed\" id=\"18172173 \" target=\"_blank\">",
"        18172173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eiermann W, Graf E, Ataseven B, et al, &ldquo;Dose-Intensified Epirubicin Versus Standard-Dose Epirubicin/Cyclophosphamide Followed by CMF in Breast Cancer Patients With 10 or More Positive Lymph Nodes: Results of a Randomised Trial (GABG-IV E-93) - The German Adjuvant Breast Cancer Group,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2010, 46(1):84-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/19879750/pubmed\" id=\"19879750\" target=\"_blank\">",
"        19879750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frustaci S, Gherlinzoni F, De Paoli A, et al, &ldquo;Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(5):1238-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/11230464/pubmed\" id=\"11230464\" target=\"_blank\">",
"        11230464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langley RE, Carmichael J, Jones AL, et al, &ldquo;Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(33):8322-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/16293863/pubmed\" id=\"16293863\" target=\"_blank\">",
"        16293863",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine MN, Pritchard KI, Bramwell VH, et al, &ldquo;Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(22):5166-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/16051958/pubmed\" id=\"16051958\" target=\"_blank\">",
"        16051958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin M, Rodr&iacute;guez-Lescure A, Ruiz A, et al, &ldquo;Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2008, 100(11):805-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/18505968/pubmed\" id=\"18505968\" target=\"_blank\">",
"        18505968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray LS, Jodrell DI, Morrison JG, et al, &ldquo;The Effect of Cimetidine on the Pharmacokinetics of Epirubicin in Patients With Advanced Breast Cancer: Preliminary Evidence of a Potentially Common Drug Interaction,&rdquo;",
"      <i>",
"       Clin Oncol (R Coll Radiol)",
"      </i>",
"      , 1998, 10(1):35-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Uterine Neoplasms,&rdquo; Version 2.2012. Available at file://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peccatori FA, Azim HA Jr, Scarfone G, et al, &ldquo;Weekly Epirubicin in the Treatment of Gestational Breast Cancer (GBC),&rdquo;",
"      <i>",
"       Breast Cancer Res Treat",
"      </i>",
"      , 2009, 115(3):591-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/18712595/pubmed\" id=\"18712595\" target=\"_blank\">",
"        18712595",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piccart MJ, Di Leo A, Beauduin M, et al, &ldquo;Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(12):3103-10",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/11408507/pubmed\" id=\"11408507\" target=\"_blank\">",
"        11408507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ring AE, Smith IE, Jones A, et al, &ldquo;Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(18):4192-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/15961766/pubmed\" id=\"15961766\" target=\"_blank\">",
"        15961766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waters JS, Norman A, Cunningham D, et al, &ldquo;Long-Term Survival After Epirubicin, Cisplatin and Fluorouracil for Gastric Cancer: Results of a Randomized Trial,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1999, 80(1-2):269-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/27/4536/abstract-text/10390007/pubmed\" id=\"10390007\" target=\"_blank\">",
"        10390007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8663 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-77.94.48.4-C709B3AB8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4536=[""].join("\n");
var outline_f4_27_4536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708733\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165602\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165603\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165642\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165606\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165607\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165608\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165609\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165581\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165566\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165584\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165648\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165582\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9294976\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165651\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165640\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165587\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165570\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299273\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165575\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165598\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165577\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165589\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165614\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165590\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323129\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165579\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165591\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165569\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165586\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8663|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/21/36181?source=related_link\">",
"      Epirubicin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_27_4537="PCFCL chest";
var content_f4_27_4537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73842%7EHEME%2F50985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73842%7EHEME%2F50985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous follicle center lymphoma with localized skin lesions on the chest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous follicle center lymphoma with confluent skin tumors on the scalp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2cHilz8v0pvbNGRxXonKLnNIzlMHHA+8aBnsKkAzj8qAHKfunHfipBz9agKFFynK9dvcfSuZ8ZeLbfw/pm5WV72cEQRdSzZxn6U0rks3pr6IXTwtMq7Dhgcda4X4j+NtMstHk09NQSW7uSIGWEZ2AnBJPauC8b+MHKR6ZYrH5siZmmY7nZz1ORXmWrSwSERs7kg5Mi8t04/I1ajbUW5pajrrG6+zSPIbWJ2V43GCxz3H9KzL7VpZrf7PDiOHduIXgj2NU9VeW4kTULsktd5Jf+9IMBs+/Q/jVVJNsZPRsbcewocmWoLcbcSkyDJ5Ax9KSJQxCswVT7ZqMEMcde4/rWk9vG8LGHhVUEn+KpWpb0JLVkBABWQgcfNgL9fWnXYmVsOAP4l28Z+lR6YhTcAuZHXCjuc/1qKUMOJcs0Zx16H2q+hn1GTS7OWbaMEFcfpULgF1LYcOOSTnBqeRDcRlowM4IOfT+lV4RuXapJA7ep/8A1UmUth0JAUlVbaxCYPPehlVVkRskq+cLyAfrT4i6JJM2McIn1Pf8BmnFBHpyuf8Alq7cHg/54pDIJW2wLuIAJJ2+1QgYYF2O4AcDq3eprp45rkFz8pUDgYH0AqrdTEzSGPIyeTnmpdikE7ZGFwG67B6+pP8ASren4yqyFSvO7Pb0qpCkRQb2KNnK4I5zVyGRUbcVaPPBAGd1C3uEtrCzJiJUbr1Yjt7A1C2WOWAAAzx/Wi5kDuWKlQei1C27YvIHPX1piQ15A8gGPl7k0sW4KRz5R5BFKB5jAcKeuOgNWLZxykh2RLl9vUFhTSXUbJ50eH91uTdPCHcKchc9AfQgdqbIytEkcGVtjk/MecDqx9zQ0RT7SXQlhyQO44qtNMSmTty2AdvYemPrVtJIhajpJfMUsD5cQIUYpJXBsoIQTu3EsT2B6CrEixW8apIMyuvTshPr/tfyqFFIeZCy7mXIIGcFe35ZocdR3KoYSszEnHXjpgVq2Vq21NylBI4BPUgYz/I5rLtkBVlB+XG8/QVv2jNKLVA4X5S7ZOBkjqacEnqKbsNv5IZboPG2PMcgNt4UL7DuaiRBGA85/egF8f3RS2v75PmIVAcRnPQg8598c06IQvIYkBMkqkEE5HTIH6VTtcjyHQzrKXmZ1jH3mQjPHpj6Uy+uHTSBDZgxwXG6SXn52I4AY+nUgVnIHZZlBUkgs+WwcCnSTGKIylFeNiBtPQ9z+lZN9y1GzIkYJBhuSADz644qJZGLM2QSuBz0q5PaAW4dNzQsQ4Vj8/0P59aqsIskOpDnoiNnH1NK1i00w8xigU4AC7ckcheuKjlB3Qt6jIHeleQOPuLkHHHcVK8YNtAYiNp69iuT0p8oXsIoYSCVmUfMQPYgVYu2xCiwSSCNiwcvxz9R14pGRBqEkQy8W/qRgnHP4VQll8wgD/V5+UevvVrewtyaIB5dgbcSMDjGeOgp8O21Yu/zqV5x79aYnysspydowRnrUrxvOG24JPzYzjFTpYDrPD1xYf8ACMxw3iqd85bfwp344BJHKjrj3rRudGbTYYJyIri0lAdXhYHPuB3HscV5/FG6R5MPHZh2rotJuVWLaGYSddjj5W/wqo22M5R6o6aLT9jxSaXNDcwSkHYCVfJ6rj1H4V1Fnq1yEjMguHaBtsithiB6A9fzrg0KxNG0WWmf5zHGOB65962odTjQB4vlcKRxwVP973quREXOvuvEp8ia2fAt5FJ3YOenTP5GubutTl1CNJ0A8z5ctx1H86wXu8F4ZGYR9VKngn1waqQX8lvAY1J2E5z6MKnlsLc3LuU28SXDS7yXZRz1IxkfTmsuW6YefGV2Fny27gqelVbu5WSYqoG1iGGOx71Su7j53353s56nn3NKSa1KijodOvJRe72YFfLDbc4B9Aa7Lw3q32SzRvmaVi2zPTJ6sf6V5nayEMGB49/5V0+k3mI1XdlmYgZ65PekldCeh9Nd+hoOM8UnpzxThjvWRoKvbApWbaAcZA6mmr65HFYN1qkdw8UVpJvfkuQx4YHGAPWnYTZp3+sW9io3MquCCwfgKuep/wAK8N1S7g1zxvetPMGghLCB0bGWHIx6Cup+J2qQ6T4aYK6S3s5KNtbLc8HJPavKNBW0XQb+6vpREFjZlZD+8LdBjt1NXFEsz/EurxjxHc3cZMiEHaWwG5HfHGc1zkZe68yNfmkAL8dSB1/xqjLIXJLMx3HPrSD5HBWYBgeGGcfnUuVzZQsSxuGieJjkMAy+x/8ArihEeVV29s4z3qFY3ZyVZAepwelSxLukUZwxGCMd/YVK1KemxHIHibHQ9celdXYJ9rsYGUI88i4jCcA9ip9/aucuJEupQ+NjABT6Z6fhVzRr9dL1KBkkEtvncyMvAbp0qouzIkroknV7e7ngB3rEcbl/+vT42LwvIAplAwf9odq09ctYLfV4JEkyLpd24/Mu71z39KyChimeUOmQ3AHPzeuPQVZCdwuRIAVlVllIxJn26CoIotkxbYuOu0HAPt7VrKsM6Rx7mL7hgjPT39aZewwx3BSJmmJJU464PH40cvUFIzcq0kTA9H+UAcLVy9EIVWfIVUIVR3Y9OO9X004QbpJlMkhbaEB4U4HX9Mjt0rH1c/viyS+ZOxyzL0TPb0/Kh6Ia1ZQLLJcNK6hEUZVAcjjotVkQupyvOd3FSIGMjBV+YjAxz1qyIDCgLrn0BNZPU1vYZHbNInnOAik4wf6U6R8fKCGCDAP8PH86EV5WHBY9APSmOdhI2BieCD0HtQIiwXBYHGepJxVi0WMkgr5nPc7Rmmxwu7kMuHHr0b1AqxNa+SEmhO5WPbnoM81UUJvoKl0Uk2m0gAJ2kFSf1zU0vlEMNiuD95OhWkeDMYutwYY3SBDwvHH05qizMs3IKtjjPerJtcnu5wb77SJA4YYEZHUYxg/SqkpETKR06ofSi5Pzo3UlVwe2MUlyQ5G7AxwKlstLYnul2GFMgs6hjk+vrVm3hQTKzFtm9lOPdeKo795VWPK9MjtWnZhi2Am3jfjr0HJ/lVRd2TLRGfbwnyWhVhufGfQDNadwn2bzw+WZFTj054H9aayIktwu0qyy+YyEYIB6frUV3M9xvZ+c4B46hRgCrWnqS9WJYSSRTf6M7BnDK7HoA+c/pxUdhdR2d+ly480RYAULlRzjr+dQ2Q/emZjtVc8noDjiobZdxihGf3jguPYdOfzqG7aFW3uSS7ZpgxyC/Unvj/8AVQ7ebGsp+WGM4A/DP51JPskiiMWS+98nouCemf61XkwFESMCoOS3bPc/hUPcpDoZSYbmV7gK3aIqT5mTzg9se9VTyVZQSvQE9aleSMOot1Y7R99hyx+nYU1ppZ3zOxbIwOMAfgKq1rAhIgokQOTtAOT26VN83liPoARhsVFGg2lGAJHzDjr9T2q0sas8Q80iMD52/hTPU+p+lVuwYgG5pX6OzBe52gjPH41VjUK+CcjGB7HFaSyRCOSK3UlB0J+8x5OT+GKy03bvmyMDnb3+lF7K4lqTI5OWC5VBjA6Z+tNVlx8xI3cnApJWYwFFbKcMVQ8D/H61GAREuM+gJpXVn6DsTqUAx071Ygk2N8sjBcYPFUx8pyABg/nUmAMkZNF9bg0ddZ3bm2InYi6LBo5h/EB0FMbUvNOZUVTn94AMA+hB7Vkxy77f7PwGIQq2MkEDt6ZyKg+0sgLkneThvb1rRS7GXKayy+YsmZDu/gPoe2fbtVZpmMOSCGB59PpVMztktuOB3AA4q/PPG+lpKuCx/wBYD13Ajp/nvTnLmVhKNiGO5IUDIyDxmmyEyXUSAjzOn4nuapzYjk+blThsn0NJE+Jd/IzgE+n0rN3a1LS6m5O8cM8kVvJ5kSnCyEY3epx2qzBeqka7W3SE5wOwrGbcJHVhhjzjrmpYWTY5BPy8fWiSaaRFkz7TIyP8KglulhlKOBn1JwoqfPFZ2r27yIZoXIZV5Bxgjv78jqKxQ2Y3iDxFJZW73Kxo1isZdZS2wOR/dB5b+vWvEtY+KOpebMlgkNsjHcvkjDZ9S3Uk16f8WLtD4LvJikbGVfLiQjiIgjJA9cdK+ZZv9YCT9apuyHFX3N7xH4qvNcES32MIAVUentWYZ/tNuIpHZIIcuVHf0z61nXZIEIzzt/rU8TJLcRRMAAUKMw4Jz0JpXdyuVJEV5bmC3tWZcSTJ5m7tj0qmSCq4GfUZ71fvbk3WnWlvg5tQy8n+HPFZoYAYP14qHvoaRv1H5xg9/wCVPRydrchh3H+etNRGeRV3Km4gBm6D3NLGGS5ADDg8EHv7UDZo2jo4lhmPzysrB+x471UMZNwkbdyMY9O9NTcAcYPJ5qa1d/tEQz8xdSM9R71dyNi5NdtdfJCCNjbkj7Jg8EfkM1cuJba4lUCJ/NSMnZHgDf3yf7tU4ikU8sSgPApZXP8Az098+noKCrrGHGVEhI47+tVciyL8rkFVhZRuHzKo6H2NLawkYkdiZ2JPynpj/CpdLtvMiA4LEDc5PT0H04JNa+g2n2iYspCQnKh27kd/oOtWiNihdwb7eOOVpE2EAQJyT3yffmsaWzZ58OjAAYIHRfrXo01jIVjClQDHmSR1+VIh0ye7t1/zmuV1BP4bYNHGW3AHr9T6n+VElcabRhsqwo4hUKeRzySabGnlwme6YnIxhvvMPYVNfNDAxjMjxnIyVG5z+PQVWMkQl5heQ4+bzG3Z/wDr/Ssy9wUzSuAAqpglR7VfhsLoPtmhERYAgsi4YHv+PrU0EEElrC4V/M7qTztP9K0NOaC4xDey/wCjt8isc5Q44J/2c4Bx3xVpEtmWsXlzPFMEgnJ3FHXaV45LDtUk0IDb4D8rYDIwzz/eH60zUbedbxllIJPMkjkbs+570+znthmC6kMc5Qqsn8BPb6H3oWmgeZShkSGOeObJifCL8uDgc8/pWdMzlSG2jb0XvitC5Zw0e9R5qNjnoT7/AJVlTAecTFuAbIwe2e3vUt2Vi4rUY7YiA68/KQeAKGQkDvxnJ6fSpkVfsG2RcOGzyecH2qGSQ5RgMKBjHaouUidF+YSsMIPlJHb8K3rC0VIGywYOhaKWOQEoe2R6Vl2McjLNEQWjQb3XGSPcfhWrp8IQEoGZG67Rx045rSOhEtSvCgneFl3ebszIGb7x7nPp3qGdEhhkITzGOCJGzgjOOB/U1euIiLJVR1woxK4/hPp7j+tUL2MhwFX2RM9McU72RKRSjDSSGTBkCcMq4GfoKkFtFEXeR9z4yiDODn1PtWiLNjabFASTdgN0JPf6iq+pxOIIoQ2CSSx7E96nzKvdmZdyea4HPkrwq4xn6VBMrNIIlX3IHNPkJzjOVU9altY43l827yIhyUXq/ov0qdy9hEtGW0+0ttYtlY1zyfU49B60iQhSgkJTeuc4yx+gq5dTtKrSyuEMvCxRDnjsfQD0qo8qicyPGBnHy7uB9TWnmibtjSi7kjwBzhiT/P6VLaQ/aHd5P3NknDy7CcDPUDufQVFF5ZuWM5YJySF689hTryeS4wB+7hH3EHCgew7/AFpgR3UoOY7dSsSjABOT9SfU1TZjgqv3elTohdGLMqegPU1GEy5+cADjBFZy10LVkLGuED7sAHBH+e1XpDbfZ4HiacOwxKrgEBv9kj8ODVFGBk3MMp6Z6Cr0MYIMJGSwGCOcnsR/hVxV9ETLuMmiXy1kjJPGSDTIFDNjJ655NTRg+R8yEAMVJUYx6VFDhLlN5ON+CPapa1QJ6Esx2zlVypX5WGe1SRxGWKTLDIDH64q9exwRzSmNcggsrt1HBGD7dKzWDLYlMEOrEjHpxxV8tnYlO4S7oX3HHBGV7HinRybXnQAFM7lHt0P6U2/UGKGXgqygMFOeSAcVBFIQ0RyVJXaT7GlLZjSLDSrHFGVAY/cy3J49qakhiJbH71if+A//AF6rzkjaBjcvSljyzLg5p6bBY0YSAehwvA96lhJMJY87uMe/aoICfJPHykkAntxThK3yKxxt4HGKbvdGZ9ryqWQ45Ycj39qZMI/s4KxqRIQuMdjUnTAB5quwYK48wgK6sMDHBNYAcn4x063n0O8inOxPLILfeGCf5g4P0NfOvifw/caJeukih4mY+XKvRwPSvqjxTaiXRLzykDyMhT5ueT0NeMfF6KV4rOe5+VuUjUcZbGST+JFWlcE7M8cuvnKSBQPlIx9O9T6RFumkY9NoT6E1Nd2wSAkcARnJPY5xiui8O6GLnwvcXgfbPFJu293XgD+Z/KpUfeLcvdOY1bTZrOQsVIToSOayHQghcg/Q16LdSIlj5d4TtWEuB1LNjCkfj+WK4FI8vk8Ac0TjbYqnK61GINxx3xwOx+tRqS2DtwR29KlRDgMvX+VKU8yZSTt39Tj86gsmYboUYH6j3P8A+qmtuWOeRcgN+6Ht3P6VNKNlsmwHcT90joMcVWw7xonbJbOe5/8ArCmyUbOmRZiklOZJHIQjoFB6n36VIrPcsqrwN23aeNoA5x+FOEpitIo7dAzlkQ7h16H9K2dAVbMXk6mKRxCy5ddw5Pb0OMnPtWqXQyfcgmJfyrDT42+0zOEQrycHrn1z/SugghVZ4bGFkZI2WMtkAOc4LMfQHvWDoEkiXlzdwfLM6m3hlbpGWHzN7YXNdBEEtbuO2jMbRkK8khYYVccAn05yfUmqTvqJrQvTXEEK3n26QJbozOFJyH7F/wASBj2HvXCX2qy3Vx50gOxyREhPJA71o+JF81rNZWIeT97LGTyqk/KD6cDp71kTxGedp0QRyAblCn5VHQD8qmTfQpJCWmltcyMZ9pdyTkMOKtrpJaP5Mb921Fzht2Op9hXReHvD13rFi9xYoVYDYvHMp7ge47k98U+C8GnSSGRFIeL7PPEyjKBT/rFPc5wT3yKmLi9BtO1zm5J45V2CEA7R0Od3+19aSVZQfMi3Mcby/wDFj+lT39mtoVuYm2LL83HQ57/Q/wD1qk0pGmkEUTqZHI2iQ4D+n+FPyYrEFzI1/DBG+H2DYi7cMgB6Z/i6mqkln5ruFUFerA9eP5VpLD5xniRD5g5Kv1HrinMcSRRMmzZwpQZ2n1z6+1O1w9DBmzLE8bHHOVJ4ORwcVBdW5SXeF2hlDKR2PAzXQ31ixSKWRQzEM+4HqB/I+1Ztwg2qHO2NvkBPbPrSa7jTMxUVgVVwzEcOR/rPUD/69Q2Nt5tysEjxxgnaWkPANaaaa8AMh3NHnbE4/vHk/wAqZfW3KTRKNznPP8JHBqGikx9opjkTY43YwrA8dcY/Sugske23bFdW9AcDJ747gHNcxkoIpYgf3gwVI4yD611kDPcwKggd5LZD5qSPjY2ein8uKuLJaKV1FiyEEIDqSXJ78cjPrj0qjafNcqbhNwAxuHXjpn9a2dTt1aaOWNZArxksW4BbjOO1S6TYG6uVRQQzFfvKWAPrxTYIiuLWSYpGuWSJCytGN2CR0+n8qp+KdNGkMtvMV8/yw8uDlV7gD39e9d9oemR6VfLqOrNJJYWzG4uYEBPmBeB9QzHGfrXneuzvqNzLI+GmmkaQkjGCTnBqWxpHOW64kViM55GR/nmpoTsRpCoZyM49K09R0q6sLsR3CoqgFm296x3ZmJEfbEakHA56/hSTsD1K6HzJxtA3HkKOwpkoG/5PmVeCe2f61YRQnm7SC2Nm4dD64qo4wp2j5QcEVdrRuNbgr/NuI7DHtijcXUbs8DjnoKRIxJjedqbsN3OKnkiAXEOWJztXHX6++KSQ2MiAdwCQnAyD0NF4nkSZAILA9cYohMZfbuJBGHb1+la99ZRz6dHImVlByiuOWH19c+tOK5tRN2Zioi7WJGHPQdiKsWhDkJ/y06o2cfhT7eFZZUjY+WWwUY9B7H0qW4sntpl2jcGOP/rH0rSzWwm0yaRGSQlk+WZcN/vDuazyh818nBDZ65rqdHaG9spYbg+Vdr++hYjIk29vr6+1Yk0O67uCBtUHcBjOAe34UOKWxMX3JNxmEcbRneUZWHfPXj3xTZUPkxRqfmIYqw6MOP14q/PaNJZ299FlBNxyehH+PGKp3Tb2hYZjCAgAfwtnOR9aqxNzLY74mU/e3ZIqGJ9ziM4XOQDWleWcySlxFtUxiUgDBKnqf61mTKVm25GQcAispKxrF3JJAzEq3+sY4x6mpo9rSq8iY45ReOfQVFI+6NW6rnDex9aF/wBYMc4y2PWm/wAANG3LG1CDq0gJI6dOlNVszMSCMHhR/U01ZDHG7AA8ghT05pgnLkM3UjOPSiTu13IS3Pt1ScZPSmS9Q3Yjac/pQp44zSuRjaec9h3rEkV40nhaNhuR1wfpXkvjj7Lezx2coWQG4IiZh86xgjofc16rb745RHK2EP3CO/sa8G8e3wg1eCa3V3a2mkBEnOSrc5Hp0rSAmYOu+H/LsNSuNsSLBOlsBnAkYDkKP73Umug8CwIfDcZabyxHGJGXAJk/eNnA9BwPxrFW5N4bRZm8/ckrCPr85U/OffjNbHw6a31HRfKnQuLRHjkRBzgnhifTn86p9xFHxRaxNbTqkQimMZV8nPl/MBtHtg8Vw13pjQPcEBT5eI8Z+8T6V2XiKeW3W3ZmfznBjcg5zhvlI+gFYt3dx3cEfn8eYjBmx8xYnKtj6Cno1qEWzm4LcJZs2PMbcVGPbufaqcSh5AT0K5x6t04rdhSN7mKFW8uOZijKTkqOMHPqaouqm/kMagLE3lqoOc4HrWTiapiaptc+VCCdic4PBFRaXYNeX1vbRMA8wKqPXP8AjU5CbZ5W3F8eWMD5cnt65xVi1V4LS1uoSGZJFXeo6HbnH1GaLXdxXsrFzT0H+tKAfZUlmYnsQQo/MmrUk4tLLybVynmqEkIHJJ6gZ6cHFR3sKRWMbK4HnRhmGMZwcH61Um3eWZZMgfM3zdc7Tj8at6ErVl7TgxiCgBI1UNknHzN6n6CnHzrmREADGe5DOF74IwKZpYElr8x52AY7lQAMfrV6wUyNbmBvLkLl1Pc4z+RxS6FJFDVFMlygaMOZ8yKx43Lnjn6VJaIYBFkh40f7mOCD1+o7VbN409hZQ3RDvYbkgfPKox3bcegbJ/E1KhV1UuBbhiQTn759cVJqoqxraDbyLr2nWkOrCx0q9lL73kKRpx3PvjHuaz/iHCYPEMvkIYRwNhGAfUj1zU7GWQx2hmS4Rm5QDgjuCO3TtVbxFFFc7HluHkIQBfNyzgAcDPtU8t3dFXsrEFhdLdFbWWSKO0kATLLuER/2u+3PPFWr3TBpsy77PMbHJy2QB2YN/dOPxFUdKt0AVJS0YfDbxgk5HAroLbLhYVHnBT+7ifqFxyxb07e2eKuPmZSXY528hkhvWxsZ5BlJPQH+VX5bdbmzQ7/9LiGXJUKSPr3+vWqV1IsBeAKQn+raT++c549QOmatl2hijjMaiZI8lMZ+U8j+Y609xIitQ03mW8j/AH3y3y5YsOhHv6+uazr6yW6aZHX7Pli20/wnPQ1qWEkaQG4g3x3EOWILZDDupFXrm186RRLEyPt8zO3Pmq3QAevf8DSvdDtZmHb2skAQXShhK4fBOMEDGfbqDnvV+TQ1jnfbKDZ3ERnS4cHCleWU+hzx9DXUWulC+sVnSKUw7Ar7SDtbsyn046UkFrPBG63MiG3K7BkFkcsMEEjo3eldFezZ5tHYpGJImB55A3fLtPPHqauaXIZE+z3DsTEoRJAOdmeM+v8AOuh1jQTBEohXOw5QnuvHJPTv+lQWumxLeLtUr8xibHARgOCD9e1Jbg0yQQH7A1vOZXYDfAynKepH4ipNG3xviKTZuBUgNjccZGD2z7d6TwrPAbkDV/NRGDIZeflf+EntxzkeldONEhUSOsXnW8sKzWksLcJ+PpnPXpmncLXMaeaSfT5EkmlyZtrg8BkUg/Keg5559K5OSP8A0p5bWItGQXO7nauTXVeXNf2IgmLK2SkaZHHzfd/Oufnjay04RkkT78TAZPrgj2zxihaiehPIv9qRXc+4sREqrnnJBAbP161xmqRiEfZkyFSQlhx81brA20R8iR1Vhl/Ut3p00EbwiQRCdFTzZNg+cnOApPai3QnbU5i4gP2TES4+fJkP07fjVeVY1hBy5QjuOpx/jWrqU8ly1zcTsjTyy7VjiQLGgHXCjgAccVBa2ct5clG4jRASSMgZPamkF7FawjjNvLJIZNoAKjHVs8VGCkULBjumfluflxU17KBN5cBIRSUUgdfWqk6s0ucAFQBtPHSiS2SGtdWJI8oKkcIewUAVr6dcGzm3yBXHPJORICOAR/Wq1nCJAjksY+mMcir0dsokiheRYiQQshOVOD3/AMK1jG2om+g6S3SaNJEXa6NkrjhlP+B4/GgxPJGkZXcN/lhAfnXPQD1Hp3q5GkkUYjkyMkgovKsO5FTzwmSMyiQFFACkDAJP8unWtLaGdyvZ2dyxnaCJpJLKP7TIV4bYDgvj2zgipYLZru4uMMhmZPNXI4cdx9atwStNFCZGYXSSYW4TA6jBVvcjoagspYkmnhnjZo8mMMuQVOR/SlYLjtGkil09rCcOyunlxAnGJBnC/iM8etY2qW7wBopQQ33Wz/Fz972PFWbkPa3McUkp3zYPm9wwPDD36c1ev3gvLOSdITGTkTL12OOCQf7pPOPenrawtncxVneaxUZPnW4Khwc5Q9sVgspXqp3Ann1Fa9rI1pcqzqAuSjgnsRj9aoyRYlkj3kgcA98dqxk9TWOhXjYgtgZyOc+lScE4VTz6Hp7VBtKsyOrK3Qg9qmhI2FerBTg/0qEWx4O5CATnqRTvMEanAJfoPQVXVmjLdfm4H0pSwbBAyKE9RWPuVG5609MAkgDd71GuDtzwKGcIuSD6ADqfaoMh85G1S2B8wHv+FfOfj+GeOSO4EhaOZ7hA2O4f+ZH8q+icFWSZhvkUc98D0FeOeMbFZdOdXk4zcFefukMzKB9SeauImeZ+HLkjXbWEEMWiGMnGCc557cVd8G6oNLvWuBue2nka2mRBj5G7/wCFc7GDputSNJuBiB9ieOKm05nd5YwD5U7jbk4BfAOAapPoxtHdeNbdbYM8TqyQkrHjlQDjqfcdPoa5JShtiw3bhF5aheS8vTH0I/kam/tW6t7eaB95jnDDcRwQOCMHvnimaEI4IpZZ42fMYVQOqsem3+vtTvcSVjJv3+yuQMGZFAJ7ZPb3NR28X2dI92fN756Ek9vf/CtBLVJL7zbos8KschfXGQo/L8Kzri4eeZccNknb2U+30qH3LQ1VMkjxMoZQS7tjBH+cVqadGkrWqlyU35GRhc9ORVCHaBLu5LEBiO564rSt3SK0RAx3k5II43H1/CiIMteIpdtraWQiXEELRiRf48tnJ/lVJm/0ZogF2DcS2c/w8irLvv8As8dwEZYo2xu6nI/yapGL9xFIAPmYjHoCp602JGhoAzKiEhQy4bP908cflWtZW5AgaGJldJCM5xuYnBBPbPP51leHhtuWtxs8+WLbGSMkOpBGPrgj8a6fSdl2l7bj5TMFmjB6CQHBXnoD6+uKa2HfUyYYoNyyMXxjG2PkZz3B/I/nVmCK1aRIrkSpN/01OFYH0IHAqXUE8zeY1UTli0qxjIDYxnA68dSO9VLq0uBDDJIXO1C21+jL/st3H60mi4yLl5Yx2qRu6ozsSHMUoyoHrg1UnuLKSyXznuTOoBUAggL259axpvPDskSRBTwCrjk+xqCKSMIqFmHljLMo4B9PyqSuY6a10+6SNJyiO2M+WxwVz0OO2e9S2t0bUT212kZ3ja6g889geg9+wxXNQ3Mkm395ISWLhmbOfQGrk00CBFkcyE8eV2b1I/xpohmiI7Ty0fCz20TYfDEF2/hjUH+H1NTSh2DXEymS6uA5fjABHPH+e1LpyBrq3nm2xrFtAwAVyx4GPYcn1FWr2eKa/ubi0mBtcswjwQCPoeh/xpsEjKsbdrmRpbNN1w5J2L8nQc8VvgxTCCKRpCmwoki9mHQY6+oFJoskUkM0dyuFLhmIXhs9M9+OtbX9m2F3M6QPJa3DYBlQ7gCOjMp4I9+KycrHRGF9Sho9xe20DoEP7pvOlUcg57KO2euKt3cskqJdLjy3f95Dt8st77ehNLfW15HeG8BQSIoVjwTOuMAhe4P+FI0k8jKY4EYMB/rOqZ64H4VLVzRJokgi82GKPcGhkyURsYPJyCP0p1xpjJFPFZRos8SBXSIfK6+pU8k+4rbNsLQwzJFArqwfiM4fgBv161feTzEhka1kWRQQsy/Jt9Bj/IpXsV7PmOF0ZLdpLoxTSWt2EWSJSuRIQOgbp6jB/wDrVpW8SJbQTafewLHMjyFAu0KTnI29sc8U2TT7iC9NxNaqLR2XPlNkN649OaVXWwu3XyBJCyPtViSyknkH1Penz9CZUbaj7Sy32kkpS2nSOfZsw3mRsehX1HtXM+JNKdNRlSNGj81vkEuevXFdoospJEkSKSBYD8zjO08c5/SsXUVN28X+kGUxgnzT8xY5/mPWqjIzdK5wcNlNcJ+8HlQyjeMrl89Tj2q/dxtJ4cnt7FTFBbfPcAH5pAR1Y98HAx0roJ9P2tDdTOVYfKxDZ8sn0A7H0qK50t/PCW+bhZM/JuyduOVbHY9jVpoylTaPLrOCSaQqp2hELYPGR/8ArxWwkw01XEigy+UEZR/edcAfgP51qXmiy6TOZJIJDFuLxkDBPbBz26Gsy1smuWu5PmdAxnLMDg+mT2PFXHTYxlvqYS2oivUEykrFvyPdUz/PFZ1tcSOmyQ+ZlskHr+ddEs4e3v5GJDCCQISAMszAGsRLfKqQMEckdMj296Ipp3RSemo8RuNwgQnnIzwR71shYrjTVR0/eqT8uOdwxk59x+oqpLA0McbXAKAnZ5g557fUU1FaCcmblC3IViQ3uprazWpN7m/pDmVCkQMsAbIikYAnHbd/e9PXiiQvC0+xcxg8OOSufmCkeoP9aoBzIZ44o1jh43nOScHggUXUsiXaG5kYRSIN0jdHXHBP6U726kWL8recktyYliEuQuxcKzj09P6VVjIjA8krLDLtB3Aj5/X2waqQ3BieeKbcYZh8ig9ff6itANC8SSQMfMYFJFJwUIH3sdwePypJ+Y7EOt+XJC8EZZyjEqgX7o6gj17jA9Ko2l4WhC7k3Nw7Y4b0JP44Na+tKiWMM0EuZFA+dfQ87gfZv51z05iAWaBiFbJdQejdCCO3/wBeht3uCWgt/bs0W5UyikJvHOBnofxrKnmLssoyJE4Zh3HatMak7F/NDbJAAwzjkDGfTpVCa22xF4WDheG9s1ElfVFx03IJ5D5rlB8si5Ibn8jUcYIQkDgY+b0pVBMByTujII47GldT/s5xmsvM0ElYbd2OD2A6UxCdo28H+tPcbdynqKhBI5FStxo+5ifyzzQxHnguQMKSv9TSMflOOvWm3CCQJE33GbJ7HgZpGA4IZsOxdIeuwNgsPf0+leW+I7MnSoIOQ84dUONwLDn88V6k8pWGVZiBJsbDf3hj+dcVrth5uk6fEvLRqZHA4+bbkEHsec1cWJngvjGNm1eVSMOVDg9mG0HI9qztAt57y+gjilVCz7QXbAGeO/H411fjO3gjuzd2+8iJwpRuqll+b8A3IPesGzgWC3EoZTIWYEHnAA449+tFtSk9CO7VzdSQyyMfLcqpc9Np6fXua3dDVFgmuRMYlbKRL0LseCR6cZGe2TXNwp9qlWMZGTncT37/AKV1unILi9jS3I+zWiEOQcjIBOBVR7g+xmXymAKAVdAhXKDaAx5b8hgCuZyUPnP90cAL1I710d5DcSWCuGxaXMgWSRsAhh8wBPoRzWDKUk2oR5eCy8dBzxUydxxLmoQWcF2DYiTyRnI35DHggj8+RSTSHzljCbYsBc4xhj1NS6bC15Fbwq0Q2PtRcYLEn7xPt0/Gn6zGdoaXKt92NAOOPvGlfQdiWy2zf64EhDsOW6dh/Krd5ak2M8tivmJC3mEIc7QOo/Ksu0ga6vUAk274sEKMkkf1rVsLL7FJPAWDqoy+xskj0zTTuFhlna77RTE5fBYRyJ14G5cVoWF2sxt2+ZJXO51bpluufTPWodFt7lII2ziBJfKBx0z901FYpEJYxqfnRxEkN5RBYHvjPv2pp6C5Wb9tfW92kjsWiv0UKDDwWwevueorPvLsW3nCe0kWR3EqHeRtPrwf51UuUNspkVjIj9Zd3cdyPxH61ZtxK1s0k0KTxjOGGVz9e3encfKUp5bS4MXl2wiGxiGVmdl56nNZVwjxusYcrEWLBWHJzyM4rdurQz+V5dqkQUFsock5rKukkKbvLdQTgbhgfp36VLZSTGWEMrPtKyEMCy4wAQOSTW3baXM7rLcRRorkAeawG0HpjnmsWFWOfMVmde6nnA6iugspStp5Fy1wLcEMiAZHPoev4VKZXK7l+CSSC6FuPJEdvGzBcjltuMjPrwBWVcxi0jh8tWUP95c/cweNx+uf0rVaC1KyAzEEJnKguG59arGxEdtK9yzMsjjO08YwMAjt+FPmRfIw02OKaTDbiS5/dr97OOo7HjqK6ixlBiY2lkZIdpJeN9h+pBPaorHT55beOOWK1ljZ9yykbcEDAHHTio763uPna1DDe+QzgBht7e5461DNopxOmvmtYDbW93C7ebgqzygsOnp29RmnWF7DOHh0yyjubxWwLot+7Rvb2/rXH7jcun226d4c52wKCXB7Z7VvaXqYsoDHZRYt2IBOQ238qmye5vG7Om0uHUZYprjUZQYWfAaRuQRxhc/rULSWqSyI8twXDbQQQ/GOxFVNQ1WTVY8PcRQpt2qd2en8qjt7qJYYUhA5UknsD349amTtsdMKd9WaUkFo5i+YnJLMHXke1c/rPlyzp9mjLPEg3c9jx0qeW4Mm3955YJxvbIyPemMYlhRbeVDLIxAZgQo9s96nmCVIxxfSWmnZhn2oxZScbi2eo+lVdNu3tD5UtpNIm0hfL+Uq5GQPp3NOktJY53tZQY0RgSpGQuT29c04WFxFKHFw5kkYKV3ldx9MU0zncSUoyytdMQwTBOcjg9Qfxq94btEuWlaybYIwcktyoPbrz9Khv3mScJsuI3GEZDyMn1Hp2p1jPHp8S+YjqVYMyumNxB6r/KncThdF7xFoLy2iwSwlnA86GVchWGMsvPRu+K4JLN9PE0RciGVAyjOQ3zcZ9xya9gGv2UekLaFEuYHbesoUloyeoH61zniG0s5piIgpMsYyqfKC2OPofX6VpGbRy1KVzy+C1jfS9QjKrhZFbzO6gvg/p61E2iGZy25W+bO1TgH/AHff2rZMa2JnYKGyBuRTg+vQ1l3N6rtMykDzSC0SnA6dRW8ZI5JQaIb7R2t3kgtZ0vLXCuHizg5GcYPIYdD+NLpVkktlcbVaZVxviK7eM8qT/Ce4I70y2ufN3MZnR15yvDfXHfnqK6HUZ4bmG01rTkZ7qNRFqlso2jP8LD+8pHIPY8VqmrENM5K+R4ZI5Y5GkjztQk87PRvU4/kRUMEL/a/s8hzbujEMwztP/wBetfWRbTW6PYyF7eY5QYw0b/3T+OKo+V9p0iUW0cpv4n3FccAAfOhHqDyPam0CM+E7rYwuxDZwjf3ecgVDG8sFwWY8jng8kZ6e9Sm+t7izCTReXN5WVkXpJg5GfQj1qtLIWwDgyKuVx0IqJXWxaR2MgWeJRJJFHayoAwxt2Z4II7EHBx9a5HULaa2uXGCy52nHO4dAfrWhpOr20lvJb3SN5jMGAPO7sc1e1SRJ7NUlIZ4fkDR4y69j9R0+oHrTbuibcrOTnDSbihBA4H/16WKY/wB3C8BgBwR2P1qW8Vkl3BlK4+/2YdsjsarRNiUMnC+/I/EVk0arUmmi5DEFtwwfcGo1TdCFWIM443EfrVpSshIjQRr12E5HvtP9KZKm1mCttXoGP8qLdRIoyR4V9xBPTjuKrhSDxyBWreRIbeLOEYEBl96zJFZZCvA5OKh/EWnofcJwevQ8Go5MoFZhwpzn2o81SDtbn265qNV9nHuWJqTAknCy+XF1VzuJHoKwbtns7orIgIhLPDIT1DjaQ3sOlaM9ssUsckfzKudyknhT3H49qTVLWOeCMIjK4cYfG4c+3ce1UgPGvGsNna3UsCoHjm3FY3+9GACMH8QGBFcJa27N5ySuEXaI8t/e6g/Q4/WvSvibDEq2jLEUuPtMi7f9kqMAHuvp6dK8/vIZIllZshtyghuvQgAimy4xuihYxlQZVG1y/H498V0djZSy6LcR2h2sVWIksAGdmz+eFrI06ERRSSsOYlLJnoTkAVeuoHN1bPG0iQGUybD2OANx/DNNbCa1MjX7aeyvbhLlQskcaoQpyuT6HvVLS0W6kHnvtP3gfTsat39v59tJLI7GNG3tkkk89Pr6VSj8yOV3XAVCRtXpjioZSNuAx280j2xzhgUIXgj1/wAK6W60a71yCO5gjjdXYLhGAKNgdR2+p61zJD27xjaGLSYaMNyPb9a6fTtRDR4uDLHEQFcgBQfbPTnGKGXFJooadoUlvdgRbVuY3wYeWbf6emTV60tp3uWgZ1I8xfOhVcEjPI+vHbpV+9X7PPbSvFIkVwQw8pw0hI75Xp24qW4+0x3ObESRwYBLTBQ+wkYYe/6ipuy+RGZ+7tJZAJJfJifDoB9054Ydiehqjdxs2oO8ke2Gd9zlsfIx/ix+vFbc9i09zNJMxmil5SQqfnA7Z/8ArVQMVxpRQPFLNaNkCNufkPcfSnfsVy2Lv9gpcb44p4o4wcBWkyp54KkjJH8uhqw/h1bCw2H7Stw0oClBmNj2KjsfY9KhjuWtIPKs7qOeF2MiNjLoTg/eP0+oqCfUNQXfBcNOEc5EX3uT7np7nNK7GoImmikiXE7+cqNzGp2N0x19PasLWrKWyvZLVlZJFILpu3D8CPaujsrO9MO918uC3cFleQNuPpnvRa6PqGqx3D2EUl3dW4MkpGDtXd155xRzWDkucrZsyfMjKCASy8qWxWzBcnylWGVSmAXjZt4QeoJ/pVSGO4ju2kCRFkPKsARg9wPStVvs14rPJZxxuG5RBsCg+nqKTKjBlawiUzpPLOBHlhEi9FOOBz0Ga2xZFNPV7qzcRBjmUY+bpnCk8/17VS1G2aNIh+5ETsREBJkxg4yPfp0NakMDLp8VvaW9yzzyFWaVSzNgD7vbGe1K/Y1S0KsMiRSAXVykqjD7jnnGMAr61q3epW00U0VlalXkAbc7Z3enFZ8cbKfNkUFycMjDLoR6duafp9s0WqQsVyvzkk8gsfX3FG2pvTp825lx2d1v85Gfer7CwTKr9f8AGtSCxfyw8qHErYJxwfWungSWXS54i8fmsSSdueh7fWrlrponjitbiItdOnmIqHcCfU9hWbudcYxWtjmYtPaSdvLZQCg6DtVsWTo6QxIwDjYJMZJ75X8K6ix0UNHO126iFBgHPU+lWYZorVlRYPMT1LZ2jHYdjS6ahza6GTDoKtAjeYFdsgGTAC1i3FvIElhDIuzIDEZz7811l99r+zOjx27byAqq/wA6D6etYlzaxPEzbhvIIZXODn296Vuw1fqczcrI5IuD5mcBXx1x6HtWtp9taRq8kiPJKvCsxLAH696rzRpC8YIQsRgoW6D1OKhuLt7MCMkGJ2+UBiF+lPbUxnFGhJp2WDPDI0aDau75SWI5yazdTgRpxFcER4G487j9B6Cte3vYJ7VY5JJ3RTvUE7fn44/DpU90ba9/49I4Cdp3Mxxn6+h7Um2ZpIzlhglhtXjtyyhgQMctge2Kfc2S3Z3S7gJSR8zkMjdifaqst+1qgUn97nhcZRB/jTF1T7O7sXX5/lJ3AAcc/SnzA4Iztc8PstlJIoLyQAEuG+YA549xXCyWJN0kc0Y3LyO24V6hpeoyXTtG8whtyp5272z2OewrJ8Q6T9qG6SDynJH3SNx46+o9auM76HNOkjjjo6lUe3bfJnLHGFT61ct9Nv8ASbxL6No/KmQoYjkI4I5TnoSORng9q2NN0u+0m6hlN7DFEwLgSjg/7y9RXRR33223js5I7a6gdW/dlw+0HnKkDK46+1bqbRzummeXa3YHTbuR7c+dYTHcAV24B9uzDP8AkGsyO5e1vbhrd8mVNpfBBOP8RXqGraUs9uYEtmkDKXWIuGeMgc5PGB7GvJbmRIJmikYqOQkiHO09MH1FaxnpcwnTsU5lWK42Ngws29P9n1Fb0fh5dRszPpJYvEu5oWIJI/vJ3+ornL2VDKsq5XzByvUZHBFX9N1X7M+6BZbd0IIZMkL7+1Gj7CIJ9PntZSt1FyPm3j09fpW5HFFcafG9tMJSARIH+Xbk9P8A69X5dTfVrNElt4Z51JEU8bYZc9sdMe2KyWiaxlaOWNrZmADKDlHFO7W4NXMy4R4A4dchsn1qutktxbmSHJkUZaPuPp6iuiu7c7EGyON2XdGysCHH+eoqnZLLDcCLzBDNyfmGQARzn+8p/Sk7dQSMKOLaoWQuozlWA4BrasrV5CRJyhGG28bs9/aui0W0tbx3hnjgXcpLRsf9YfY+vofwNCad9huN9qcxlijJICF+nNLqVa5yd5bSx2sy7VeNGDFyORjj8qo3cIZl+XAZeucgV1+rkq5t5YGRMAAMQPcAkdawWQwthQHwc7fT396OW9mK9j67GMk5/wD1UilwAAMHue1GTzTl6/erEzGD5HZ+cEYJ64/Co3dI3SNWwhYFTg/KanGOnIx3FMYrsnV/unLAn2FMR5V8QUW/1e2iBKiHcZA3AVi3GPTNcfrNt+5KXW1n3hPMUckdc/UV185in1EteF2jvFdcjko3Y/gQDWLrEJWKAyDegIkznkjuaLnZGFo2MBLTZ9mib5xMC3Trj1H4Va06RJJYzMGMKRnvyS2f05q9NErxRGT/AFoyoK8HBQkEfjWZNCYxA8bBvkCscdDj+dVcxcNSlfpvizAn7syAsB0znj9B+tUzYJFGzqSFYEhcZ6noK6eKDy7vyn/1EiCRUPocZP4UPFFbXE8DyRvLG527OQccDH0B4NS3ctUznhYLPGwlm8p2GXbqUI7D1bH8qmsdOkuptltuY4xh+7DrntWrFYedE0SsWiRvlcnKgng/TrSaV5a3BILKmAyKgy2R1A9PWpbLVPWzLlvZXR0+3hT5oo92+MIA+OmScc+grd0nSfNtd4fAYnAD4+oIPer2jwm/ZrmYi2AU7Z+NoOeFYDuR2IHtS6kyxKJ4xvU/KwH3RjqCOxrOU+5tGn2IrTTDLNIAWbauUXeVCN7H+9/Okns2+0x/byse35FhUbSozxx3FXdKae4Xz4dv2aVW2iRvlJHoeoNSXVydUulttUj3GJAiynKheMAZ7c460lJG6p9imnhYX8LToggbzSjgLujzjgt/dJqvFpk1ndywWqrcRYxvUsVyPQGustn0/wDs61RAw1B8xtIM4Zfw4cHH1pZIzZ20sVyGOAMW8agY5+9gdOMY/GnzDVI5CR7ie5X9xlIyQwfryenpVi1EQ1GA3LywoMh2T5ZOvQjoQf1q9PC/lgyhYwxLMqnLLkcKfUUicgBgzMmFWVOgHuDz9KTkaqmiCPQrRdRjkvGK2spIRl+U+2B2APUVU1PRra3Kmwl858kpMjEBcHrmtSb7MoeKSNGDjKeZ8wJ9R+FXNOiti62yvJMSCViBwowOFNO1zOUbGJp9o19MrO6TymT/AEhGISQ5xnnoBWxIkq2scNvA0UiZLvwcgZ/1ZJ7j6VHqA06MeasTNeBufLUxhFA6A+5/LFOge6ugLZLwPaM25sIHI4yB6n049jTRmV9Rjt47e1uLSJXg6NCH3vgfxtjn8Kh8JW91d6hHNCUVYiTHFJyDnvmt6HRmvdOuLhxMlqgKkIm0/gTzil0eBNNQAyRugQhQAV8sjsf8e9Nps6Kckkb0fhq6L2M9nDtcKVXv5nPLEema6zRrK2tpp7bys3O5ZJpWAwFP8Of6Vg6Zq8s8tsLCUojMIpbhuOnIjT1z+ldbK8MMlzKSPNcBnGclcDtj0qbEylJ6MydT06fXLuWPTVWCCLlNy4Uv6Y/OqGraVKI5o41tsQgb/IUhQ/0PfvWtqmpynT7dNKcQA5BdiMhT1I9z+lJFp5EMpEd48B+U4z+8f1A6le+e9Z3uVGTitdjhLwBIhLJBIsbcAKNu9j3UZ4HHWq1zYf2fIbvUmtRcSp8ltPGXxGR94Hpn8a7PUtK0yC2vLe9mDahxsdgSUJGeFHRQKzNTggbw/AqnzJIlLyrjIVOg46k+gpm3OraHIf2KkFpHPNK8MkmWiQJzgep9/SucvpJb2RkcJFt+RF29fUj0/wA4ruxLp0fkR6i00zJb5Jjk/wBSxIIXB6nGcjtXM+MgovUv9PRRbOu7yXxuYdP++uKq1zCbuzHuI57Syb7OvnWyn5y/3x75rc8N6pHcOllbyW+HAxLcJhQx/hA9OetcrZazbPOEnk35+QORzjn/APVVVriCykR4nUwuzRb1JOwjBx+RppMxk0jrtZsre2tJkivY7hiSwKLglgeRn2xXO3V1H/ZgkiiQebJtZlGScfwr/M1HEzeU32aBlWQlQzNlnH07CqGi3P2ZLlGK+eW25YZ2j0HpScQdQ2NNJlaRmUKvG8FhtB/h+pqpr7XcE6Lb3U8e4nOHxuUckk9j0qzG803nrCyymMIZTs4UA/eJ6YGfxzXN+IrqWC+jYz7pUOWlJwBk9h6VSRnKXc2LKS3t7XEkhdnO4Oed7Y/vMCT+HFaF+T9jGqT+VFsTZGtuQGB6Zc8cH0/SuPXUYJItzPLNIBtQZ+UZ7+1YfifV5IIUtV3B/vbicnkf5/OrjZGUpE+teJ5ZPOtGmcW2474oGwZm/wBpuwrGWxu78BsQxRHlUAPA7KfWneHtIl1S6jjgZUcn7zdvSvTrHQLPSNQhRhDMYk8yWSWU84GT16A88DmrjJpkOPMeN3VvJGXXblQTyAQtMhdoZFzuTaRnsR6ivbPC6W19b3MV/bxRrbhmCkj5iSSuFPJHP8qxdd8BwXSLNppaG4YZktnIDKe//wBbtj6VfqRydjh7K5tHumC252MSQVciRB9RwT71uvaySohF3MYJD/y8kcfUjn9Krp4UutPv1F7EEj+4XMnl7SeASRnjJ69D7UxtEntrvbNHIsgbb5sUg2uR3B71SIaJ/sctvC6rKWhblUdN6j3B6j6iqcyTXU0av5byDAR1cYOPT39q7m00eV7W2mN053giMOS7Egc56DAHPFUJbF76V7K0trdkiTzHcNjZ7qe5749aTaKUXuYFo9yVMU1oJtpyEZtu0+oI5Brfm1ScWEEN3blLdsxupOd3HAye4q1PG5tFAWGdkwv2iI7H+jA9frWRrWoxoPJPmeXGhHz4JZsYb2xz+lCQPQg1hoPKEdysattwCpyGC8hvrzXJX7GJ1B5yCwKnir87furZXGYz0B7YOP61nPB9oEwhA81CcqDwfcU3dbEb7n2H27+tKDnp+NM5FL1HAxWJkSbirVk+J5jb6Ncsmd0mEHsT/wDWrTB54Fct44ueLSzRgWdjI49BjAoKgrySOMv1YqWjUCWLDIexI6gfhVQIkkO1lBkYMM+30rWUK6BMEDBGetZ9zABLG0DMjICXH+fes0z1FHQxplYi1iBbYuEAzzj3/OkuogSI4SBlAwDDJ3LkYz61p28DSqLgJEJkcMrk/Kee4qncq0V6zFSodmK8cHPXH41TZnGnd6iWLtv2yp5k0JLL/un7y+4qhqYWW4cRbw7ElMdfYetbFrbpPcCQzCBET95J68dD+NU7aK532rOPLkGTEzdGGcEA1Ny/Z20LugM0EFxb3ltuLrnGOTggEY6nn8qludNFu6XVtOvlBgY5F6KP7vsanNqLW5YSb1iILM68ZBHHB5U5/PFbF9c/6EqXQimXkKxTgkDhWApXHyt6jdPsr3XNRMWnxL5scYaQDhD/AHST3J5xnpTp4Y/KhWGFk/gkVZMlyPUHofeotCll0y+ZbR5Y2eJQrnnCg55B67SeK39LtdQlaa9ha3mvpJgEDSAtMR1YL1GR37VDjzbjTtuYjyf2bclDDKhkQM4SPhCOzA9+M5FdP9ti1S0a7jEL3QfDTrHmM8f7XVvUYplhcma5RNTt3jutzb7h1POP4Sf4h9OtQRraw6aZrgkojv5brhEAz1CZz14pJqOiNU0xttZzSX62do8s9xPIWA2BUA67se/PAxitLUppIIZFvbxGlixyV+b06j+tZCa/HJHI32U+aFCj5vmPB+Yf4VnWKG72gCUoRubncSx70m7G8IOT1Gzp9ovV2M0itkuxGM/hVu5iEdsNjhGDEbXXLZ9ea0P7La3sxPsk2ycRYOOfXPt3qw+kIlk/nMzqcN0xk+tQm+pu7dDkr/TpfK8u3iJkZcNIzZI9qZaahd2CwoJIllSML0HzAf1ro7i2muX+VfJVOpHUVj39oHZg8Iby8gSKP5+9NSZnUhzIri9lurxWmM7MAXYhl4/DofpVpdUNrMsoj27WysjJs5PsPX8qzorDz3imiMkbhRtyMD1x/nrV7VNPvnWNzO7yMd23b8nHQ4/Piq5+pzOgztvDF5Z3drJcagjm68wJNGhy78/dRPf1JwRWZrl1La3t7p91GAJJw3lA/Mje/wBB6cVV8Na1/YLzXEsX2kTQeTIrnyy3vge/f0rK1PWkvb+C8htha3cTHdCBuDjHygHJPAq+e6I5JJ7HXaHB9nsJS8aSq8n3Y2J2gc8D09a7bTbqRLaNruBFaVAy8cOB0we/vXk0HinUniEs9ncfZ0JY+QwBOPQ/071Sl8Yhpk+ywTQPv+YlyyhT6L2I/WoWjuNKb3R3Ws3k13ez3kJWJYMFolI2sdwXKj6kfzrc8O+J7x90SxSPIxK7SehxksD06CuEE2nmYynUBcHygGBz8pPJxx17Vpwa7AFk8wPGgjBGI9u1vTHfNDRbldcrR0+qySLdRfb7aFDcHz3EPMuwHhSx/iPcCp/EdnZw2lokDot1Ou+KINkruIwxPfiuRj1K/vVe8YgBG3GV/wCE9Bn8OgrLtNSkd7y5lmDXEuIY5f8AnmF6bfU8U0Jps1dT8P2umwxz6jdqYzPsngU8sx+6/rgZ5rB8R/MIHtLOWO1RXVpZFAEhPA2e/tXU3GoabqOlyM80jvtEjRiPapUfeLMeSepzXFXV5FNfXEaXUz2cW7yUJ6DbwQD0z+dWK76nnHiSBYpi8YKF+XUdj3xVfSbuDyjBcruTJKhjgDjg4qTVJmnlllcKEGVUDoD6fpXOO4eNsMoVTkgNyfYe1PY5aktTftNRnWbes0i2YJRpMZbb6L79qda6jHpms7jGZopFOAx3E5/i9M/yqhbahHN/ozL/AKM2N6ggFufuqe1OjiiHmG8Dx2QZhCsbZeNscNk/w56iqauYczuXZdWkkYJbg28JY5YuSZPr7VganIhid2Mkm04xjgVbjbLOqrhRkM/Qn6ZovY0Yv5qBFdcEBsnp3/nSQ22QWtyjwRrDbhHXJ3Mck/hXOaoWk1SRXIL7sHHTNa9tP9hYZVS27BbbnmsKWfOpNM3OXLcii2libo7rRGg06G3eJnFxw0Yx/F6n+dWvEzXMlzGvl3LXcyZLXDfM4PU47Vi6ZqSGbfIZArEbmSPLEgdPata0vIJr+W6LmPBOzedzkjoD25P8q1j2GmjC083X9pGMyObkALvJy3AwMfhiu90J3lS4gvbmb7RGNwMq/ex1Unr9K5ZrxINfXUI4wi5BJ6AsByR9ewqfWNbWa9W6VEj81QAm7kgdzVW6F8ytod1cS2cekK8FujxROMNM2ST/AHQeuB60xksZLG5uIYIo7guM4PEr9gB7nuMYrirTWoVEqNJmJMASP0A74XuaSPUrma2mS3YrbI+4ySjBIz1x9KFfYHJNanQ+KL8QwxC3I3GMxB1G3LEfN+Q4rG0yYTWoDZS3twFHOM/l7k1h65q8l3DDIJD5SSNg44P+cCmWtwyWJiZgsbxkhevfNVYyc7HW6Dcm4fAaN5HjJy3Qdck+pOa4jVrp57yGLbjyywI9MnNWba/22DRqSkgG489hWLZSeZNLcTfMztlfXqOKCWyw0mYmXOVCk8+/B/pWbFdyRzlo2w/Gcjnirl3IrGdWG3ZnH41kyKQWzzIDSk2JH2qOg/lS84FIOvOKB09qyMiDULtLGykuJc4XgD1J6CvN7y4km1G5edss/wAxPpxwK6rxbdhporZSAsY8xyfXsPyripmDPKVGGAC4z94f41LZ1UIdSdZJBIiJhcgYPpUlxZvPEwj5UHcwHXpyR+FQWzqzLKxOMcbR09q14pDGjuwCjZ+npUX1PRirozokikjhZGLARnG4cjtisycSz74yCCPlVcZKtnp/OtK5jnhZ54lzHgA7uimm38ccJD7sTFPvDjc2M9aVzXk0uUrOPNvNAwBIwevDrnqO9XIdtpIY5E3OrZWOZeBn/Drn3qOBXvLcPDEuVQujYwWAHzMB6CrtmkUxMk8jOFUqgkGNw6Dikx8txlrBKYWBYyROc5PJUjqM1e8tmtI2e1k8uVAVboHI4Yj0P86tQK9pG021WcoNofjZ+Hc4pdVvo57WI7dkEQx5ecAE/wAQHvSTKdO+wCZbDT7i4S4V75UiWONRuCZOGJ7E7cdayY7qazuxJPcvHdtws4789eO/akskke2D+WotZR8xKE454Oe+K6zS9Oe6hZHWK5bZglxkbRyD/wDWqlbqZSoogiv7u8haWe7WY/Mu+ZwW9BhcdO9Yu9rotHN/pcu8ZnwMrjoB2UcdK2dU0m9gv1iBiaVIhIEAwqoegyPumn6Xo7DUGt549ryASggEduhz/On5IcYKOpRk0AvFPfykyRSSCOFmO2Rz2Cgf/qrV8JwPpl8Yb2NlSJyGAw5BHbFXEhN15VzFE5kjHygkncV9PYVBDb28iSWkxMPk7pTPEc7xjp9OlZtdTVPSzLdiFvL8Ksxk5Z2AztXv+HNR3d+HYQpIpWMnaFbcGPqDTLLRbu4uUgt7hYknj8xXYhtwHqAcj6VcufC6osMCP5cyruXI4JJ5Gahplc8U9WWvDZsluYJb/Y0f8UbdM+/qfrUnjf8AsuYpDpaKJJ+diLwqjvj1Nc7qOmXmlozXDiSMDcVU4OPTH9ar2d2927XcjbJWHygjgL0wPWi4KCcudMfb2Rhs/wCHMZ3KG7HPA+tLfo6wiVklkXIZih4Xsa6bQrJLue3ur4jypW3lQ2FCnj8TXU+KbG0a2+Yvk/u4ILdcEHGAzEcnAzxTsRKqoySPLmS0vrOWKNkxEu4s5wwPsKxIbSK2vXuZCWtEYImRja3Y8V1WsLFp4NnGomhhZCbgRLgP3IzznB6dKg0cWTpewzRB0UZeXy/mUkjaC2cJn15PaqS1G3oc5cSQSXDfZLea5kMnI3LHGW7Kvr9KtWroLQ+TawRySPtfzG3OwH3s+nXoK277QLS3nnhcIQSBbXCkqHk6EAdhnjPqDVfStKll1CRroMpjd45pYwSAy+hHv3FUzN2kiKOzmtp1WKxjnzwJJY9qJkdOep9zUV0jJA9vIRNKJAVGfujPKg961rc/2nfXHkp5SnES/Of4R80jZ7n+ZrEuHa31WRLdiFiU4DjPT1I69aaaS0QkkSeJrqWLNtAEZAgLxRZIHuSe/WuXF7PZ3BmcKsSNn513AEjtWzDcibzZBBI9w5O75uAADmuT1UzzWks0sxEckm1I/U9zil6Boj0m11DTf7Ktb+d47mWcOskMaACNgDtGP19K53w4sd0dUuZGggBhfdcTKWCAAAkKO/v71zGmXUZnihuWdYF+9g4/DPYVW1bUDDaSIypbrtcbRn58ncM/pVpHPUlY5HUrjdM6wOzIzMQw43c4yBWDcq6zKqLyOgFXy+20RmyTz/8AqqF4jiPGd2OO2abRx3LyRwxyLIw+XHCjnB9TVyeeBod85dnPKKo4HHT+dZcMipar5e13yUK9h3p1pGZ4TII2UoR+pqkSyNtQl5EMChBgbifmI7VXe4lXBxlhwy5ztPY1oXGnfZ0G4kNkrs7g5zimMix2rsVC5yQCOWIpWaYbmdeI7Wof7o43EjjIP+BrIhDLdbsA9gD0ro5P+POTq5aPdyOAf/1d6xmiENxas4OyRV5A5I9qb01IT6F2SQFE4K/LztU4zVeIMgx8zA9mz3ro57Z1s0k2COF8CPPLN7mr+m20dvCQwWSdwVjBAO0dSx9Kqw0ciYpZoN3nPIqkDk8L7fpVZIHklRSxz057V6DJp8aWgaVI1VmDAkcyZHGPasG401UuozcKUYhsgDO38qtu47WHaRp9uJgLmQOSp4UZIx3o1a48xtzttgHRR0yODn8qqtclIBj91uGzjrj+I+1Ub28V3LJu+zp0X1btmi6EyWecyRWykL5UPBQjHJzn8elQmdjtGTgDbkdefSq7nzLc5dgEG4nH3mJqzYKWjkuCAdpIIHpjFMlkO7GUc7Mqeep/L8Kz4JDG6kdM1YZ1M8m7PC5Geue1VnByxA+VT0PXNHoBPOS0r7myCM/4VVdec87gMfWnMx84Nzkj/wDVSo3mAlm3P3Ujr/8AXpb7hsfZ+fqfam3E4t7WWYjIRS2M9aUH149azPEshTS2UHmRwvH51Bkld2OSunlvWadush3dKyWUo7MvPuRyK279Xh8sJhdwwBis6VMbw3OByfU1lfqelGNrJEKqUZVDcE7vZvY1pz3DXGEjUAt8+c5UAf8A6qz4oxKyRBSrEfN6g1btYCJHLfKB8oPqKlHZBF1989pHbcY4kkYj7xznH1rE11Hl1L7Ky7AFDNg4NdX8lvFM0a8xjEeehPYiuUvlP9qLI8hkKrh8jr3JxSRqi5ZRAXMscUTP5SblxjjjGfpn0qbSZBLFMZthZcRhiu7OTzt9Mf1qjHerlWiLfNkgrwRntWzZWjxWbSW5BiHPPJw1S3c0irbk01uqxI11HcFZ1by2jO4Fh/FgdhWVb2kV3eO8rlo4w2cH5lHY49z27VueHjJO7zZkFt55tXmDbVCAZIHv1rFv3jGrmPTUBht7gkSW7EeYT93BPpwKa0VzSKu2i/aW73FupjieGOHgNtI69Ac1vGy8m2iSxvVS4aPMqgMNmepJ/wAK3/C1jAmlvNdyhsIzbXO1Xlx93n0P51VhjkvLq7exx/qi0yMuFypHC91HGTSXcylK7t2MPTZHgVGug0USOGdsljNjnof5Gtx0Fxay6jdSSxvKwSGMnkRk8k+gxWdb3XmNkwFmQFs+Zxjvz6c103h+6s42Akt1jkykgbZw2OcZOccUc1yZ97El7aR6THZPd3qyRxIfKto1+YqeRkj+tYuj/ZreTU7pxGgucQLHICdodssfpx1rd8SW2nRTvcid1JBZomk3O2e2309qwr0tc2bRWZ2ywp5rEkDkn7gPfFUlfUwUvdMgXEEbK8QZriM/fU/dPbb9PzqFNakmvnCNOrhGADMThv4snpnNUtVuxa+Y1s8mwnDxMMgsfvcj8xTtIufma9lUSqAFY7OD77R3x3qGTzXNrX55RaW8t5E8m+M7HBxu6cH3xXJ6XqxWeOFt2zJ2Bhny17AH0rrr+6ElsJZlJikIeOF8EfX2rFm0h5rWK6SBI7SaRo0ycAjPJB7Cjl7G1KVlqbWga8lraJCtsk/l9FwTsznkn1967SCdY7CO+uI0aQ5AkVsAL6Z7D17mvL547lr50061jWOPG6OFsR46ckck961dLt7i6jWGadRb7mACncwAPZc+tVYc4rqWL7xFBNqVw72EYDL5UUajCBs/eA7nis7ItAlgtx52lhheyNHHgyyZz39MY9utJNHbveukMRtpoEJWPdl5G9D7nqfQVmT3HlXRitAVkgh2uCSQWbPXPbnAAqku5nOaWiNS61db5ZJJP3QnA2qOWC5O1PYf571r6d9ruRaI4lbdC7pEGABQcHgdBgdT74rjraIxXctruc+TAplQd3PPHuK1bGW7gjtblZXRX2mQydNnTbx1XHbvTZkpJm1p91DZ2N9JOGhMw3qMDc5ByB7CpfD+hfa3ury5DuyoCkcaj53YZwT2xisHVpJLi6Cqm6WXAchui9eR2z6VsWWoW9tFYwzW0wuVl80yrIQGxyFx+FIrVrQshbfTdCnNvEk9wwcSqi7mhyvcepPfoK821i2FxYTzQpmOFE3PjHzEYx+YNeh3fiGO20i5t9JsxZJesxmfO95CQSwGeg5wK88vo5JbtbVUZGjXO1j/ABE/xUXFr1MC8gEVqhiDkMuSccK59T+Ncz4nk2TSxecZdpGTnOSev+FehasiWWlfZlZWIlLsW6u3vjoK8v1mMmTymbHJLN+NWtjlqyuQ29sXt0nbOzOPYH0qK/ZJ4/LhyoH8XpjsK0LiXba2toinyzksAMEnjBJqKK0MSqV4+Ybc981VuiMOlyPwvaxCf/SwTEwJI6n2/Gujs7SSe8FvAoSUgsAp4Che9Z+mqtvqEO8gYbc7eg6Y9617Wf7PeOFBzKrKzDqiE4JoWiKsQa9aJERLEGNuHEayMMBpMfMPwrkrhnmujEx4UgsMfd9q6XUpClu6lvMgSUBADx8ucsB78VhTQZjkba4ma4ZDjvxkD9abVyG+gtxIhEixRgxrCwLY65/pWfrMBgh0YuNgaEPnPJGa3GEUdowMi5MZRkx1yen9aoa1GL+/0aGfd5EFqpl2nkRgZOKpq6M72kS3upiKFUVUZ3VRGp5CD/69WLGVobffISrE5bA5cnsfYViDy5r1ZJSY1ADBV67ewB+mKjubkSOwaQpg8IG3E+xpN9Skzrvtxa6W81CRHxysTNgZxxu/wFZGo6l50lvKSoQMQE+7uOPvH+lYUeoICSsZlfBUA9qqz30syt5pDIwA2Y6Y9PSlzWGbmuRpeaZFqdkQCCYbm2xgwsOQ2P7rdfrxWRZqsw2kZij+Zs/xH0p2nSu1wsYbzEfj5jyR/db19jWnqFimlwwyWzBopcsYzy0YH3g39D3qrt+8Re2jMq9IEQjHc78gYxntV7w6N8csb/MjqTz2A5JqNo1ltZHJy0Y8xRjAKnvVcO1mG7DymHB45p31uNaqxWuFYXLYJwSRUUzK03K7ScbsevrVueGRQpXIcKDgDPGM/wBaqyKFKM+CjDDYP3TTtZANlMglKysSAAFz1A7UyZDDKdwIyAdwqZlScRnI342HnGD2/Oh1eazJOd8Z2nPXPSj0BH2UDxxx7VheJpG3wxLk4Bc+1bi9cetctr0u+9umMhAQLGPbjmspaIVJXkZNzIZbiMsWOz05wKapV87hjJwBirtlHF9llYFcqMlR3FVztZ/3RHyrx7GsW+h6VNdSmh8u9ckc5xgVtBCYiUDZADJ7GsoARySEj5sgkdselbtn5k8kY+UjHr3/AM8UmdcO4lw8qzxTOVVTgFieGOP0rA1QpHdyO20bmIJz3xwK2SPMa4lkjXcspBLDOwccfSsTWdPZ0SVCpQtlo16E5IzQtRvTUoad+8h/dAbIiWXePvHHSuraRLWwhfeHVSUZNmPLJ4BNczp7hXMMqFYy5wTwCM449K3rd1aCKPYzMGZJSxzknvn9RSNyWJX063uftLbZ4gzNDj5FlzjkfSs+GS2g06ycb5boTSBkHV+PlAHtyfxq9EZrnR5JI3VpnPksz/8ALQ5+VsHrjoayLSI6dJGzu8s/kszEHo2ecj9OKqw4s7rw/b315pTXl5NGqJIpjjkc/K+eAU9cDvWjZFruS/aORsyRk8fxHPzZ9qxYRDPZo7sPtZj2jkgAY+99R2rWEt1pMtpFGIi91b+TMYxwoY9RnuQPwqLkPU55Swvtx/eRrgNGeRJ7YHUV6BpsLXts9zaLHAYEDCKJQ4x1b3PXGK5C/iW3nuoyhRocbUX+H1wa19LnuJR5VjPDZ+ZD+9klk2MQOoH1z6VK0FU95XRDd30dvebrsqkR+dDuy+70Hv8AWsPXCbGfMUhuIGYvn++euc+39M1qstq2psIlZ4cERnBGdo+Yn3P+FVfEIhtGeC2LSsiK7wquXjPr6Dr+NWZSh2M65eJdNedIQwnXLOwzs5+99f05qHR9LeXlZI02Z+VwQrA9hVjTLS5lNxdW8bSxRrulTG1dvYD/AAqSFXjtQrA4LcspGVXqDk9Md6NUYWsaVvNH5c1jLFEZGKhQkZLL7g/pioLprhbJheRo0aPtiATc8uOpGDgYHb0rXSYlre3hWO1jJDeefv5A6DHJP6VQs7q9F8+TEsc2eVAB2k8n8fY00xxbI7JooXzpa4up4Tv+XaYsnBBHQeuepFS6VOdEhsrseTOitJHHglXmbo3bjaT1qTUli/tS4miuQ/lhQysTveTHLsO6A4Fc9d30cETzJgCMGFNo+6zHkn3P/wBeqHKehmWFyHnmG8CUK4WQk8MSSSPWs+0v/NZ7xtql5lMjEHp7fgM/U0WDm3W7lnEblUMccQH3+eTnsBn8TWd9nK6HDISTC7MIlIxlT3/E4q4o46k7m3o12sw1G9Yscx4G4feOcc/nW1bGFYHWKUFQAsSnJZiTjA+neuYs4msNPuY3DGGCJm2j+IEDGfxPP0rSh+12kMEilTa7Q5TPzR5HAYjpnrj0qmiYXbNbQHeO8jmmkjhRLhozu5LEKef6Ust5KjqfMMohJWIt0BPJOfTmswzqp3SDM0zeYoTjY3/16uJH/o7I5D7I1AKHjJ69e/QZrNo600W9PnWRLma9bAjUxxIAMlivykD2IzXIwzM1xMJ2kaYsGdj1Izzn3rV06WazvCZVDSAkdd2wHjArDmjMV1JuZSr+YM7u2eKEtCajsx/iJ4p5JXjWVbdvnbcQT7ZxXCOonunYgGJFwCevrXWMftO9WJVX2LkdAvrXIXiItyBGTjJP5k4z+Fax2OKbu7DxDvthKx+dSCPfPH9Ku3MCPHBJ/BHgHA445x/MVHHAJbSRFRmbH4Adf6VDBIRaGAEfvW3HJ4HOPwqupLdlYhvYmsr1wwPLbo891PIP5VYecvbuXX5yAC444H/66qXJkl2tMXPyfKx5wBxVW5uJEQKQdqoCeev1pNWJUhNTkX7PCu8/eJYjocntSPORZSOJcmSTftHbC4zn9Kxr2YlLdznYSPx70twxaKBY8hTkHb35oEy/GwkjQK2796oPvnNUNXlP9oXMStyAIQPYdf5Vq6PCtvdRIRuWMb3H+1z/AFrCtM3d5PMSxLuxLAZwAeT/AEpvYhb3H3JVzPMsZZjtVRk4Q4xtx+FUljVnIdlRe2081ryBCimZFVJCXZZJOT6cD0px08QIkjW3mAn5SFOG9+f5UnG44uxlSxhgDEjIB3f+KmJbtI37tR8xzkVtSW0kiAtwccBsgfQChEkhKRQyIDu3KE5+f0zS5SuYs6Xp8VtKyTsPkQyOR0wBVVro33nSSNhkIC57r0/Sql5PPAJopDtaUYdc84B4B/GqGZw4yoTYM5anzW0E1c3LJoorm1SZs28chhlPojjH6GqupRLp91JbTgM8bEM55APbH9aLJ18+ZQCyTxck9yDnNTeK4/30cjIEby13ADOTjqfrgGq6XRN9TJkmmkmkMzHfj9R0o2rscOBtI3AKclQf85pkA3ozOfmUYB9vStDy1QW12ChjaILKvoCMZ/nSjruU3YpWsZZhFL0ZSDjqMc5qzo/zPciTGGA3EHqfX8c0+W2MKloyWeJ8p/tKB0qIutvdiaP5VcKyj69a0SsTe59eJ1HXNcVfS+bcXJ4BklP6V2iHGODXn8TFribeeA7EfnWEtjShuXLeMiMnpk5PuPSmzKsDFQuGJJJU544xVi05kViCEVcnjrUmpArOXAAUjBx0FYX1PVpLQoPGF3KfmbO5Se9a9iGV3ikXAZCTTFtQ8Vu4VhsIDZ7+9bUVrHIVkGQdvGP1+tTKRsnbQx7uEwLIzkGEkOD6Er0NNu44C625i8wFAQU4wTzg1sTqZYzIEDKilMkdB1/MGkvkE0NoUUl0Xax4x9c+vNJMd76HIahpv2VppImbynXJBPJI6j2OafbW5gmhkt7iTeyK/wApyN2Mc/hnitq8s5riWYzSkjaFkaQdAcYOPwFZdsqxTPEcr5eVJB9OwPpVt2VyoStodL4Z07TWuZkeIzwW8IdIiTtBPWT6jpj3rW8YaLEbC2vDYeU0in5GwG47gfTmsHR75LTVLWQDzIMos244VznjIrtZRbLaLG/2h5OZWjun3MUY/wAJB4+n40KQTupJnmFjNJZRNOHWUHAycHjOMV0Ud00ln50sm9o8fK5+cjPpVS+sLaS4SJV+zlWPzE53rnjcPccU6fT1tZZNqyyROhPDZaH0BPt6dxUOK6GjaY7UG866AEUfmxsW2Mx4Hb6mrk+rNJe27SIhvDgh2xgYP3fcmsWyurgyRyvbiYy4KgSbSD7579ya2LfSrOK3kN0Hknl+aR0cMnfgHqfrTQOy3I7u9R7mFIpBHdLNzjGFycls9+vI9qj0VY5/EkiXL5QAwNIx+VyQSFJHTPHNJNZR31xDBaWphALeXMpz91en09axNMu3tWfMp3SSfO7sMEd+v0oWjCyasjsJlhtkc26WahY2hltreRnWN+xDd+Kxr61maFZLE7fkU+VtJAGOPxJ61uxz/bI4HQxOpctsii4GBwxx19ax7q9ubRms4I2LNLsZ5vlLMehHooHar6anPNFSO+lgsoVYLLMF+VSSfl7njkfWtTSbhlPm3lvCrsMqj/TjjuO9Phs0hulVxBMJgd7r/GRwQB2x2zTdQEccEe8COKMEfMeXY+nehdzN+Zm25VL+4nugHYbW8oZwBxyT25PT2rBu1ZZrm4nIEbKJFH8LMSflH862w8ry3YlHljDTynnEgIwB/KsTXRILS0ij3Ff3fXkZPLfjgDpWkUc1WdjLtvMw6zxHZO4DS9AFHOPoTRLPFJYlnz5YXzlx/CFJ4A9ORj6VLrN6kMkkiNw6sSvdRk8Ht05/GsnXrk6e9k0sSmHy0Ix/Fk/Nx2GK0scrl1L5EltpksvmqUmt0SQnnJ3jd/Suu0KLytE86eSN/MQK42cHBwF+uDXFWrLDa3gH+kpLhoznCBAcnHvgjPvXXeFrmaaO1QyN5RB2jb1znB9gD+tJqxUZDbqxka7ukVEiFryyg8licAn3/wAaZbxyzXLrGNska+ZtAyML/SpXulN7cyTSbni2y+T1JB7k+2OKm0QtGsF85YJcKXwCMlAaixtGdjPecqM5BkLiPcB1JrC1aDy5JpI1yiFSVU9Ox/PNXbmdbq8meMj92xcbPulh0IFVfODWzMd2HIPIyMEHr+NOKJnO+pl6nmCxuvJAkRoGVT/dxjJ/U1y6kZt5Ff7sascjPzdP5Vu/aWlsbuMMQ6JJ83XnHPFZNuIZbSFmcRSeXg5BIcDk49K1scznqTabctFdGGIZ8+MgZP8AFkEfqP1rKkYNc3Hl42Lk46bh7frUwnCS2sqjP7w4APQf5zVaaRBdyIPuMTj1wQT/AFppEN3Yw3a/Y/LLFXI3ADnIB6e1Y+rXDSSuE3DfxkntU1tO0mySdhuTIBxweO9ULiUPco8fJClip6A54FS9UNaMl1Ty42txj7qZP+fwqxZR+bsDttULlUJ6Y5z7c1TulInlDdUAjOeue9bOlWwluFNyx8pcFwvYDkgU0tSW9AvZ0tIJ5huz5OwFv4nI/pknNRabZj+zIm27o9m9gTg9cA4FV/EjyXuqRQFtu/EjkjgDHBwPQCurWwQ6XEEwwj2RJuGMjPHA6nnpTtdsnZIx44CLqCBIQkh2qo27fmrQ1DSpnu1ihhlKED+IZz0yD25zUur+Q2tuJbqMCNdpbHy9MkCsy71hml26eu5Ewc5OGwMAkGmykLYWUb6lJG7OIIgxyG7j+RqhsXdOGDMoQuMMePfNV49UmtILhA0IaUjdjJJAPT8aRL/Hlb9oLDax6AIe+KlA2VbiJpIJJmZSIsLJzk8/dP6YqtC9pLCULSCbGMscp+nNE8v2W7kicEjOxgG6r2FRahqL3cq7ooo0hG1EjTaFx/M/WobSKSZPHN5BDKpVkyMHvVm9uZLqKFJznEKBn64AXg/pisZWdz82SSM/jVuFcpG7N907Bn+VNSuDiNicJCBj59ytycAY4x9Oasqx8xUiwYdrgjttJ6VCwiMS+WW3sjlwegAPFWNLQfZp3BIbgRjGeSP0FC3B9y9bvI1lDKQrNG20jHLADA/SoLyFDYgqDlHHH+z/APrxWnpdlJJpUVwi7mKudpHGAR1NUZ432RRKuQE5OOSCT1rXoZ9T6sVsEHsK4a4iaDU7lCQE84nDDtXbDPrzXIao6/2ndgjo2R+VYT2NaHxF+zUFHGQSW4+lWbyHzYFBOWyzuenB4qtojeYsoc8YGPxrV2NKI1dsLs2k49+M+1cz3PXg9B2m27zRScbsnj2q2jtCqoyDKtn3yP8AOKfooAEcR3AqTuJ5ye1WNTtwWilUdflbnH0NZt6l7kbWiQ27xu52SOGBHHBOSKmjtU+1nzWERkhLAYwGOcE+3QVLaTRv5cJO116Fuef8OKbKkL3LLKM/uzgEH1HH86TuNMyHlSOWYTRu/wA2Wyedo6n8q5vWWis7xQNzpI+FQd/p616De2yy3CYwQEwBjJIxj+f865PxXaLHZ28uzK88gcg1otR05e8jEs5JTEI5ynkysFOBgA543E10+mLNdfZ42nM8vn+RBEzAjYo4JP8Adyf0rm7RWuV+ysGKyLs2MQOQOOela+nRxzSwSKQJYkZQEG0sBjHP86VzreqOgis1bVne7kXZGpBZSMdhx/e5p8xhceW0RKZO9ST8/bOD3z0q5H9k1DW7RjhHMIKoBnBAxwB07/jzVPxffGSZPKV9yx/LJHySc43H0JqonM7yaRzdxNFa6hItxbtEcZc4zuycYA7Z962bALMkdtaosN3kMDNIu0ZH3APpzk1RtrSMSzNczu7KFwJSTuP19q0Eia0VmMcfmxOG2hQeo6cU9zSa0samnwRabdrc6kYYEttzJsYuZGA4Jx9fxrg1sLW51Bmk+YFTJuYHjqduK6cyXF4rQ7UVVBYPjdkep7DrxWFZQ3N5diH7SfP3FdpXCjHQ49fam9iIJxu2bFvGlvYR28DOtxJubcj9j7Z9KzrNUgCSXQKL88iyM2WdscBR9cVa1S1+wWJlhlDzT24Vf3YDEg8kY6DHT8ayprd21a2jkxGkSq5AJ2A9cAepNCXQnR6mteSC1VxdASM23cwP3ie31rL1CeWK5j+ZRbkK75GSoU8E/wCFFnG0rAHJjLsSxbO1845J70amsaIZJJA8pQs24dVBx+QqkjmqTUSVLr/iRX80pCXGoSxxxM4yQB8zfhxXDeJr8uljCjllEkj/ACnlQvAWujn1NbjT7fYjSXEF4yRjB2jcgGSfwri1sp7y3XyGGYpXiMgPBYv2PYZ710RjoedOd2W9dtp1jKyRqI7iEN/wLA4/xqPXwl7q9uiK5t4bYJGGPTBIB/PNaMumzwQ3Mbzi4uWkLIoYuR8nOfTOKybwyNfWrRiUN5Cnbu2qcE5HFO6M7Nk2nXItFaAWUzQhSqGToSevA/n9K6HwzNexXkbbGjhZNpYHnaexPYcVTs4Et70S6ks8KSjOFUsG9QPzq/YzLm4jiSWKEENum7IeuPeocrm0YW3G28I/tCR55EQSuRHGnyjHIye5qnqeqSWFwptiq24IjIJ3bxt+7+RpwYz6hcXQC/uCkUcQH3gSP61z+tTma8RFdWaOViZAPlKdM+vXihRuOUrIuxXCqkskhaNNgCgDAbuMfhxSXErkSLKro7oQUU4xzkjHsKzoLj7VPcRSy7ZYSHVT8wycen4VZdzJcTfaHDNENrFR3K4P8v1q0jFy0OWFwV84qxCNlTjv6f59qpRTGRVRCGWOUljnoCP/AK1LdnclwVGBG+Tg9R6/rVKyKrLLtBzKokVs8YHUfnTIL9uoEyM5Cr5u0A9Pp/KobkIRK/GV2qeOWx1NTvj/AEZp9yhgZpMdeR/PpWYsuLuWNJPMRGJBx14p7E7kjokVpEijLl/MIPQqB3/E1nlEt/tMr4bYcj0ZvSt2O2EgkLNhkVQEJxlz0/DqfwrnNVOwxQOxChizf40pKyuNO7GxOWkyBjew967PT0h06OZbjAVkDOxH8J5yPQY/pXKWNuJL23jcgQ7N7EnhRjvV/wATXMsknkgASXOBtXjjAx+HtTjomxSV2kVLBn1HU7i6A2+cxGAM+WvoPfFbVzqMiwwWNo5VLcFnIPJJ6nPbjimWdnPa6fG6wbN64QKMtJ2Jz6ds1V1G5t9OiNnbhbi8IBkKnMaf7P8AtEdzRstQ3ZX1CSNriWaOI7WIYKGJVB6Fj1+tZ13cyCNUIZd3JC8bvSm30pxHvcE7eeP0A7VTLlj0Dhf7w4qJMuKJLdljcylcoOx5JPoDSXUjALuIZ3+aU4xtPZB9KlEqoisTmRD8i44z/ePsO3qapXDNI+5sEHPU1LdkUldlrVM3EVvc4UEr5bkDncvQn6j+VVSm9+TgEfManiJaMxtkRsOT6HtT4VMkuNqqgG5yRyAOM0NXBaILSJcbm6ZwD6cUkvBUKCq43Hn9asz3EckDRxRjd5mQ/crgAD9M028gEdtGSQHZslmPSnbQXUZEu62Jxl5ZNis392t7QrUxadO00Y8sgMzEfd5OCPqBismC3kSe2gmR1AJk6csu3OR7Gu5vI005FsI3ikaUQMuD8pBXecn2HH1rSC6sib6Il0VFtLFrO4QKYo905/uoAGI/EmuCa8aW7kmj+RTuYhTxg8Ba6jXNRC+G7iViwubyc9Om05LY/DAxXExyAQNxgsMYHanJ7IUFpc+v1B9ea5PWU/4nFyh53rkH0OBXWY5rnPEjMmpI5IwUG0Y44PesJbGlB2kJayeTJa7AAHUKcDgkHk10Vw4S7SLqq4U4/rWHYZntBgDzI2DqD046g1qpKs7M33XbuR90g965ZHrQZsQQvJIJF27QM5/vjPXFXrYrMibthVSQR1FRaJKVBFz+7XOQQOKdPEYtQWSPAgnw3A+VW7isTQbcWSQSmOMbUkOVbPJz2qeGJbm+jeTjywynH8TY5/SrRibULUQoyrOiblZhwMfzqhprODtYtmNvmLDBJ9adxGrbok9qwwPtC52k9SK5PxHaST6dLGBvKAuAvb1rZu8w6rF5ZxbM5AAPAY9s+hq14hVLadbk4WF8g46bsc5pp6gtDy60Mc1vtferkgccEVqaFZ+TOjRecxYnbL0wf4l9zUGp2ZGome3IUHBJ67RV20YIVSW4YAS+bg8KT03KPpirsdilobxeR5TNCrLfGIrHtOAu3IOPQ1SnltYdNl+yK3l3Aj5flsKRjB/2iT+VVru5jDSeTJ+8VHV5FJO5c8kf407Rp7VrORZleRoHCRkcDAPJA+uPyqkQl1J5bVF067nEhVi6xhcg5PUj2GO/rVzTtNmuZiYy0gli2Lk+Wvmc7V569Dk1iRwx20zrcZLMc8EnBzkkCtm11LydIazhdp90g8oPgheevsTzSuU07aG4SgjFibYqbNMMgAHzcfO3vniqEVvNZXguTC6JlJS+M4z0I9ieKf8AaJUiuRdtZssyeYr78tIF6rnvj09qy7rxMbtpCVeKSZtrODuUoMDAHaqMlF9CprV+0EmPK+cKYI8nO1SeOPxNZmnRPO00sLOUKhHcgfd7fjxmmarcK94chZN0h8od9owM4rPlvHSFIIAVgaTPsTnkn19qtIxlKy0NcCFzLbxL5JVg8rk54HUke/pWT4vm8uYPA5YqokmJH3QTwv8AgKdp2oxtMkrkmxXc7YX5pNvRQe5JxWZrs72ysLz96l3IrXA/u7eSPYitoK551ab2K7p9otNWjUvvlkjlKKcEkAhgvtyD9Ki02JZdGQxSrGjTuTu4ziQY49Oafp5xpcstwxKurY8sYIwCwP5cZ9qztD1mW50k2lvarvhL4cgMAAM7vX+nFW+xzrc7G8ltkEChHa6uAWmkdgc7TyAB0OO1c140tIdPvbbym4b7zbcBR1XAqvpssUk5iDSieNg4zydmPn+jEn9K2PF9tJPpll5cAkniCxks2BGMkZPfPAqDWJdjMCabaxXCeT5i4VySzuccH2ycVTuZElilWTi5MRVGB4LAHKn8hiq3h2fZJ596/mymNkKk/cOf046Cs6Z5mikNvMdskwi3fU8kj1IFJRLlI2THCILVriZUhSLJZfvK24Dn1PNcbqbeVqf7vjykAcr0Hzcmul1lWTT90KMqSSKyqAC2Bxz+ANcZqFz9rvd6oEMrKuwHjBJzWkUYTfQs6LIsV+bwRqwkd8p2HzcH8DipYHHlXss9wgdHwyPk+aSf4cehOfpVOMNbWkwhkXLyiPA67cc06zk3WCu4xsbAGeuO/wCo/KrSMmzBvIhDMlorMBIB5p64z1+uBWQ7NFdNArA7HZFOMZB/zmumuRE4muflUxx7Mjo/YsPc9a5e7Vo7wSpliMFs88+v0qZIcXc2ppFlt5yNxwAo9QAMYFZcOxrpVHCu3OTjgClE7pb3ScbScAH2HX9ao2TsLiLau5gNxA54FDewJbmz9qABMrK7qwcq2cNjtWLfyJcXh3HCKNzEDv1x+uKZfXH+lTFSdrDgHjrzS2luZDvf5EH7xmNJu+g0ramxoixwWVzeXs3lIwzHHglpSD932Hv7VU0pDcai1/fAvHH+8KZ+8o7e2aiQy6pMiqCtugLlB3x7V2ejaRDBpK3l5EXaaTdHZg/eVTxk9VXnP8qpK9uxLdvUqiW8vbVTKkcMLHLsY8mT0RfUD0HFYF/cRpK620Aiizg7Op9s/wCFdhr5gtzJ5rRzXT8tGikLFn+EAcDHA2j8a466t5pLjywDwcOFGcHso96qQomayB+OmBn1P51A6hTuGcdwPWuusdMsbazju7tDuLFEhVsknuSf888VftvDUtzbLfsi20DbhCowTJjryenpUuBSn2OIjsnchpgckcbRkAVJLaFWYRxh1HJJG3Nei2elafHGtxN8lvAmTuPzSP0OPbJrnNXvbORroxBY4wcBBgjHYEjvS5UPmZz6WjvE8jrhFGd3b6VSkcYKxEl2zuArQunuZrVQQ0dvn93GT98nufyzUU0EdvFtyTIwzyOee5/oKlopOwaZaGRo1fhW3E/7oGTUt5++kiXaSBh35547VasyY7NpNq7yhiUEfcyeT9cVDdKyyOQScthOe3GeP0qrWRN7sSO5KTRTZYFTtTnJVR0H/wBarc2oPNLbZJdljLHHJyRj8qyZ3y0UKqAyEg4OcEnnJp0V4sMzvAgQAbS5GTj29KV7ByljxDM888NvGCYolXvwGPUVlHaIX2sGbjGPrTTJJOXaVnJb5jk5xUlrGJGjjJxnliPSp5uZ3LSsj6/GSfasHxPFvaF93Yr9Oc1unPIOc1ma8m+1Jycod2B3pPYik7SRm6PM4TzQQGU4dfU1vGJ0RZYEO1v9YD29DXJQyeUwePPlt8zcdR3rutJnQ24t2ILA5GT2rknoepBmlAv2m0WIkklM7l649q0rBo9RgjhuBjb8uehPo1YM9s9jcR39uWMaZLID931OKuQOECyxPmV13IAeCe4rHzNjTt91pNLaSkeYpCGUdMdR9KZf2zzOJoTtfaCVPH3f6066UTWcN7G5BjJG8jhl7qffuKtW8n2y3XbzNsG0564PB/pQFyBPKmtGkIDQ5yARzntke3T8afJs1DSpopm/efL7YPQfgaWweGS9IkB8ticpjGD3H51Wurd7O8QgnY+TFx94dwR6jpimmBzhs1TzluFOYyccdf8A6wrLnRGlR5MLM/yLkZw3/wBcf0r0C+gS5tvtSptMfEmO3oa5W/s1eba8QVieWPAYHsDWqLjUOUm1E293DGp/eQDlSMlgfvY9hTdMMioJXbYSQrAnPH0/rVrXNHSzlS9tmLCLJaPnc6+mfXNZemzSSWSqRscjIDdWXOCabWh0wkmtDoZ7lblZGjATGFcMfu+hH1xUEcqiX91h2ERfb90Z9TWbJJIuwzOfLVjkLwWHue9MuY47tokgaRkUnJGcjAyM/wCe1KxadtC9pjp9jkubmQvJuBC46Z64HWopdzSp/romfIkJGABnj9P1pLAyRuslxtdcg78frkVLLG4sJZJWYySsVAzkFvUf7IB496pIzqTsmzKMgl1Rim/7MqhQc8k9hn68mrOtw+SLBI2G64zGpXOCN2CcetPtIIo55JNqyKRsjToGOOT71bvbVFtdPZGBcEs56nG5ThR2GM1rFHnVpWM54TaR28CoA0DNKQW5HOFUdvx9653xBIYpsK3Lt5QTHDuTliPUDPWrGt3MatMmWf8AeOzq3GxA2Vx6Z/xrH060uNT1KxjEZknnl3RjvgnoPbj9K3SsjzpO7Oi1q4aw8MXBjjX5H+zpIB1yuDj6f1rktKkktYrloCyNJ8i/THT6V0vxAkV7u00S0lEwswRcSqflZjy2Pr0/CspSlrrCHy9zRxqgQ/dLYyW+lCE9C1oLNZ6YWTYb+6OGeTqiKMnntk9T9BXVEsvhk29uD5k24yTdWAbBz+YIriNJldkujGoLTSBI37KAcnH14rqJ5ntQ7ShVgCgDyuQH7j6c1D3NY7GRYLjzcEeXIvyKT0weST64qFJYgtlavtVgTI7k59ep/HFVLO+b+2oyCgjQsDkZDZBzVASpu3OcksYSp9KuMSZy1On3R3UOorv8qRY98QPGMkHA9eB19q43WLWaPUYVLNIk21/M6c/xfiK2RemDRbaUMGlDM+3u4PAH4dqh1uINpUUqygqsY+bHJbJ/nzVpGLZz95L/AKWqrgDazf8AAQMD9K0tRiFnZ2sDKFeSISHnJTgEH2JzWcCks7XDvnFtgluxAxj9KlvryEvC+5pMIR8xzn2BpolmZd3IlsnVyv7kYRfXuRms15c3C5Ajhc/dXPyr6U69Y2zmE43Bsg9s1DblXV3BPyL0fmperGtivqCPbxyo5DYkPzjnOaj0mVopmKEglCGYf3CMFfoe9T6qytCNx5ZQ2PTnjFZ7t5UCR85Ycn+lQ9GWtUPvEHmK6fMNoyewb0p0MxCCPILP97PQ+30p9usTxyJPlV2FlYf3sfKMfUYqHT4wZd7KMZGAT+lLqPodN4dtYkXM4YhiP3adWPZR7eprqZNUgSG8luWgScsCRGpDFwMKq/3UXqTXEfbvKiJQHdkxxgHgeuP8asaQxFyWvmLxZ3OT/Fj19Rmt4u2hjJX1O00zTJ71ptQZl3BNzS4CFAR1UdATzgnoOa5DVNbQzS2umBIrVPkeePuO6oTzg/3jyevTima74jmlgmhjlIgkIO0HhsdCfWuWWRmBi3ZBbn0xUTnrZFQhfVnR21y17LHlxHaQAAHHQeg/zk5rsY7qb7C888mFjUJGrEbEGOw7t9Olc74YGmvZzzahBOwjC/ZNj4XP8TMMcn0ParNypv8AR5tSkHlQGYW8cWevdvwp301C2pFNcXfiG7iinuHW2xgnH3FHQKB39hVaew3JFJ5Sw2y52RN0AH8THuSasWtzBbPHOTIwGQViO0bOh565PIz2FPvJ7nUbuC5ukEcJU+TGowqgdFUemO5p2E3qZd3CGmtdxkXCl2Zl5VfUCqHlNdXRZ2Ywgls5546VoXYeWUo0gVSN0jnjgdfcn2qrLIBJFFGuyPI+Qnt6sfU9TSaGmWLyRYRHEo+UAysAOoIx19e1Zm4rOvmhvNVsEHtxnOfriqs85kdzncT0PsP8ae822CCMjAiQEY9zk59SePyqea5XLYfOZY9jyrgIrYz3JOMn8f5Vn7x5ewluDnGeDUt60myNHPzyfvGz156Z/Wq7qVVPfp71nLc0iizbR7opWHcLz0281ZmiAhUKwxIeSO3sfen6fEkiNGuSxAOD0z/9apLkRgQJFyg+ZsdSe9WloQ5an1c7bEyeCenqT6Vmaxdxss5iY7VABA+8SR90VovnzYm7LkfiRWJqF6tjqEqXSlIJZF2SqAPLJGCT6ipIRi6eS8TxHCmNh97oP/rVr6fcNGEVgBg4J7gf4Vzmq3Rg1hTCGaFV27m7j8OMVt2r+eqXC8lwPf65rCpGx6FKfMkd9p9y02ml5XRmRsMo6sPX8qu3OkiKBLizY4Ul1j649SP8K5/T5zBFG8WGh/iX2NdRYXR8tWQq6fw46YrlasdSd9QsvLa2crlYHGZQDwrdiB6Z6+lJPAbG4V9jpDIucJ0V/Uex9KsahHHCRdxEBHws8O3IHuPY1LpksMkYhmZmiR8Av8wweMfgcfhQJvqOmDXmy/tEzcRACSNB/rAP4vciqbXlteOIZT5QdvvEZMT/AN4f1Hp9KbeQ3mhXyTQTEws+5A3Rv9kkd8dD3FWtXtra+s21Sw/1pG5kHO7jnI7MPXvR1GUJbqfT3NrKgG3kFed+f4h6qaiu1VZAoChWUBVzkf8A6vQ1X0+ZbqKGG5aQyRZETE4KccjB7HipLhES0SKfMUzDLSEcYzwQK0SJvZ2Mu9fzIp7eUBoZDsXdxgdSfwrmLrSTlbnSmykjEqmOcf8A6q6m6j2TP5bK3lkoSTkFcdz3zWQkElrAwAZS5JYk8qOpGO3arSLhOxiTssgNvKVbnh1OMf8A1qtWqm0h80sxQnCM3O7nt7e9WL622p5jKruq+cxT+FSe/p+NQSW0dxHmIyCckuDwPzHbinY29rpYS3uflcS7VVW3BUTg+1S3M0UVhN52OWHyo2TyeBn0GeapxAb0Qq/nOSY1PTGOpqS9hhWzKcgRljLu5DOeN2e5BppGU5plOW5AvRuZRDCh+6PUYB/KprS5+y2trLcEOtu8kqgHg9Ai/pn8Kge02XMhu08q3hRYnZ+Mtjhcep6msW71BpmunYYt1g8qNU/hJPPX8vxraMTgrVNLFHWQUsbmQ7Gmuj5QiOTt75H68e9bNvPp/hlBNI8keqzQAIwP+pXGGbI6Me3pVOK9stK0qHUtS2z3CJmC3xhnZu5PYDHX06Vzk0z6hdw3V0I5pJ13iIDaFIP6Lnp61oc1y1p8xutU825HlQyLtyRwidvxPf61JqpddTimA2mePgHqOoGf0rMe72anK0JkMMSEl26HjGcfWnXCTS6dcXRY/u0Rt57Etxj3xTFfUt6bdxRWdhEpRNjEcDLbj3966HVtQiRZrdNrmNQoxjOT14rh0nj+0Rtx5RIl8teqkdR7Ui3QnvrmeQmNAu7jqfQe3NHKVz6E95J5dysiHagfa31HXFV7BZby6llDZwXZiDjtz/Oqt5MFiCPkgOHYHqc9P55q7ouLbT55mOJAXbJ6FeB+JzgVSRnJl29vQWWAYTagjjCjA4xis5NSE1rJAp3R7Nq5/h2vkH8f61n6nczRW6s5PnHnn1PTn2qrI3kwooG0Ogwf7xOcke2RTvYmw+eXyrORtw2Skr9MVWvJwwId/nCbc45Y4FQTOXkZe7IM0xJF2lZED4bg9xxxUNlWE1RzK8ch++4yRjuOD/jUCFIrViG+fOCuO2OtJqAcW8JY8DKkY5BqJCpAVSWDYz7HFJ7lJaCTsdiAYKnpx0qA4kkHOQCPoKazFeASQTxz1qzEFWdgRkFSenqKS1HsJaK0k7BUZ41RjIRzhfX+VPlVoHjt0AyQCvH+sB7/AEplrGwMqq2GI5weMe59KdKzTSI2SWjGA564x0+lCWgPcdHumm2qVARdoOeg7n+dWNQuyMRRhkQgDHt/9aqlsBbR75R8zj5QR0Hr+JqG4Zi6OxyuOG9+9O9kK12Q3Mm48YAHyjHoKWzjMsgUk88H3FQyqyud2MirFvI0A3J/rG4HsazWr1NHotDvtGktZb2XdGsOm2gDNEHyXYDhQepGRk1kanqfnWVnZoVihjZ5SmM8sxOf6UqwQ2drsYszsgO4kjnHJrEYx3F0fNWVEIGAoyQO3B7VszJHQadAJ3JLLhVyzSOEAB7n1+grVnitLaASS3SuTlAojO/IGcKp6D3rnLJrZZwturSmMbnaUgKnYHjqfaujt7S2ge4fV52eYKCFXpGD3b1Y/wB3t3q46ozejMJkcNHuwZm+Zhj5YUzkAn17mqGpJDFA0iuSHPA9f9o/XtW1Cy6hO9paFIrBG3TSykL5jdizdlHoP1rC8QTRXEzPAU+zeZtG0EAkDkjNTLYqO5mqqCSPzWIUjJA6/T2phOLkRvxh+eOcUeZiV23AA4HXOBTXX77Altpxn1HrWXkbCXL+ZM0h7knBP5UxSWGTndkY4/SnmIh0DAg9eR0q5YWsjy5QB4Y+ZGPHHuf60rNsLpIu2q+RprNEM3Ejc8fdU9PxqGBSNQEavhVOCx4xxj86vSSIsUgRFyRvC54VfU/zqJtOlsrtIbhQJECzScghdwyoOO+CD+NaMyvuz6oLAjnoar3rIrRrcFDbSKyN5gyASOM1KBg8fkazdVkSSSO3BAJPzn0FQ3ZXCnBzlZHm+vJDHZyXDXBZi3ltH5gGwD7uB3FWPCGtizlEN0wdMnHfr2FddrOi2d3bTPcQKzooCsTwvpgVhax4ams7yJpYoxE9uNogbczOPvFh261lzqWjO90HDVHc6Ncxj5CQ3Pyg9xXTWWLdT5KlreTnbj7uPT0FeSaRqEtuscdyCOSMg/d5xivSPD+pCSNFYg9sZ61hUhbU3pzvodvpsvnpEVAbB2lXH5A0moad5AMsIzCy7pNucj3x6Z6+lUrGRFuraRcAY2sj8B89s/55roLW5VHEUzEOM+W3TI7gj16Z/OsrlyT6GXI0V9pzR3TII9m0sOCjf3h7Vm2UM2mTC2m+X/loCBw6/wB6tbUrVrUtdaeV8tgfMUDOPoO49Mc1WDi604RTv5JUgiTO4oT6d/woFcxtet4ZnhmtJM3DPhhtwHA5yPT3rNuNVkmtzbXMZTLbFdjyCOg+nvVu8vZIreZbqz+z3kJJDv8AdkB4D89M4rIur6C5gVRbI9wdpdic7cdsdzW0VoZSeppJMLeOFWUBQx8vAwR7+5qO8ij+zTymPZjhYm5DsemffviqljDNFKbibeHfPltJyAoHAx7dag1a7kjtUhiDO8fRnHOf735cVVnfQV0SXEcrQyxzhjOeZCxCj/dPvgVDHaTpA8w3RTyxkKhXJyff09Km0+7s5djzy7lHHT52kPBBz0OPWptQu5dreT5cAjHyDdwo9m7/ANKtITnY525jNokpkLsyAqGB56dz2rOeRDdIrzu0EYGxYwGdiOigfXk1BqQvZplDxsIy+QBkq4zkkt9ay9SnntLNjEyxyOSplU8gA+p5/LFaKJlKo7WH6veRPtk4FuFdWUncS2cnPpz+JrLimhhtJbiQZt4UKmPOSSe5HrnnFUmY3GUgBZUGckjDMO/0rJuZmkuPKjcsFXO3PVvU+tbJWRyydx+qOLyMXNxKZAekZ6licYP0FXHuioabCb3h2ICMhckjt2Azj3rL25tGVdrFJNoc+/XFPuGYSwwpGQQoViOyrnH58mnYlMddSJjaiMsZ2qPQgDH6daTU7iQaPBbM+yORw/l46joGP4dqp6jOzyxqjAkqOg4A7D6/0qvql0XmVScuqZYtySe1Sxo0LG4iEkiNxG7NtJ528YB/AZqgwZFjic/NK5eQDoQOFPvmmxzC3IcH5UUDB7/3qFd4kYMT5cv+pbHIUdvamhMTWrpLi8fy0woQLgevTNaslwLXT7m3aKJln2M0v3tgQ9F+p61zqnzbmXzMAgZx6Cobq9eSMwhhtzj24ouK1yS7kN7chIuVTj/gR/w4FPv5VNwkSqD5SbMg9SD1qKzZbUrJCRujwRkdXPp9KkijAtTK4O/fuY9cjof55pFIgwSyvtJySh/LiqMTfOyknpkYPcVoWEhQleR5bHOfpxWaGAm5GR0x70houSuJrSaFxtkQgqfUVQjfazhxlAPmA+lWoGGyaRjlsZwTn2wahkQCNGGQG+Trye4ofcF2KjkKVOPbmtDYZY4vLUmQR7Ax7n1qvhmmgDIFV23Z+la9qTLYyIGUbX3KzHHbpmiKCTsVZAFtsWkTBZvlIkOWTHJH5g/hSRusU5ZZCkQARyOcqOSPrxVmUNbSpcbAykDdEe56fn1qjcRLFBiMttJ3kHqvt/8AXqrWJTuR3c5ubiabAUyMTjqEBycU2zmMcDsBGWUFcOAwZWHP4iqTu2T6s2QR6CkLE4YAKWPHHfFZ3NOURx853fKOakf5ZogCMD5sd6fNPHPFGXjxMMBiG4b8KjuFcSA7V+7uJ6cZpNdik7mze3MvlAqf+WaJu/X86p2sb3DzBWXGMlj1Prj1p135rWtu0iqigYX1Oec+9V1mbCqpJLHlh1aqvqQttDp9HltrG1E0iNLIsnmCPHyknpuPX8BUV9fy6nemZyEhhGPLjXaE9gPf86z9NKSSNI553YYgfdU/X+fWn3F6saslrGohA2IwOdw9c1rfQytqWbiQT4tyv2e3Qfdzn8z61hai5liDDmNG2LgcdP8ACgySSDAcFAwYjPBPrj0FQljJA0h5YydB06VnJ30NIxsxgj3EEFSFGSDU5UeUrgjcX59uKiiBVwGK9DkEZwakkJFuuWOB8wB7HOP/AK+alFtl7RrQXM6iZgN3JBPPua6PUDB9nW3hiht44G4EY4I9z/ET2/GuU06Vo2k8tiJpMAMPTvWlHLG8a7ZCu0khTwF7bvf2rSL0Mpp3NeOKN7F5UhDBmK+nmSf3V9lHJrJB8y58uNx5a5aRh/eFXf7R87TZ3ZUUQQiC1UjaSC38I+ucnrUEcC22nJEWVzjI7HJxyf8APaqvclKx9NzyJbwPK/AUZJrI06JjK08oy7ngml1aYXFylmuTGDmQj+VaUcYWDKKWI6ZrhrT6HpYKlb3maFpFCqE3GPm4+oqO4gtxCyRIFVWyjhe+OhpLCXznIdAFTopNX4rUzO67flOTuJ4z7Vz3aPRaT3OG8Q6MfsJuLaEDy5MMN+flPXj1Bxim+Gb+QS7XyfkB3YwfY4rpbu0eWK4t5XVc5BP94GsK802dbtbyFTEypghOhAHX2raMrqzOWpT5XzRO90yf7REY3ZVZyNrk8Y/HvXQWcolZre6ASeLsByr+x9D/AFrzLRNSEkfmxsDgkMo6A13cN0mqwRyq+y4CDy8Dr6g/0PvWUo20GpX1OqCqZkU5BQBkw3B9vY5qtf6WXkaeD5JgpPlkZyfX3rK02++ZvtCFJI+Dnqp9/WtpLtjEqRuPNQgr2BHoT2pCafQ5DV746lo3lXiNCxyPNccgDt9OORXFXc9vBLJ9vTytiqVMTAYUdSPY/wAsV3vjbymiumWZ445lDSRFcqGAIyD2Jz2rzIWp1S3AdFNy0Z8xmYnaoP3R6D1reGxlLctafezT3AmQy3ETMOXLbQOp2881KksWoSyzyRzhlVjgSDk56H0zWZpViNL0kNFI8kdw5UAkj8BUDTCJ5JL19kDPt8tTj8j3P6VaRDdjVvLMT2RW3whYfL5nHTklSOSOcVzFx/atqiHzFSMZYBV3MR9W7e1bKXkV0bWOIOsauBvkOVA6k/X+VQ65q0AjKWnzIpxyMEBj+pP8hVJkNLqc5c69PHERMzTGM/dMhABPJymMelZdybu6Q3V6TDagbQWUgA+3r16Cti/Fo96DEoYKQJfl+VcdTjNS6k1vdE4mYxLE0uZAfn2j5VAHTPArZM55I5nz7UPBExkIU9kxz+NVpoUtwXEUkakgk/xfQfhmr729xKIbhbVIIYgDI/XGehyenTpWbvhubyXDjY4OJJSW2nP3h3J44+tWZuyIZZvtCSSxosUCuHhhXtnj8T1pNR1QW0MxDu11I2CCBgL6fXtj61Vu71YwIrZtsaE+WcYOT3xWHc5kvESRjsU5JJ/Ok3bYEr7l6yk828kluHOFBkkI7n0H8qrSFpZSWwcHLdsd8UTXBTciLiN2DYAwSB0x9ahlDSyKRknocevp/iakZYLSLL5pG7ad3qDUEl48m6NnLDcXQH1PUUy6nVSYkPI5YjoT9ar28h5lbJAAxmi47F2FZlsbm6AXCOqOCwyS2cADueDUMURnXLglR0bpj0qFVe7kEaElmfhc9fc+las/kw2USHc1yWIiiUct2yacdSXoVoYzJMluu3nlm7DPeunme3Ec8dugaJlWID1xx/8AXrMtoFtZZEdw17IQHGMqgHqfar+jxG91K2WMqVQ5JfkdeWx371eyFuzL8UaRP4evvKnOXeJTgeh5z+HSueckrI5GcYz7e9ej+MHbVLNGkVRIjgiXOSQ3AGOted4+yTsGUMp+V1PHGe1RJGiIS21H4yCwOfXjpVuJPMSLDLgtnOMYwKqSqUU7AWRjgEjrV/SojMqRnIGWDflmlHewpbXGTBh5QZceWh2nv1zk/gasWqiZpc/LhVAUdCccVHfxywW6zYGxnkKNkcjoeO30oZyInRCcnG046YwRTJNBUt57QCaR48AsjhckMByv06e4rOTbuEd4SqOu4yKM8Hj8qRJmDlJVIR+pz/F6j3pzr9nUtLhlQ5Geh9DVXuK1tCpeWDJbB4mDKp5CnJxj73/6qzgjMhZVJAIBPvWsr/u2jiKlSd7RuecjuG7Gs6Q72LxgE91PWs5JdDSLfUg4DfLggc1c1IhzFLtAODnHfk1TPK8DaPTNTSMXWIEcKCR7g81PQt7pjg5NvhuFByvufWpbZCzxhwAqoZM+gAJqGF3j8wxNjzEMZ4zlT1FLGheF2jJG1Pm54AppiY/zCY4lyRuHAHGPU1ZmCNM4JCxRKRgnhmPQCqsOEmQyfMAAsaZ6+59v50+4WR0VkHyK5wM87up4+lO5NtSJld5EAZdz8ZJ4/H8qlkmWK3MNqxZc7zIy45IwSB/Wi2QG4Dbd5QbgP73/ANb1pbm3C3Uy7sE/NGMcNnnFFtNB6XsxfIXfMVJCLFx359PzqvI6ycNgY4z/AHh6VdmDIrBGwjorHb6Ef41QQAQ+YV53gBvw6UPsEe5PbDMz/MBjj60+CTcMnDRxgv5bDOe1Nij2wGZiQznCDuTnrQiMDKjHLrnP4/8A16WwPU1LErLfwmb5La3UyMPUYyFHv2qVrwRSSPPCspYFkU8BGYHB98ZrNtmJj2HBVlwzeig5JHvTSwyZHJwwAGe4q76Ecup9IaUPlEpJLuckmukQkLjtzRRXmT3Pcp/CUpnK3WB0DYrb0mZzIYycoOg9KKKRpLYy/E908cgQKpBHccj6VkvcyS6VKXJPBGMniiiqhuZ1PhOU8NXc1tcERPgPIVIPoTXo+iXMtveIsTYUgZH5/wCFFFbVepxU9jqb1i9pJcg7Jo1VlZffsfUUJdzS2sTSNly4+bv0zRRXPI6IGf4jbzYYkb7qyIwA+oGK4XTJXkv76InCRSbBjuCe/rRRW0TOfUqeIbmWxuDBAx2ysVJbkgZ7elQX8A+w6ahd2ElwysSecYHFFFaLYx6kHiO6fTdPRbYLsL7mRhkMfX6/Sucsm89AXyHkkLbgxyCfTnFFFbR2Oep8R1X2O3WO4AiXbbupRe2SMnPrWnrVnbWXhG51YQrLdrt278hRk88LjP40UVfQzZ5TdX11qc1vHeTyPGQMIDhV+gHSsy7mbzWbC4EeQuOPp9KKKpkFUtugEhC79y4IGNox0FY9zw49yBRRUyKRLCzPtLsWJzyevTgfSoblyEQL8obqBRRS6D6jHI8rAAAGRxVe5Yq20E4x3oopMcTZ0CJBbGXHzYJ/TNaFuqItrKUV57pyHlYZZQOy+g+lFFax2RjPdlaTK28zKSHeXyyw4O30ro/D6i3trmaH5XVVHrnPrRRQUiLU53NpAeN07iVzjkndj8q5FVEzyGTkkvzRRSYyvPGqpCwz84BI7dKuaa7PZXiOdwYqxz3IBGfyoopLcb2MqT55yp6FC/44q1duftfACgKi4H+6Bn60UVJQ2ZR5Uf8A1zz/AOPGtG5PmxFGwFeLzCB2OcHH1xzRRVozfQxLtFSb5Rj5R0+lQ3AG1GAwSob86KKzl1No9BkeCgYgE9KUsSYsnOzKDPoKKKkoenyyADoDnFSZKBdp+WThl7GiiqJYSnbcW0vVmCsc9M5q1pyCS5m35OGYfmDRRTjuKWxBFlZLaRWKvjIIrTliiOn6XciNVldyGx0b5/T8aKKpEy3JpI1j1ee2+9F++hOepUHIz+NYK5EaDOQHPWiilMIF+9+V7JF4Crx+dRxEf2oz4BO/cQeh+ooooe4lsRBjDcssZwMkn3wafK2UIKqd678/3T7elFFIbP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4537=[""].join("\n");
var outline_f4_27_4537=null;
var title_f4_27_4538="Bone problems in childhood cancer patients";
var content_f4_27_4538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bone problems in childhood cancer patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/27/4538/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/27/4538/contributors\">",
"     Susan R Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/27/4538/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/27/4538/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/27/4538/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/27/4538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/27/4538/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/27/4538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents may experience bone problems and endocrine problems during and after therapy for oncologic problems. The bone problems, which may be acute or chronic, and symptomatic or asymptomatic, will be discussed in this topic review.",
"   </p>",
"   <p>",
"    The related endocrine problems will be discussed briefly here, and in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=see_link\">",
"     \"Pubertal development and gonadal function in survivors of childhood cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal bone formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone forms by deposition of osteoid through osteoblast activity. Resorption of osteoid occurs through osteoclast activity. Resorption actively occurs even in growing children. This allows bone remodeling as bones increase in circumference and length. Length is added to bones in the epiphyseal plate, a metabolically active zone in which chondrocytes and cartilage are converted to osteocytes and calcified matrix. The relatively faster rate of bone formation compared to rate of bone resorption leads to growth in bone size and increase in bone mineral density (BMD). Bone strength and fracture risk are related to bone size, BMD, and microstructural architecture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both bone size and BMD increase gradually through the childhood years with more rapid increases during puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Calcium is added to bone most rapidly between ages 9 and 15 years in girls, and between ages 10 and 18 years in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/3\">",
"     3",
"    </a>",
"    ]. After adult height is achieved, bone size remains stable, but BMD continues to increase until age reaches the mid-to-late 20s (peak bone mass). Subsequently, bone mass and BMD decline very gradually throughout the rest of adult life. If peak bone mass is reduced, osteoporosis and fractures may occur earlier in adult life. Bone growth and remodeling are regulated by endogenous hormones, including growth hormone, sex steroids, growth factors, and cytokines, as well as exogenous factors such as nutrition and weight-bearing exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effects of cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood cancer can affect bone metabolism and growth through a variety of mechanisms. The relative contributions of these factors to bone disease in a particular patient, and the contribution of genetics, are often unclear.",
"   </p>",
"   <p>",
"    Cancer itself can affect bone metabolism by interfering with nutrition, physical activity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pubertal progression during critical periods of growth and bone accumulation",
"   </p>",
"   <p>",
"    Cancer treatment can alter bone metabolism through several mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local effects on bone (antimetabolites such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      , glucocorticoids,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      regional radiation).",
"     </li>",
"     <li>",
"      Central nervous system effects from chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cranial radiation, causing pituitary hormone dysfunction (eg, growth hormone deficiency or hypogonadism).",
"     </li>",
"     <li>",
"      Peripheral effects of chemotherapy or radiation on endocrine organs associated with bone metabolism (gonads, thyroid, or kidneys).",
"     </li>",
"     <li>",
"      Dietary modifications during and after cancer therapy. As an example, one study showed that cancer survivors were more likely than controls to have vitamin D deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children are particularly sensitive to the above effects because of their rapid bone growth and turnover.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     AVASCULAR NECROSIS (OSTEONECROSIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avascular necrosis (AVN), also known as aseptic osteonecrosis, is a serious complication of chemotherapy that can destroy the bone underlying the articular surface of the joints, especially the weight-bearing joints of the lower extremities. AVN is usually associated with high dose glucocorticoid treatment, but it has occasionally been reported in association with other types of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. Adolescent patients are disproportionately affected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/6,8,9,12\">",
"     6,8,9,12",
"    </a>",
"    ]. AVN commonly presents with pain upon weight-bearing but may be asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 2 and 10 percent of children treated for acute lymphoblastic leukemia (ALL) develop symptomatic AVN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/8,9,12-16\">",
"     8,9,12-16",
"    </a>",
"    ]. In one study, the rate of symptomatic AVN was 17 percent (10 percent in children younger than 10 years, and 45 percent in children older than 10 years), and the overall rate of asymptomatic disease was 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/16\">",
"     16",
"    </a>",
"    ]. These rates are higher than in previous reports, probably because this study employed routine screening by magnetic resonance imaging (MRI) during reinduction therapy, and identified symptomatic disease when minimal dysfunction was present. Most cases of AVN occur during or shortly after chemotherapy, ranging from 6 to 53 months after initiation of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/6,12,14\">",
"     6,12,14",
"    </a>",
"    ]. One long-term study suggests that AVN can develop years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AVN is a particularly common complication of treatment for ALL, but it also affects a substantial portion of patients undergoing hematopoietic cell transplant (HCT) who receive glucocorticoids as primary treatment or for graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. AVN is also seen in association with other malignancies that are treated with glucocorticoids, including non-Hodgkin's lymphoma, Hodgkin's disease, and other leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's age and the dose and duration of glucocorticoid treatment are important risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/8,17\">",
"     8,17",
"    </a>",
"    ]. Most cases of chemotherapy-associated AVN occur in children and adolescents over 10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/6,12,16\">",
"     6,12,16",
"    </a>",
"    ]. This is probably because rapid bone growth and bone turnover in this age group accelerate the pathologic effects of the glucocorticoids. Several studies have suggested that the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    rather than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    , and exposure to radiation therapy (particularly gonadal radiation) contribute to the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/17\">",
"     17",
"    </a>",
"    ]. Studies conflict in their conclusions about whether white race and female gender confer additional risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/9,12,16,17,19,20\">",
"     9,12,16,17,19,20",
"    </a>",
"    ]. Genetic polymorphisms, elevated lipid levels, and obesity may also contribute to the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/16,19,21\">",
"     16,19,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are the main cause of AVN in children with malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/6\">",
"     6",
"    </a>",
"    ]. The reasons for this association and other contributing factors are not clear. AVN probably begins with an interruption of the blood supply to the bone, possibly because of fat emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/22\">",
"     22",
"    </a>",
"    ]. Subsequently, the adjacent area becomes hyperemic, resulting in demineralization and trabecular thinning. When subjected to physical stress (such as weight-bearing), the bone collapses. The potential contribution from other components of chemotherapy (particularly antimetabolites such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/47/15095?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    ) has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVN typically presents as a limp and bone or joint pain, usually occurring while the patient is receiving high dose glucocorticoids. Most cases of symptomatic AVN involve weight-bearing joints (eg, the femoral head and femoral and tibial condyles), but multiple joints are often affected in the same patient [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/6,12\">",
"     6,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The joint is usually initially evaluated by plain radiograph, mostly to identify other potential sources of pain, such as fracture or bony metastasis. However, a normal plain radiograph does not exclude AVN, and any patient at risk for AVN with unexplained joint pain should be further evaluated by MRI, which is far more sensitive and specific than plain radiographs for detection of AVN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The sensitivity and specificity of radionucleotide bone scans is intermediate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for AVN usually depends on the severity of the lesion, but there are no established criteria for determining severity in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/25\">",
"     25",
"    </a>",
"    ]. Most cases are treated with an initial trial of conservative therapy, with advancement to surgical intervention when necessary.",
"   </p>",
"   <p>",
"    Conservative therapy includes restriction of weight-bearing and avoidance of abduction; pendulum exercises may be helpful. If possible, a decrease or modification of glucocorticoid dose may improve the condition.",
"   </p>",
"   <p>",
"    Conservative therapy is ineffective for many patients with chemotherapy-related AVN of the hip or knee. In several small series of patients who developed chemotherapy-related AVN, 30 to 60 percent of patients required surgical intervention, consisting of core decompression or joint replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/6,14,26\">",
"     6,14,26",
"    </a>",
"    ]. More extensive AVN is more likely to require surgical intervention. In one series, 80 percent of patients with lesions occupying more than 30 percent of the femoral head volume had joint collapse within two years of diagnosis, and 50 percent required arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other treatment approaches include bisphosphonates, prostacyclin analog (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    ), electrical stimulation, or hyperbaric oxygen, but none of these interventions has been sufficiently studied to determine if they are useful [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/6,28,29\">",
"     6,28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link&amp;anchor=H34#H34\">",
"     \"Osteonecrosis (avascular necrosis of bone)\", section on 'Treatment options'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H28\">",
"     'Prevention and treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SLIPPED CAPITAL FEMORAL EPIPHYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slipped capital femoral epiphysis (SCFE) is a displacement of the proximal femur upwards through the epiphyseal growth plate, giving the appearance of downward displacement of the epiphysis itself.",
"   </p>",
"   <p>",
"    The risk for SCFE may be raised by increased bone resorption or impaired development of bone. SCFE occurs with increased frequency in overweight or actively growing children and adolescents, in patients after renal transplant or in renal failure, in girls with Turner syndrome, in obese pubertal boys, and in patients with growth hormone deficiency or those receiving growth hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/30\">",
"     30",
"    </a>",
"    ]. The latter is relevant for survivors of childhood cancer, some of whom develop growth hormone deficiency. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Growth hormone deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There appears to be a weak association between SCFE and radiation therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy. Direct radiation to the hip appears to be the most consistent association, although the relative contribution of these factors has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/31\">",
"     31",
"    </a>",
"    ]. Most of the reported cases underwent cancer treatment in early childhood, and presented with SCFE during late childhood (mean 10 years), which is younger than usual age of onset of SCFE in the absence of cancer treatment.",
"   </p>",
"   <p>",
"    The evaluation, diagnosis, and management of SCFE are discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ALTERED EPIPHYSEAL GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiphyseal growth is altered temporarily during cancer therapy but is altered also in a lasting manner after certain types of chemotherapy and after irradiation to epiphyses. Children undergoing intensive chemotherapy for ALL typically display a marked deceleration in growth velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/32\">",
"     32",
"    </a>",
"    ], generally followed by catch-up growth after chemotherapy is complete [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Agents that directly alter bone growth include glucocorticoids,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , actinomycin D,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct radiation to long bones and the vertebral column can retard bone growth. The risk is increased in younger patients and with regional radiation doses of more than 20 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regional or cranial radiation and chemotherapy can also have indirect effects on bone growth by disrupting growth-promoting hormones, including growth hormone, IGF-I, gonadal steroids, and thyroid hormones. Hypothyroidism is an important consequence of radiotherapy and contributes to growth failure. Hyperthyroidism is less common, but when present, it can impair bone mineralization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=see_link\">",
"     \"Pubertal development and gonadal function in survivors of childhood cancer\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Reduced bone mineral density'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Abnormality of each of these factors may disrupt epiphyseal growth. The effects on longitudinal growth may be seen only transiently during chemotherapy, or may compromise adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. In most cases, trunk length (sitting height) is affected more than standing height, because of additive effects on each of the many epiphyses in the vertebral column [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients undergoing treatment at an age when growth is normally rapid (early childhood or early puberty) are most likely to have measurable effects on linear growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     REDUCED BONE MINERAL DENSITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced bone mineral density (BMD) is particularly common among survivors of hematologic malignancies and brain tumors. Some of the risk seems to be related to the underlying cancer: bone mineral is already decreased, compared to normal for age, at the time of diagnosis of ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/39\">",
"     39",
"    </a>",
"    ]. Chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy further increase these risks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced BMD is often clinically invisible and unrecognized until a fracture occurs. Symptoms of fractures associated with osteoporosis may include bone pain, abnormal gait, vertebral collapse, back pain, or low-impact fractures.",
"   </p>",
"   <p>",
"    Most survivors of childhood cancer will regain bone mass with increasing time after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. However, BMD may be permanently reduced if the cancer or its treatment reduces peak bone mass, so children treated during puberty are particularly at risk. In addition, there may be progressive effects on BMD if the individual has a treatment-related endocrinopathy (eg, growth hormone deficiency or hypogonadism), or nephropathy causing chronic renal phosphate loss (eg. Fanconi syndrome associated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, osteopenia is defined as BMD that is more than 1 SD below the mean (expressed as a T-score &lt; -1), and osteoporosis is defined as BMD that is more than 2.5 SD below the mean (with the mean based on the standard of young adult women). BMD is most commonly measured by dual-energy x-ray absorptiometry (DXA) or, at some centers, by quantitative computed tomography (QCT). (See",
"    <a class=\"local\" href=\"#H25\">",
"     'BMD measurement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In children, comparison of BMD to adult standards is not a good predictor of current fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/27\">",
"     27",
"    </a>",
"    ]. Therefore, use of age- and gender-based standards (Z-scores) is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/25,44\">",
"     25,44",
"    </a>",
"    ]. A Z-score &lt; -2.0 defines reduced BMD. In children, the term \"osteoporosis\" is not used unless there is a clinically significant fracture history, such as fracture of lower extremity long bone, two episodes of upper extremity long bone fractures, or vertebral compression fracture.",
"   </p>",
"   <p>",
"    Primary osteoporosis results from the gradual losses of BMD resulting from aging and menopause. Secondary osteoporosis is caused by other medical disorders, including cancer and cancer treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have reported reduced BMD in long-term survivors of cancer in pediatric patients, particularly those affected by brain tumors or leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/14,40,42,46-61\">",
"     14,40,42,46-61",
"    </a>",
"    ]. Therapy for solid tumors can also lead to reduced BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/62\">",
"     62",
"    </a>",
"    ]. Reduced BMD (as measured in the lumbar spine) has been reported in 8 to 23 percent of survivors who received chemotherapy prior to epiphyseal closure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/46\">",
"     46",
"    </a>",
"    ], and in 45 percent of survivors treated with cranial radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/43\">",
"     43",
"    </a>",
"    ]. Other studies showed no decrease in bone mass, perhaps because these studies described longer-term outcomes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    results of more recent treatment protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cancer treatment during adulthood appears to be less likely to reduce BMD. As an example, decreased BMD was seen in children, but not adults, two years after hematopoietic cell transplantation (HCT) for myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/54\">",
"     54",
"    </a>",
"    ]. Similarly, among 25 individuals treated with HCT for leukemia or lymphoma during adulthood, decreased bone mass was not observed when measured by DXA eight years later [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for decreased BMD include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cranial irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/42,59,65\">",
"       42,59,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/55,66,67\">",
"       55,66,67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41,65,68-71\">",
"       41,65,68-71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (eg, doses &gt;40,000",
"      <span class=\"nowrap\">",
"       mg/m2)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41,68,72,73\">",
"       41,68,72,73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alkylating agents (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/65\">",
"       65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Younger age at diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/55,74\">",
"       55,74",
"      </a>",
"      ] (prior to puberty)",
"     </li>",
"     <li>",
"      Male gender, Caucasian race [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/42,57,65\">",
"       42,57,65",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer and cancer treatments can affect BMD through several mechanisms. In many cases, several factors will contribute to reduced BMD in the same individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are an important component of chemotherapy for many childhood cancers. They contribute to bone loss through a variety of mechanisms, including direct inhibitory effects on osteoblasts and by inhibiting production of growth hormone, insulin-like growth factor I (IGF-I), androgens, and estrogens. These mechanisms are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Glucocorticoids are more likely to cause reduced BMD in patients exposed to cumulative doses &gt;9000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent (&gt;36,000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    equivalent). Patients treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    are more likely to have reduced BMD as compared with those treated with prednisone, even at doses that are considered equivalent for glucocorticoid replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. For comparison, physiologic doses of glucocorticoids are hydrocortisone 10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily divided into two or three doses, prednisone 2.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily divided into two doses, or dexamethasone 0.125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once daily (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other chemotherapeutic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimetabolite drugs, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , reduce BMD by directly inhibiting formation of new bone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41,73\">",
"     41,73",
"    </a>",
"    ]. Reduced BMD has been noted with methotrexate doses exceeding 40,000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41,42,68\">",
"     41,42,68",
"    </a>",
"    ]. Because of the complex protocols used, studies have not been able to distinguish whether lower doses of methotrexate also contribute to the risk. Alkylating agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , can reduce BMD through toxicity to the gonads (thus reducing gonadal steroid production) or kidneys (causing renal phosphate loss); these effects may be acute or chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Growth hormone deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer treatment, particularly cranial radiation, can have permanent effects on the hypothalamic-pituitary axis, causing growth hormone deficiency (GHD). The highest risk for GHD has been observed in patients exposed to radiation doses of 18 Gy or more to the cranium. Patients undergoing total body irradiation doses of more than 12 Gy for HCT are also at risk for GHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41\">",
"     41",
"    </a>",
"    ]. GHD is the most common pituitary hormone abnormality after cranial radiation, and is almost universal among patients treated with doses above 35 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/35,75\">",
"     35,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GHD inhibits bone formation both directly and indirectly by reducing serum 1,25-OH vitamin D concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41,76\">",
"     41,76",
"    </a>",
"    ]. In patients with reduced BMD because of GHD, treatment with growth hormone enhances BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/77\">",
"     77",
"    </a>",
"    ]. DXA tends to underestimate bone density in individuals with short stature. Thus, individuals with short stature and GHD may have falsely abnormal measurements of BMD, and it may be difficult to distinguish those with true deficits of bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer treatment may cause hypogonadism, either through direct effects on the gonads (primary hypogonadism), or indirect effects on hypothalamic-pituitary axis (secondary hypogonadism). &nbsp;Hypogonadism is the most prominent cause of bone loss following HCT in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/67,80,81\">",
"     67,80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=see_link\">",
"     \"Pubertal development and gonadal function in survivors of childhood cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary hypogonadism may be caused by direct toxicity to the gonads from regional radiation or chemotherapy (eg, alkylating agents) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/75\">",
"     75",
"    </a>",
"    ]. Gonadal dysfunction is associated with radiation doses of 10 Gy or more in prepubertal females, and 5 Gy or more in pubertal females. Doses of 20 Gy or more cause Leydig cell dysfunction and androgen deficiency in males [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41,75\">",
"     41,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary hypogonadism may be caused by high dose cranial radiation, which causes gonadotropin releasing hormone deficiency and hypogonadism in 2 to 5 percent of individuals receiving doses at or above 40 Gy; this rate is considerably lower than that of GHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/75\">",
"     75",
"    </a>",
"    ]. Paradoxically, lower doses of cranial radiation have been associated with higher rates of early puberty due to loss of inhibitory influences controlling timing of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Either of the above processes can cause deficiencies of estrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    androgens, which reduce bone mineral density. These gonadal hormones inhibit bone resorption, and androgens also stimulate bone formation (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=see_link&amp;anchor=H341630#H341630\">",
"     \"Pathogenesis of osteoporosis\", section on 'Sex steroid deficiency'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose radiation to the thyroid gland commonly causes hypothyroidism. Hyperthyroidism is less common but was detected in 5 percent of individuals treated with radiation therapy for Hodgkin's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/82\">",
"     82",
"    </a>",
"    ]. When present, hyperthyroidism can lead to increased bone resorption and bone loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illness itself may result in reduced BMD because of prolonged immobilization, altered diet, and elevated immune cytokines. Habits of daily living, such as deficient intake of calcium or vitamin D, smoking, or decreased exercise, can also contribute to reduced BMD in cancer survivors, as in other individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41,49\">",
"     41,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link\">",
"     \"Calcium requirements in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional factors that predispose to osteopenia include genetic variants in vitamin D receptor, and familial patterns in the timing of puberty. A family history of osteoporosis suggests the possibility of this type of heritable factor.",
"   </p>",
"   <p>",
"    Direct radiation to bone can reduce bone strength and increase fracture risk even without affecting BMD. Clinically important effects are most often seen in long bones and the vertebral column in patients treated for solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/35\">",
"     35",
"    </a>",
"    ]. The risk is increased in younger patients and those receiving radiation doses of more than 20 Gy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of BMD in the growing child presents a challenge for accuracy and consistency. BMD varies with age and gender, and must be analyzed by comparing results to age- and gender-based normative data. However, BMD also varies with height and pubertal stage, and these factors are rarely included in normative data sets. Even comparison of longitudinal data in the same patient is complicated because of the process of growth, which prevents measurement of exactly the same part of the bone over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     BMD measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines from the Children's Oncology Group recommend that all patients treated with agents that predispose to reduced BMD (including glucocorticoids, cranial radiation,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or HCT) have a quantitative measure of BMD at the time of entry into long-term follow up, which typically occurs two years after completion of cancer chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41,74\">",
"     41,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BMD should be measured with either dual energy x-ray absorptiometry (DXA) or quantitative computed tomography (QCT). The methodology employed may influence the results, and the optimal approach has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DXA measures areal BMD, providing an estimate of bone mass at a specific site. The process involves x-ray beam attenuation across a cross-section of bone",
"      <span class=\"nowrap\">",
"       (g/cm2).",
"      </span>",
"      Results must be interpreted using age- and gender-specific standards (Z-scores) and not adult standards (T-scores). Since DXA provides a two-dimensional measurement of BMD, test results are affected by bone size [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/83\">",
"       83",
"      </a>",
"      ]. Adjustment for bone size discrepant from normal has been found to lead to fewer false positives. No particular method of size adjustment is perfect (height age, bone age, or other method), but applying some adjustment for bone size improves accuracy of DXA interpretation. The clinician can adjust the result for bone size by interpretation of Z-score for height age [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/25,44\">",
"       25,44",
"      </a>",
"      ], but the mathematical adjustment is not always sufficient. Thus, standard DXA Z-score for age and gender may systematically underestimate BMD in shorter patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42583?source=see_link\">",
"       \"Overview of dual-energy x-ray absorptiometry\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H14\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      QCT measures volumetric BMD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/25\">",
"       25",
"      </a>",
"      ]. The result is expressed as",
"      <span class=\"nowrap\">",
"       g/cm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and, thus, does not require adjustment for bone size of the patient. This technique provides distinct measures of trabecular and cortical bone dimension and density, and is thus more sensitive than DXA in detecting changes in BMD. However, as noted previously, the technique is not widely available and requires higher doses of radiation than DXA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results from the baseline evaluation and other clinical factors should determine the need for follow-up. In general, patients with normal BMD study results (eg, Z-score &gt; -1) do not require follow up examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients with significant BMD deficits (eg, Z-scores &lt; -2), recurrent fractures, or medical risk factors for decreasing BMD such as growth hormone deficiency (GHD) or hypogonadism, require endocrine evaluation and treatment, counseling to optimize lifestyle factors affecting bone health, and long-term follow up of BMD. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Prevention and treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative bone ultrasound has been used to assess bone structure and elasticity, but this technique does not measure BMD. The amount of overlying soft tissue can influence the results.",
"   </p>",
"   <p>",
"    Metabolic markers of bone formation and bone resorption (bone turnover markers), such as serum osteocalcin and urine pyridinoline cross-links, can be measured in the serum and the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/84\">",
"     84",
"    </a>",
"    ]. These markers do not currently have a role in screening for osteoporosis or selection of candidates for therapy but might be useful in monitoring response to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44487?source=see_link\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Endocrine evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be carefully monitored for growth rates and pubertal progression during and after cancer treatment. Patients with the following characteristics should be further evaluated for specific endocrine deficiencies (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7286?source=see_link\">",
"     \"Endocrine surveillance in childhood cancer survivors\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with growth failure or deceleration should be evaluated for GHD and thyroid hormone abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"       \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=see_link\">",
"       \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with delayed or interrupted progression of puberty, or accelerated puberty should be evaluated for abnormalities of the hypothalamic-pituitary-gonadal axis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=see_link\">",
"       \"Pubertal development and gonadal function in survivors of childhood cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that patients with significant BMD deficits (eg, Z-scores &lt; -2) or those who have been exposed to high-risk treatments, including high dose cranial radiation or gonadal radiation, should also be screened for the above endocrinopathies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of reduced BMD starts with prevention. It is important to maintain recommended intakes of calcium (usually 1000 to 1500 mg daily, depending on age) and vitamin D (400 to 800 units daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/79,85,86\">",
"     79,85,86",
"    </a>",
"    ], even during cancer therapy. The patient should be encouraged to adopt habits that promote bone health (weight-bearing exercise, and avoid smoking) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link&amp;anchor=H14#H14\">",
"     \"Calcium requirements in adolescents\", section on 'Other factors in bone health'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early identification and therapy of hormone deficits have the potential to preserve BMD. In patients with established hypogonadism, it is important to provide replacement of gonadal steroids as appropriate to the patient's age, height, and pubertal status. Patients with GHD should be treated with growth hormone, and in this setting, growth hormone therapy can augment BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7286?source=see_link\">",
"     \"Endocrine surveillance in childhood cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=see_link\">",
"     \"Pubertal development and gonadal function in survivors of childhood cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates have been used in adults during active cancer, and are generally safe and effective for increasing BMD; they may also reduce bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/91\">",
"     91",
"    </a>",
"    ]. Experience in use of bisphosphonates in children is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. The most extensive experience has been with children with osteogenesis imperfecta who show improved growth rate and decreased bone pain with bisphosphonate therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26185?source=see_link\">",
"     \"Osteogenesis imperfecta: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several important reasons for caution when considering bisphosphonates in children and adolescents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bisphosphonates, which are anticatabolic agents that suppress bone remodeling, may have different effects when administered to patients during active bone growth as compared with adults.",
"     </li>",
"     <li>",
"      The bone matrix created by bisphosphonates is more brittle than normal bone [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/94\">",
"       94",
"      </a>",
"      ], and bisphosphonates have extremely long half-lives (several years) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Associations between measures of reduced BMD and fracture risk have not been clearly established for children, making it difficult to select pediatric patients who would benefit most from bisphosphonate treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, bisphosphonates should not be used as standard therapy for pediatric cancer patients with reduced BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. These drugs are generally reserved for pediatric patients with severe reductions in BMD and pathological extremity fractures or vertebral compression.",
"   </p>",
"   <p>",
"    Other treatments that have been used for patients with severe osteoporosis include calcitonin and selective estrogen receptor modulators, parathyroid hormone (teriparatide), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    (an anti-osteoclastic monoclonal antibody) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/27/4538/abstract/74\">",
"     74",
"    </a>",
"    ]. However, minimal information is available on the safety or efficacy of these drugs in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children affected by cancer are at risk for several important skeletal problems during and after treatment, including osteonecrosis of the joints, reduced bone mineral density (BMD) and osteoporosis, and transient or permanent effects on linear growth. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some cases, reductions in bone mineralization and linear growth are caused by disruption of growth hormone, gonadal hormones, or thyroid hormones. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Reduced bone mineral density'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Altered epiphyseal growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All childhood cancer patients should be counseled to maintain recommended intakes of calcium (usually 1000 to 1500 mg daily, depending on age) and vitamin D (600 to 1000 units daily), even during cancer therapy. Patients should be encouraged to adopt habits supporting bone health (weight-bearing exercise, avoid smoking). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Avascular necrosis typically presents as a limp and pain in weight-bearing joints, usually occurring while the patient is receiving high dose glucocorticoids. A normal plain radiograph does not exclude AVN, and any patient at risk for AVN with unexplained joint pain should be further evaluated by MRI. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Avascular necrosis (Osteonecrosis)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients exposed to therapies expected to reduce BMD (including glucocorticoids, cranial radiation,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      , or hematopoietic cell transplant) have a quantitative measure of BMD (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The initial assessment should be done at the time of entry into long-term follow up, or when symptomatic disease develops, whichever comes first. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'BMD measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All childhood cancer patients should be carefully monitored for growth rates and pubertal progression during and after cancer treatment. Patients with growth failure or deceleration, or those with delayed or interrupted progression of puberty, or accelerated puberty should be evaluated accordingly. Patients with significant BMD deficits (Z-scores &lt; -2) should be evaluated for endocrinopathies. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Endocrine evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7286?source=see_link\">",
"       \"Endocrine surveillance in childhood cancer survivors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/1\">",
"      Gordon CL, Halton JM, Atkinson SA, Webber CE. The contributions of growth and puberty to peak bone mass. Growth Dev Aging 1991; 55:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/2\">",
"      Ross JL, Long L, Marin G, et al. Pubertal changes in bone mineral content of the wrist and spine in normal boys and girls. Clin Pediatr Endocrinol 1994; 3:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/3\">",
"      Abrams SA. Calcium turnover and nutrition through the life cycle. Proc Nutr Soc 2001; 60:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/4\">",
"      van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev 2003; 24:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/5\">",
"      Sinha A, Avery P, Turner S, et al. Vitamin D status in paediatric patients with cancer. Pediatr Blood Cancer 2011; 57:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/6\">",
"      Lackner H, Benesch M, Moser A, et al. Aseptic osteonecrosis in children and adolescents treated for hemato-oncologic diseases: a 13-year longitudinal observational study. J Pediatr Hematol Oncol 2005; 27:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/7\">",
"      Ishii E, Yoshida N, Miyazaki S. Avascular necrosis of bone in neuroblastoma treated with combination chemotherapy. Eur J Pediatr 1984; 143:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/8\">",
"      B&uuml;rger B, Beier R, Zimmermann M, et al. Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. Pediatr Blood Cancer 2005; 44:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/9\">",
"      Aric&ograve; M, Boccalatte MF, Silvestri D, et al. Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica 2003; 88:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/10\">",
"      Niinim&auml;ki RA, Harila-Saari AH, Jartti AE, et al. Osteonecrosis in children treated for lymphoma or solid tumors. J Pediatr Hematol Oncol 2008; 30:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/11\">",
"      H&ouml;gler W, Wehl G, van Staa T, et al. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database. Pediatr Blood Cancer 2007; 48:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/12\">",
"      Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 2000; 18:3262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/13\">",
"      Soci&eacute; G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Mo&euml;lle (SFGM). Br J Haematol 1997; 97:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/14\">",
"      Wiesmann A, Pereira P, B&ouml;hm P, et al. Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options. Bone Marrow Transplant 1998; 22:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/15\">",
"      Ojala AE, Lanning FP, P&auml;&auml;kk&ouml; E, Lanning BM. Osteonecrosis in children treated for acute lymphoblastic leukemia: a magnetic resonance imaging study after treatment. Med Pediatr Oncol 1997; 29:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/16\">",
"      Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011; 117:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/17\">",
"      Kadan-Lottick NS, Dinu I, Wasilewski-Masker K, et al. Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2008; 26:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/18\">",
"      Faraci M, Calevo MG, Lanino E, et al. Osteonecrosis after allogeneic stem cell transplantation in childhood. A case-control study in Italy. Haematologica 2006; 91:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/19\">",
"      Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004; 22:3930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/20\">",
"      Armstrong GT, Sklar CA, Hudson MM, Robison LL. Long-term health status among survivors of childhood cancer: does sex matter? J Clin Oncol 2007; 25:4477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/21\">",
"      Niinim&auml;ki RA, Harila-Saari AH, Jartti AE, et al. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J Clin Oncol 2007; 25:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/22\">",
"      Wang KZ, Mao LZ, Hu CG. [Experimental study on mechanism of steroid-induced avascular necrosis of femoral head]. Zhonghua Wai Ke Za Zhi 1994; 32:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/23\">",
"      Ribeiro RC, Fletcher BD, Kennedy W, et al. Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. Leukemia 2001; 15:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/24\">",
"      Sansgiri RK, Neel MD, Soto-Fourier M, Kaste SC. Unique MRI findings as an early predictor of osteonecrosis in pediatric acute lymphoblastic leukemia. AJR Am J Roentgenol 2012; 198:W432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/25\">",
"      Kaste SC. Skeletal toxicities of treatment in children with cancer. Pediatr Blood Cancer 2008; 50:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/26\">",
"      Castro FP Jr, Barrack RL. Core decompression and conservative treatment for avascular necrosis of the femoral head: a meta-analysis. Am J Orthop (Belle Mead NJ) 2000; 29:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/27\">",
"      Karimova EJ, Rai SN, Howard SC, et al. Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. J Clin Oncol 2007; 25:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/28\">",
"      Aigner N, Petje G, Schneider W, et al. Juvenile bone-marrow oedema of the acetabulum treated by iloprost. J Bone Joint Surg Br 2002; 84:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/29\">",
"      Bernbeck B, Krauth KA, Scherer A, et al. Aseptic osteonecrosis in a child with nephroblastoma healed by hyperbaric oxygen therapy. Med Pediatr Oncol 2002; 39:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/30\">",
"      Seller K, Raab P, Wild A, Krauspe R. Risk-benefit analysis of prophylactic pinning in slipped capital femoral epiphysis. J Pediatr Orthop B 2001; 10:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/31\">",
"      Liu SC, Tsai CC, Huang CH. Atypical slipped capital femoral epiphysis after radiotherapy and chemotherapy. Clin Orthop Relat Res 2004; :212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/32\">",
"      Viana MB, Vilela MI. Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: a review. Pediatr Blood Cancer 2008; 50:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/33\">",
"      Caruso-Nicoletti M, Mancuso M, Spadaro G, et al. Growth and growth hormone in children during and after therapy for acute lymphoblastic leukaemia. Eur J Pediatr 1993; 152:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/34\">",
"      Ahmed SF, Wallace WH, Crofton PM, et al. Short-term changes in lower leg length in children treated for acute lymphoblastic leukaemia. J Pediatr Endocrinol Metab 1999; 12:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/35\">",
"      van Leeuwen BL, Kamps WA, Jansen HW, Hoekstra HJ. The effect of chemotherapy on the growing skeleton. Cancer Treat Rev 2000; 26:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/36\">",
"      Xian CJ, Cool JC, Scherer MA, et al. Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects. Bone 2007; 41:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/37\">",
"      Bongers ME, Francken AB, Rouw&eacute; C, et al. Reduction of adult height in childhood acute lymphoblastic leukemia survivors after prophylactic cranial irradiation. Pediatr Blood Cancer 2005; 45:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/38\">",
"      Davies HA, Didcock E, Didi M, et al. Disproportionate short stature after cranial irradiation and combination chemotherapy for leukaemia. Arch Dis Child 1994; 70:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/39\">",
"      Arikoski P, Komulainen J, Riikonen P, et al. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocrinol Metab 1999; 84:3174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/40\">",
"      Halton JM, Atkinson SA, Barr RD. Growth and body composition in response to chemotherapy in children with acute lymphoblastic leukemia. Int J Cancer Suppl 1998; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/41\">",
"      Wasilewski-Masker K, Kaste SC, Hudson MM, et al. Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. Pediatrics 2008; 121:e705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/42\">",
"      Kaste SC, Jones-Wallace D, Rose SR, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001; 15:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/43\">",
"      Hesseling PB, Hough SF, Nel ED, et al. Bone mineral density in long-term survivors of childhood cancer. Int J Cancer Suppl 1998; 11:44.",
"     </a>",
"    </li>",
"    <li>",
"     Position statement, the International Society for Clinical Densitometry. www.iscd.org. (Accessed on March 12, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/45\">",
"      Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin North Am 2003; 32:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/46\">",
"      Kaste SC, Chesney RW, Hudson MM, et al. Bone mineral status during and after therapy of childhood cancer: an increasing population with multiple risk factors for impaired bone health. J Bone Miner Res 1999; 14:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/47\">",
"      Arikoski P, Komulainen J, Voutilainen R, et al. Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998; 20:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/48\">",
"      Mithal NP, Almond MK, Evans K, Hoskin PJ. Reduced bone mineral density in long-term survivors of medulloblastoma. Br J Radiol 1993; 66:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/49\">",
"      Haddy TB, Mosher RB, Reaman GH. Osteoporosis in survivors of acute lymphoblastic leukemia. Oncologist 2001; 6:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/50\">",
"      Nysom K, Holm K, Michaelsen KF, et al. Bone mass after treatment of malignant lymphoma in childhood. Med Pediatr Oncol 2001; 37:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/51\">",
"      Nysom K, M&oslash;lgaard C, Holm K, et al. Bone mass and body composition after cessation of therapy for childhood cancer. Int J Cancer Suppl 1998; 11:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/52\">",
"      Hoorweg-Nijman JJ, Kardos G, Roos JC, et al. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukaemia. Clin Endocrinol (Oxf) 1999; 50:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/53\">",
"      Brennan BM, Rahim A, Adams JA, et al. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood. Br J Cancer 1999; 79:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/54\">",
"      Bhatia S, Ramsay NK, Weisdorf D, et al. Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies. Bone Marrow Transplant 1998; 22:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/55\">",
"      Perkins JL, Kunin-Batson AS, Youngren NM, et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer 2007; 49:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/56\">",
"      Athanassiadou F, Tragiannidis A, Rousso I, et al. Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment. Pediatr Hematol Oncol 2005; 22:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/57\">",
"      M&uuml;ller HL, Schneider P, Bueb K, et al. Volumetric bone mineral density in patients with childhood craniopharyngioma. Exp Clin Endocrinol Diabetes 2003; 111:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/58\">",
"      Kelly KM, Thornton JC, Hughes D, et al. Total body bone measurements: a cross-sectional study in children with acute lymphoblastic leukemia during and following completion of therapy. Pediatr Blood Cancer 2009; 52:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/59\">",
"      Odame I, Duckworth J, Talsma D, et al. Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood. Pediatr Blood Cancer 2006; 46:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/60\">",
"      Davies JH, Evans BA, Jones E, et al. Osteopenia, excess adiposity and hyperleptinaemia during 2 years of treatment for childhood acute lymphoblastic leukaemia without cranial irradiation. Clin Endocrinol (Oxf) 2004; 60:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/61\">",
"      Thomas IH, Donohue JE, Ness KK, et al. Bone mineral density in young adult survivors of acute lymphoblastic leukemia. Cancer 2008; 113:3248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/62\">",
"      Muszynska-Roslan K, Konstantynowicz J, Panasiuk A, Krawczuk-Rybak M. Is the treatment for childhood solid tumors associated with lower bone mass than that for leukemia and Hodgkin disease? Pediatr Hematol Oncol 2009; 26:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/63\">",
"      Kadan-Lottick N, Marshall JA, Bar&oacute;n AE, et al. Normal bone mineral density after treatment for childhood acute lymphoblastic leukemia diagnosed between 1991 and 1998. J Pediatr 2001; 138:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/64\">",
"      Nysom K, Holm K, Michaelsen KF, et al. Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant 2000; 25:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/65\">",
"      Benmiloud S, Steffens M, Beauloye V, et al. Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood. Horm Res Paediatr 2010; 74:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/66\">",
"      Mattano L. The skeletal remains: porosis and necrosis of bone in the marrow transplantation setting. Pediatr Transplant 2003; 7 Suppl 3:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/67\">",
"      Le Meignen M, Auquier P, Barlogis V, et al. Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities. Blood 2011; 118:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/68\">",
"      Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 2004; 22:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/69\">",
"      Strauss AJ, Su JT, Dalton VM, et al. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol 2001; 19:3066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/70\">",
"      Atkinson SA, Halton JM, Bradley C, et al. Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition. Int J Cancer Suppl 1998; 11:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/71\">",
"      Alikasifoglu A, Yetgin S, Cetin M, et al. Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments. Am J Hematol 2005; 80:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/72\">",
"      Holzer G, Krepler P, Koschat MA, et al. Bone mineral density in long-term survivors of highly malignant osteosarcoma. J Bone Joint Surg Br 2003; 85:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/73\">",
"      Fan C, Georgiou KR, King TJ, Xian CJ. Methotrexate toxicity in growing long bones of young rats: a model for studying cancer chemotherapy-induced bone growth defects in children. J Biomed Biotechnol 2011; 2011:903097.",
"     </a>",
"    </li>",
"    <li>",
"     Hudson MM, Landier W, Bhatia S. Long-term follow-up guidelines for surviviros of childhood, adolescent, and young adult cancers. In: Children's Oncology Group, ed. Version 2. www.survivorshipguidelines.org (Accessed on January 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/75\">",
"      Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours. Endocr Relat Cancer 2004; 11:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/76\">",
"      G&oacute;mez JM. The role of insulin-like growth factor I components in the regulation of vitamin D. Curr Pharm Biotechnol 2006; 7:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/77\">",
"      Keilholz U, Max R, Scheibenbogen C, et al. Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation. Cancer 1997; 79:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/78\">",
"      Leonard MB. Assessment of bone health in children and adolescents with cancer: promises and pitfalls of current techniques. Med Pediatr Oncol 2003; 41:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/79\">",
"      Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/80\">",
"      Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/81\">",
"      Howell SJ, Radford JA, Adams JE, Shalet SM. The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. Clin Endocrinol (Oxf) 2000; 52:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/82\">",
"      Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85:3227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/83\">",
"      Fewtrell MS, Gordon I, Biassoni L, Cole TJ. Dual X-ray absorptiometry (DXA) of the lumbar spine in a clinical paediatric setting: does the method of size-adjustment matter? Bone 2005; 37:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/84\">",
"      Mora S, Pitukcheewanont P, Kaufman FR, et al. Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res 1999; 14:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/85\">",
"      Sweet MG, Sweet JM, Jeremiah MP, Galazka SS. Diagnosis and treatment of osteoporosis. Am Fam Physician 2009; 79:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/86\">",
"      Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/87\">",
"      Kelly AK. Physical activity prescription for childhood cancer survivors. Curr Sports Med Rep 2011; 10:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/88\">",
"      Joyce ED, Nolan VG, Ness KK, et al. Association of muscle strength and bone mineral density in adult survivors of childhood acute lymphoblastic leukemia. Arch Phys Med Rehabil 2011; 92:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/89\">",
"      Gonc EN, Kandemir N. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency. Clin Endocrinol (Oxf) 2007; 66:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/90\">",
"      van den Heijkant S, Hoorweg-Nijman G, Huisman J, et al. Effects of growth hormone therapy on bone mass, metabolic balance, and well-being in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2011; 33:e231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/91\">",
"      Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/92\">",
"      Lethaby C, Wiernikowski J, Sala A, et al. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. J Pediatr Hematol Oncol 2007; 29:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/93\">",
"      Wiernikowski JT, Barr RD, Webber C, et al. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study. J Oncol Pharm Pract 2005; 11:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/94\">",
"      Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/95\">",
"      Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007; 356:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/96\">",
"      Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007; :CD005324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/27/4538/abstract/97\">",
"      Bachrach LK, Ward LM. Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009; 94:400.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5830 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4538=[""].join("\n");
var outline_f4_27_4538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal bone formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effects of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AVASCULAR NECROSIS (OSTEONECROSIS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SLIPPED CAPITAL FEMORAL EPIPHYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ALTERED EPIPHYSEAL GROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      REDUCED BONE MINERAL DENSITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - BMD measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Endocrine evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5830|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42972\" title=\"table 1\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=related_link\">",
"      Calcium requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7286?source=related_link\">",
"      Endocrine surveillance in childhood cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=related_link\">",
"      Growth failure after childhood cancer: Role of growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=related_link\">",
"      Growth failure after childhood cancer: Role of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26185?source=related_link\">",
"      Osteogenesis imperfecta: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=related_link\">",
"      Pubertal development and gonadal function in survivors of childhood cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44487?source=related_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_27_4539="Avoiding warfarin assoc ICH";
var content_f4_27_4539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Avoiding ICH during warfarin therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Elderly patients and those with intrinsic cerebrovascular disease are at high risk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep INRs &le;3.0.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin combined with aspirin should be used with caution in elderly patients and those with cerebrovascular disease and the benefits versus risks carefully weighed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Modest blood pressure lowering profoundly reduces ICH risk; systolic blood pressure should optimally be lowered to &lt;140 mmHg.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005; 36:1588. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4539=[""].join("\n");
var outline_f4_27_4539=null;
var title_f4_27_4540="Hormone therapy plus NSAIDs for desmoids";
var content_f4_27_4540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Combinations of hormonal therapy plus NSAIDs in the treatment of desmoid tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agents used",
"       </td>",
"       <td class=\"subtitle1\">",
"        No of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of therapy (in months)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulindac plus tamoxifen",
"       </td>",
"       <td>",
"        25*",
"       </td>",
"       <td>",
"        5-84 (median 24)",
"       </td>",
"       <td>",
"        <p>",
"         3 CR",
"        </p>",
"        <p>",
"         3 PR",
"        </p>",
"        <p>",
"         11 SD",
"        </p>",
"        <p>",
"         7 PD",
"        </p>",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Hansmann, A; 2003",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hormonal agent (testolactone/tamoxifen) combined with an NSAID (indomethacin, sulindac, or piroxicam)",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1-92 (median 52)",
"       </td>",
"       <td>",
"        <p>",
"         1 CR",
"        </p>",
"        <p>",
"         4 PR",
"        </p>",
"        <p>",
"         1 SD",
"        </p>",
"        <p>",
"         1 PD",
"        </p>",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Waddell, W; 1991",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sulindac or indomethacin plus tamoxifen",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        9-36 (median 20)",
"       </td>",
"       <td>",
"        <p>",
"         2 SD",
"        </p>",
"        <p>",
"         2 PD",
"        </p>",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Klein, W; 1987",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OR: overall response; CR: complete response; PR: partial response; NSAIDs: non-steroidal anti-inflammatory drugs; SD: stable disease; PD: progressive disease; NR: not reported.",
"     <br>",
"      * 1 out of 25 patients had a complete (R0) resection and was on combination therapy adjuvantly. This patient is not counted for responses.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4540=[""].join("\n");
var outline_f4_27_4540=null;
var title_f4_27_4541="Common causes of in-toeing";
var content_f4_27_4541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of common causes of in-toeing in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metatarsus adductus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Internal tibial torsion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Increased femoral anteversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Description",
"        </strong>",
"       </td>",
"       <td>",
"        Medial deviation of the forefoot on the hindfoot",
"       </td>",
"       <td>",
"        Internal (medial) rotation of the tibia relative to the transcondylar axis of the femur",
"       </td>",
"       <td>",
"        Increased angle between the axis of the femoral neck and the transcondylar axis of the femur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Most common age group",
"        </strong>",
"       </td>",
"       <td>",
"        Birth to 1 year",
"       </td>",
"       <td>",
"        1 to 3 or 4 years",
"       </td>",
"       <td>",
"        &gt;3 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Foot progression angle",
"        </strong>",
"       </td>",
"       <td>",
"        Internal",
"       </td>",
"       <td>",
"        Internal",
"       </td>",
"       <td>",
"        Internal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patellar progression angle",
"        </strong>",
"       </td>",
"       <td>",
"        Neutral/external",
"       </td>",
"       <td>",
"        Neutral/external",
"       </td>",
"       <td>",
"        Internal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Evaluation",
"        </strong>",
"       </td>",
"       <td>",
"        Heel bisector line* falls lateral to second toe",
"       </td>",
"       <td>",
"        Thigh foot angle",
"        <sup>",
"         &bull;",
"        </sup>",
"        is neutral or internal (negative)",
"       </td>",
"       <td>",
"        Symmetrically increased internal (medial) hip rotation",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Laterality",
"        </strong>",
"       </td>",
"       <td>",
"        Usually bilateral; may be unilateral with L&gt;R",
"       </td>",
"       <td>",
"        Usually bilateral; may be unilateral with L&gt;R",
"       </td>",
"       <td>",
"        Bilateral; other conditions should be considered if unilateral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Other clinical features",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         May be associated with other \"packaging problems\"",
"        </p>",
"        <p>",
"         Normal range of motion at ankle and subtalar joint",
"        </p>",
"       </td>",
"       <td>",
"        Medial malleolus level with or posterior to lateral malleolus when seated with thigh directly in front of hip joint and the knee pointed straight ahead",
"       </td>",
"       <td>",
"        <p>",
"         Sits in \"W\" position",
"        </p>",
"        <p>",
"         Runs with \"egg-beater\" or \"wind-mill\" pattern",
"        </p>",
"        <p>",
"         More common in girls",
"        </p>",
"        <p>",
"         Tends to run in families",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Natural history",
"        </strong>",
"       </td>",
"       <td>",
"        Resolves by age 1 year",
"       </td>",
"       <td>",
"        Resolves by age 5 years",
"       </td>",
"       <td>",
"        Resolves by age 11 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The heel bisector line is measured with the child prone, the knee flexed, and ankle dorsiflexed so that the plantar surface of the foot is parallel to the ceiling. A visual line is approximated parallel to the heel and extended distally to the toes. (See text for details).",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      The thigh-foot angle is measured with the child prone, the knee flexed, and the ankle dorsiflexed so that the plantar surface of the foot is parallel to the ceiling. A visual line is approximated along the long axis of the thigh and a second line along the long axis of the heel. The angle between these two lines is the thigh-foot angle. (See text for details).",
"      <br>",
"       &Delta; Internal hip rotation is measured with the child prone and the knees flexed. The lower leg is rotated away from the axis of the body. (See text for details).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4541=[""].join("\n");
var outline_f4_27_4541=null;
var title_f4_27_4542="Staging gest trop neoplas";
var content_f4_27_4542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Staging gestational trophoblastic neoplasia (TNM and International Federation of Gynecology and Obstetrics [FIGO])",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       TNM categories",
"      </td>",
"      <td class=\"subtitle2\">",
"       FIGO stages",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"3\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       I",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor confined to uterus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       II",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor extends to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       TNM categories",
"      </td>",
"      <td class=\"subtitle2\">",
"       FIGO stages",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"3\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       M1",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       M1a",
"      </td>",
"      <td class=\"sublist_other\">",
"       III",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Lung metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       M1b",
"      </td>",
"      <td class=\"sublist_other\">",
"       IV",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       All other distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Prognostic scoring index for gestational trophoblastic tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" rowspan=\"2\">",
"       Prognostic factor",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"4\">",
"       Risk score*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3\">",
"       0",
"      </td>",
"      <td class=\"subtitle3\">",
"       1",
"      </td>",
"      <td class=\"subtitle3\">",
"       2",
"      </td>",
"      <td class=\"subtitle3\">",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age",
"      </td>",
"      <td>",
"       &lt;40",
"      </td>",
"      <td>",
"       &ge;40",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antecedent pregnancy",
"      </td>",
"      <td>",
"       Hydatidiform mole",
"      </td>",
"      <td>",
"       Abortion",
"      </td>",
"      <td>",
"       Term pregnancy",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interval months from index pregnancy",
"      </td>",
"      <td>",
"       &lt;4",
"      </td>",
"      <td>",
"       4-6",
"      </td>",
"      <td>",
"       7-12",
"      </td>",
"      <td>",
"       &gt;12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pretreatment serum hCG (IU/mL)",
"      </td>",
"      <td>",
"       &lt;1000",
"      </td>",
"      <td>",
"       1000 to &lt;10,000",
"      </td>",
"      <td>",
"       10,000 to &lt;100,000",
"      </td>",
"      <td>",
"       &ge;100,000",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Largest tumor size, including uterus (cm)",
"      </td>",
"      <td>",
"       &lt;3",
"      </td>",
"      <td>",
"       3-5",
"      </td>",
"      <td>",
"       &gt;5",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Site of metastases",
"      </td>",
"      <td>",
"       Lung",
"      </td>",
"      <td>",
"       Spleen, kidney",
"      </td>",
"      <td>",
"       Gastrointestinal tract",
"      </td>",
"      <td>",
"       Brain, liver",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Number of metastases identified",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       1-4",
"      </td>",
"      <td>",
"       5-8",
"      </td>",
"      <td>",
"       &gt;8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Previous failed chemotherapy",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Single drug",
"      </td>",
"      <td>",
"       Two or more drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Total score",
"       </strong>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle2\">",
"       T",
"      </td>",
"      <td class=\"subtitle2\">",
"       M",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Risk factors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"2\">",
"       Unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IA",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"2\">",
"       Low risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IB",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"2\">",
"       High risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"2\">",
"       Unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIA",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"2\">",
"       Low risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIB",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"2\">",
"       High risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage III",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       M1a",
"      </td>",
"      <td colspan=\"2\">",
"       Unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIA",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       M1a",
"      </td>",
"      <td colspan=\"2\">",
"       Low risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       M1a",
"      </td>",
"      <td colspan=\"2\">",
"       High risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IV",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       M1b",
"      </td>",
"      <td colspan=\"2\">",
"       Unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVA",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       M1b",
"      </td>",
"      <td colspan=\"2\">",
"       Low risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       M1b",
"      </td>",
"      <td colspan=\"2\">",
"       High risk",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Low risk is a score of 6 or less. High risk is a score of 7 or greater.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4542=[""].join("\n");
var outline_f4_27_4542=null;
var title_f4_27_4543="Severe retinal hemorrhage";
var content_f4_27_4543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe retinal hemorrhage from central retinal vein obstruction associated with a direct cavernous-carotid fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Bennett, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_27_4543=[""].join("\n");
var outline_f4_27_4543=null;
